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 Abstract 
 	  
Understanding of transcriptional machinery of early embryo development and epigenetic 
mechanisms of reprogramming is essential for embryogenesis and the success of animal 
biotechnology.  This dissertation presents (1) transcriptional profiles of bovine in vivo pre-
implantation development (Chapter Two); (2) bovine imprinted gene expression patterns across 
mammalian species (Chapter Three); (3) effects of High Hydrostatic Pressure (HHP) on 
expression profiles of in vitro produced embryos (Chapter Four); (4) roles of BAF complex in 
reprogramming (Chapter Five).  
In the first section, we reported comprehensive transcriptome dynamics of single matured 
bovine oocytes and pre-implantation embryos developed in vivo using the RNA-seq technologies.  
Subsequently, using weighted gene co-expression network analysis, we found 12 stage-specific 
modules of co-expressed genes and identified potential master regulators of embryo development.  
Finally, we conducted the first comparison of embryonic expression profiles across three 
mammalian species, human, mouse and bovine. We found that the three species share more 
maternally deposited genes than embryonic genome activated genes and demonstrated that 
bovine embryos are better models for human embryonic development. 
With the “gold standards” in vivo embryo transcriptome datasets, we characterized all 
currently known bovine imprinted genes and compared them to their counterparts in humans, 
mice and pigs in the second section.  We found interesting expression patterns such as high 
levels of paternally expressed and low levels of maternally expressed genes in bovine oocytes.  
We also report drastic variations of species-specific levels of expression of imprinted genes. 
In the third section, we evaluated the effects of HHP on the transcriptome of bovine IVF 
blastocysts by the DNA Microarray technology.  We found a positive effect of HHP on bovine 
IVF blastocysts mediated by specific gene expression changes. 
In the fourth section, we aimed to better understand the mechanism of reprogramming 
and to further improve its efficiency by studying the roles of somatic BAF components, Brm and 
Baf170, during reprogramming in the mouse model.  We found that Brm and Baf170 inhibit 
reprogramming in a stage-specific fashion.  We further showed that inhibiting somatic BAF 
improves complete reprogramming by facilitating the activation of the “pluripotency circuitry” 
and by constituting to the Stat3-regulated epigenetic network during pluripotency establishment. 
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1.1.  Embryonic Pre-implantation Development. 
Mammalian pre-implantation development is a complex process including fertilization, 
cleavage divisions, compaction, and blastulation.  During this process, massive degradation of 
oocyte-stored maternal RNAs/proteins and gradual activation of the embryonic genome take 
place 1.  Embryonic genome activation (EGA) is initiated at species-specific stages.  This is at 2-
cell stage in the mouse 2-4 and between 4- and 8-cell stages in humans 5.  However, the exact 
timing of EGA in bovine is still debated 6-11.  The characterization of normal maternal and 
embryonic transcriptomes is essential for the understanding embryogenesis and has important 
implications for assisted reproductive technology (ART).   
In vivo derived embryos from livestock species such as cattle are valuable models 
because, first, cattle is an economically important species for which ART has been well-
developed 12.  The characterization of in vivo developed embryos can provide a reference base 
for those generated by various in vitro techniques.  This enhances our ability to improve assisted 
embryo biotechnologies such as embryo culture conditions.  Second, bovine embryos are 
increasingly used as an alternative to those of the mouse for the analysis of human pre-
implantation development that is limited by a scarcity of material, ethical and legal confines. 
To date, few molecular and cellular studies have been conducted using in vivo embryos 
due to high expense and small sample size.  Through a collaboration with Xinjiang Academy of 
Animal Sciences, we generated bovine in vivo produced embryos at different stages and profiled 
the transcriptomes of these embryos by RNA-seq.  The data are presented in the second chapter 
of this dissertation. 
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1.2.  Transcriptome Profiling of Pre-implantation Development by Microarray and RNA 
Sequencing (RNA-seq) Technology 
Various technologies including hybridization or sequence-based approaches have been 
developed to deduce and quantify embryonic transcriptomes.  During the past decade and until 
recently, hybridization-based DNA microarray had been the most successful and widely used 
transcriptome analysis method 13-15.  However, microarray has significant limitations including 
(1) detecting only printed genes; (2) relative low detection limit; (3) variations from 
hybridization; and (4) inability to detect alternative splicing and novel transcripts.  The 
introduction of state-of-the-art technology, high throughput next generation sequencing (NGS) 
technologies 16 such as RNA sequencing (RNA-seq) revolutionized functional genomics and 
potentially overcame all problems associated with the DNA microarray 17.  RNA-seq allows 
single-base resolution 18, unlimited capture of gene expression levels depending only on the 
depth of sequencing 19, gene fusion detection 20, small RNA characterization 21 and detection of 
alternative splicing events 22,23.   
It is essential to capture transcriptome of few or even single-cell in study of early 
embryos.  Previously, researchers have integrated either in vitro transcription-based (IVT) linear 
amplification 3,4,24,25, PCR-based exponential amplification 26,27, or a combination of both 28,29 
into DNA microarray for small amounts of starting materials, or even a single cell.  More 
recently, such amplification approaches have been combined with the RNA-seq system 19,30, 
promoting rapid advances in the field early embryonic development 31,32, and revealing the 
molecular constituents and pathways of totipotency and pluripotency of the early embryos.   
Moreover, a number of either hybridization- or sequencing-based technologies are now 
emerging that allows reliable transcriptomics from minute cell quantities including 
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hybridization-based, the NanosString nCounter System 33 and sequencing-based, nanoCAGE 34.  
In addition, PCR array and Fluidigm 35,36 offer platforms that perform quantitative real-time 
polymerase chain reaction (qRT-PCR) on gene panels in a multiplexed manner and has been 
used to profile single cells.  These approaches are advantageous for the determination of the 
expression levels of a subset of transcripts across cells of interest. 
1.3.  Transcriptome and Post-transcriptome Modifications 
With the complete catalogue of transcripts and spatio-temporal expression patterns of 
each gene during different stages of embryo development, identifying and dissecting complex 
biological networks that drive physiological functions are now possible.  To this extent, we are 
set forth to mining specific categories of gene activities in order to understand their roles in early 
embryos.  These specific subsets of genes include those associated with genomic imprinting, X-
chromosome compensation,, oxidative phosphorylation, epigenetic modifications of histones, 
etc..  
Genomic imprinting, parent-of-origin-dependent gene expression 37, plays important roles 
in embryonic and placental development as well as in maternal behavior 38.  However, the 
identification of imprinted genes in farm species and their roles in development lag behind those 
in the mouse and human 39.  Because imprints are established during gametogenesis and embryo 
development 40, environmental factors such as in vitro culture and manipulations of oocytes and 
embryos affect their expression which can last through the entire life of the animals 41.  
Qualitative and quantitative expression profiles of imprinted genes from in vivo pre-implantation 
embryos are essential gold standards for embryos produced from biotechnologies.  In the Chapter 
three of this dissertation , we characterized all currently known bovine imprinted genes and 
compared them to their counterparts in humans, mice and pigs in the second section. 
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1.4.  Environment Effects on Embryonic Development 
Development depends on both genetics and the environment.  Early embryos undergo 
dynamic changes of gene activities and are particularly sensitive to environmental factors.  
Although the use of in vitro fertilization (IVF) in cattle and other species such as humans has 
been valuable to both science and industry, the optimal conditions for fertilization, embryo 
culture and preservation are still yet to be identified.  Negative consequences on IVF derived 
embryos, fetuses, placentas, and offspring differ significantly in morphology and developmental 
competence compared with those produced in vivo 42.  Cryopreservation of gametes and embryos 
is an artificial manipulation that can introduce stress from osmotic, oxidative, cold/heat shock, 
nutritional and mechanic changes.  A relatively recent invention indicated that treating embryos 
with a well-defined and properly applied sublethal high hydrostatic pressure (HHP) can induce 
general adaptation and increase tolerance of the embryos to various in vitro procedures 43.  For 
example, HHP treatment has been shown to improve the survival rates, fertilizing ability and 
developmental competence of cryopreserved oocytes 44,45, sperm 46,47, embryos 48-50 and 
embryonic stem cells 51.  Re-expansion and hatching rates of embryos after vitrification-warming 
were also found to be affected by the duration between termination of HHP treatment and the 
initiation of vitrification 49,52.  When perfected, such invention can be applied to human embryos 
to improve IVF success.  However, the molecular mechanisms of HHP action have yet to be 
ascertained.  When few clues are available for such effects, a throughput gene expression 
approach such as the DNA microarray is the method of choice to interrogate all possible 
molecular pathways involved.  In Chapter four of this dissertation, we evaluated the effects of 
HHP on the transcriptome of bovine IVF blastocysts by the DNA Microarray technology. 
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1.5.  Reprogramming Somatic Cells to Stem Cells of Embryonic Properties 
Induced pluripotent stem cells (iPSCs) are embryonic stem cell (ESC) - like cells 
reprogrammed using ectopic transcription factors Oct4, Sox2, Klf4, and c-Myc (OKSM) 53,54.  
This technology holds great potential for regenerative medicine in producing patient-specific 
pluripotent cells while bypassing controversial embryo manipulations. iPSCs have been 
successfully generated from mice and humans by using various combination of reprogramming 
factors 53-55 in the form of modified RNA 56, proteins 57 and small molecules 58.  A variety of 
chromatin modifiers have also been reported to facilitate epigenetic changes leading to authentic 
iPSC reprogramming 59,60 as reprogramming is achieved by overcoming a series of epigenetic 
barriers 61.  Despite these advances, the reprogramming efficiency of somatic cells remains 
extremely low 62.  
Despite the historic success with generating iPSCs in mice and humans, derivation of 
pluripotent stem cells from agricultural species, especially cattle, has been extremely challenging 
for its ill-defined molecular mechanisms and optimized culture conditions in the previous 
reported incompletely reprogrammed bovine iPSCs 63-67, which negatively impact their potential 
applications, such as genetic manipulations by using cutting-edge genomic editing technologies 
of TALENs 68,69 and CRISPRs 70,71. 
Acquisition of induced pluripotency requires an intricate interplay among specialized 
transcriptional circuitries, signaling pathways and chromatin remodeling.  In addition to DNA 
and histone modifications, ATP-dependent enzymes that remodel chromatin are important 
controllers of chromatin structure and assembly, and are major contributors to regulations of 
gene expression 72,73.  The SWI/SNF (SWItch/Sucrose NonFermentable or BAF, Brg/Brahma-
associated factors) complexes are epigenetic modifiers of chromatin structure and undergo 
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progressive changes in subunit composition during cellular differentiation.  For example, in 
ESCs esBAF contains Brg1 and Baf155, while their homologs, Brm and Baf170, are present in 
BAF of somatic cells.  Components of esBAF have been shown to be important in both 
maintenance of mouse ESCs and iPSC induction.  Deficiency in Brg1, Baf47, Baf155, or Baf250 
impaired the ability of mESCs to proliferate and to maintain pluripotency 74-79.  Brg1 and 
Baf155, combined with Oct4, Sox2, Klf4 and c-Myc, can synergistically increase reprogramming 
efficiency 80.  It is likely that progressive subunit changes of BAF complex occur while cells 
transit from differentiated to pluripotent states.  The mechanisms of acquisition of components of 
esBAF and disposition of the somatic BAF during pluripotency establish, however, remain 
unclear.   
Our understanding of epigenetic mechanisms of reprogramming using mouse model will 
provide insights to bypassing hurdle of bovine iPSCs generation in the future and further for 
transgenic animal work in agriculture and disease model establishment.  In Chapter five of this 
dissertation, we determined roles of somatic BAF components, Brm and Baf170, during 
reprogramming by using shRNA-mediated knockdown studies in the mouse model.   
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Chapter Two 
Transcriptional Profiles of Bovine In Vivo Pre-implantation 
Development 
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2.1. Abstract 
During mammalian pre-implantation embryonic development dramatic and orchestrated 
changes occur in gene transcription.  The identification of the complete changes has not been 
possible until the development of the Next Generation Sequencing Technology.  Here we report 
comprehensive transcriptome dynamics of single matured bovine oocytes and pre-implantation 
embryos developed in vivo.  Surprisingly, more than half of the estimated 22,000 bovine genes, 
11,488 to 12,729 involved in more than 100 pathways, is expressed in oocytes and early 
embryos.  Despite the similarity in the total numbers of genes expressed across stages, the nature 
of the expressed genes is dramatically different.  A total of 2,845 genes were differentially 
expressed among different stages, of which the largest change was observed between the 4- and 
8-cell stages, demonstrating that the bovine embryonic genome is activated at this transition.  
Additionally, 774 genes were identified as only expressed/highly enriched in particular stages of 
development, suggesting their stage-specific roles in embryogenesis.  Using weighted gene co-
expression network analysis, we found 12 stage-specific modules of co-expressed genes that can 
be used to represent the corresponding stage of development.  Furthermore, we identified 
conserved key members (or hub genes) of the bovine expressed gene networks.  Their vast 
association with other embryonic genes suggests that they may have important regulatory roles 
in embryo development; yet, the majority of the hub genes are relatively unknown/under-studied 
in embryos.  We also conducted the first comparison of embryonic expression profiles across 
three mammalian species, human, mouse and bovine, for which RNA-seq data are available.  We 
found that the three species share more maternally deposited genes than embryonic genome 
activated genes.  More importantly, there are more similarities in embryonic transcriptomes 
between bovine and humans than between humans and mice, demonstrating that bovine embryos 
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are better models for human embryonic development.  This study provides a comprehensive 
examination of gene activities in bovine embryos and identified little-known potential master 
regulators of pre-implantation development.  
Key words: pre-implantation development; embryonic genome activation; RNA-seq; stage 
specific module; hub genes, bovine, human, mouse  
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2.2.	  Introduction	  
Mammalian pre-implantation embryonic development is a complex process including 
fertilization, cleavage divisions, compaction, and blastulation.  During this process, massive 
degradation of oocyte-stored maternal RNA/proteins and gradual activation of the embryonic 
genome take place 1.  Earlier studies employing RNA polymerase II inhibitor suggested that the 
timing of EGA is correlated with the speed of embryonic development.  For example, a-amanitin 
halted embryo development at the 2-cell stage in mice 2-4 and between 4- and 8-cell stages in 
humans 5.  However, the exact timing of EGA in bovine is still debated.  Developmental block of 
cultured bovine embryos occur between the 8- and 16-cell stages 6-8, suggesting EGA at this 
transition. Similar conclusion was reached by studying expression profiles of bovine in vitro 
embryos using microarray 9 or the RNA sequencing (RNA-seq) technology 10.  However, a 
microarray study utilizing pooled in vivo bovine embryos suggested that bovine EGA occurs 
between the 4- and 8-cell stages 11.  
To date, the most comprehensive transcriptome profiling of bovine in vivo embryos was 
carried out using the Affymetrix GeneChip Bovine Genome Array. Although this microarray 
contains roughly 23,000 bovine transcripts, these represent only 12,752 genes (personal 
communications with Affymetrix), approximately half of the mammalian genes.  Previous data 
are also impacted by hybridization variations of microarray and the use of pooled embryos 8,11.  
Although more comprehensive data were obtained using RNA-seq, they were restricted to 
bovine blastocysts only 12,13 or with the use of in vitro embryos 10.  As a result, the complete 
descriptions of gene activities during bovine in vivo embryonic development are still not 
available.  Moreover, the timing of EGA should not be established using expression data from 
half of the genome or in vitro embryos.  The RNA-seq technology provides unique benefits for 
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studying gene expression with high resolutions and reproducibility, as well as for detecting novel 
transcripts and alternative splicing events 14,15.  Here we applied the Solid RNA-seq platform on 
single in vivo matured oocytes and in vivo developed embryos from the 2-cell to the blastocyst 
stages and obtained their comprehensive transcriptome dynamics.  The identification of highly 
connected, yet relatively little known or completely unknown hub genes that are potentially 
master regulators of gene expression opens up unprecedented opportunities for further 
understanding of early development.  Furthermore, we used RNA-seq datasets recently generated 
in humans and mice and carried out a comprehensive stage-specific comparison across the three 
mammalian species.  We found that the three species shared more maternally deposited genes 
than embryonic genome activated genes.  More significantly, there are more similarities between 
bovine and human embryonic transcriptomes than those between humans and mice.  The data 
obtained here will function as a comprehensive reference base for embryos generated from 
reproductive biotechnologies in the bovine as well as in the human for which the use of in vivo 
embryos is highly limited. 
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2.3.	  Materials	  and	  Methods	  
2.3.1.	  Ethics	  statement.	  
Oocytes and embryos were obtained from healthy Holstein cows in the Institute of 
Animal Science, Xinjiang Academy of Animal Science, Urumqi, Xinjiang, P. R. China.  The 
animal protocol was approved by the Animal Care and Use Committee of Xinjiang Academy of 
Animal Science (Research license 200815).  
2.3.2.	  Collection	  of	  In	  Vivo	  Matured	  Oocytes	  and	  Pre-­‐implantation	  Embryos	  
Multiparous Holstein cows (n= 10) were synchronized and superovulated as described 
16,17.  Artificial insemination using semen from one of three bulls with proven fertility was 
conducted at 12 and 24 hours post standing heat (Day 0).  Donor animals were sacrificed at 30 
hours, and 2-4 days after estrus to collect in vivo developed oocytes and embryos at the 2- to 16-
cell stages by oviductal flushing.  Early morulae, compact morulae and blastocysts were 
collected by routine non-surgical uterine flushing on Days 5, 6 and 7.  All oocytes and embryos 
were examined and staged under light microscopy.  Only morphologically intact embryos 
meeting the standards of Grade 1 by the International Embryo Transfer Society were included in 
this study.  Embryos were washed twice in D-PBS before frozen and stored individually in 
RNAlater (Ambion, Grand Island, NY) in liquid nitrogen. 
2.3.3.	  RNA	  Isolation,	  Linear	  Amplification,	  Library	  Construction	  and	  Sequencing	  
Following the reproducible procedures of RNA extraction and linear amplification from 
our previous study 18, we isolated total RNA from individual oocytes/embryos using TRIzol 
(Invitrogen, Grand Island, NY) and co-precipitated the RNA with linear acrylamide (Ambion).  
The quality of the total RNA was examined with the Aglient RNA 6000 Pico kit (Aglient 
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Technologies, Santa Clara, CA) using the Aglient Bioanalyzer 2100.  RNA was then amplified 
twice using the TargetAmp 2-round aminoallyl-aRNA amplification kit 1.0 (Epicentre, Madison, 
WI) according to the manufacturer’s instructions.  500 ng of amplified RNA (aRNA) were used 
to construct the sequencing library following the manufacturer’s instructions by SOLiD™ Total 
RNA-seq Kit (Life Technologies, Grand Island, NY).  After the sequencing library was prepared, 
we used an Agilent 2100 bioanlyzer to analyze the quality of the libraries.  The sequencing 
libraries were then barcoded, multiplexed, and sequenced on a 5500xl Genetic Analyzer at the 
Center for Applied Genetics and Technology, University of Connecticut.  We obtained 430 
million sequencing reads with a read length of 75-bp from 16 single oocytes and embryos.  The 
high correlation coefficients between samples of the same development stage demonstrated the 
reproducibility of the method (Table S2.1).   
2.3.4.	  Mapping,	  Assembly	  and	  Gene	  Expression	  Analysis	  	  
Sequencing adapters were trimmed using Cutadapt (https://code.google.com/p/cutadapt/) 
and sequencing reads of low quality were pre-filtered by FASTX-Toolkit before mapping 
(http://hannonlab.cshl.edu/fastx_toolkit/), using the options “fastq_quality_trimmer-Q 33-v-t20-l 
30-I”.  The quality of reads after filtering was examined using ‘fastQC’ 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).  Filtered reads were mapped to the 
Btau_4.6.1 assembly using Tophat 19.  Individual mapped reads were fed to Cufflinks 19 to 
construct transcriptome models.  Any novel genes and transcripts that did not fit the supplied 
gene models (NCBI RefGene) were also assembled.  Cuffmerge 19 was used to converge 
individual transcriptome to produce a master gene model.  Genes and transcripts mapped to 
uncertain chromosomes and contigs were eliminated.   
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The merged gene model and mapping result BAM files from each RNA-seq library were 
used to quantify the expression levels of all genes using the Python package, HTSeq 20.  A matrix 
of Pearson correlation coefficient was created using R, which was in turn used to create the 
heatmap.  Principle component analysis (PCA) was analyzed by using R.  Differentially 
expressed genes between two consecutive developmental stages were identified using default 
parameters in DESeq 20.  In each comparison, only genes whose sum of expression across all 
compared samples was greater than the 25th percentile were used. Genes were deemed 
differentially expressed between subsequent developmental stages if they showed a P-value of 
less than 0.05 (Negative Binomial Distribution).  Expression pattern clusters were generated by 
the K-means clustering algorithm using R.  For gene expression patterns, correlations between 
pattern indicators and tested genes were calculated.  P-values associated with correlations were 
also calculated and the Bonferroni correction was applied to adjust the P-value for multiple 
testing. Genes with adjusted P-value of less than 0.05 were considered to have followed the 
corresponding expression pattern. 
2.3.5.	  Detection	  of	  Co-­‐expressed	  Gene	  Modules	  
The R package for weighted gene co-expression network analysis (WGCNA) 21 was used 
to detect co-expressed gene modules.  A weighted gene co-expression network was first 
constructed, in which genes were nodes and connected with weighted edges.  The connection 
weights between any pair of two nodes i and j were computed by , 
where  is the correlation between the expression levels of nodes 𝑖 and 𝑗 across all stages. 
The topological overlap matrix W which measures the topological similarity of every two genes 
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where  with d indexing the nodes that connect to both i and j, and 
 with d indexing the nodes that connect to the node i. 
This topological overlap matrix has been shown to produce more biologically meaningful 
co-expressed gene clusters 22.  We computed the distance matrix D by .  A 
dendrogram of clusters was obtained by applying a hierarchical clustering algorithm 23 on the 
matrix D.  The dynamic cutting algorithm reported by Langfelder et al. 24 was used to cut the 
dendrogram to obtain the clusters of co-expressed genes.  
An eigengene was calculated for each cluster as the principal component that explained 
the largest variance of the data in the cluster.  It was a weighted sum of expression profiles of all 
genes in the cluster where the expression profile of a gene is a vector comprising the values of 
gene expression at the seven different stages.  The eigengene served as the representative of the 
gene expression profiles in the cluster.  Then, clusters whose eigengenes were interrelated with 
correlation of more than 0.7 were merged. The final clusters of genes were referred to as gene 
co-expression modules. 
2.3.6.	  Stage-­‐specific	  Module	  Identification	  
To detect modules whose eigengene showed high expression levels at a specific stage but 
low in others, we used a unit vector to indicate each stage.  In other words, the entry of this unit 
vector for the corresponding stage was one, and zero for the others.  We then computed the 
correlations between each stage-indicator vector and the eigengene of each module, which also 
yielded a P-value associated with each correlation.  Smaller P-values corresponded to more 
significant correlations.  If a module received P< 0.05 for the correlation at a particular stage, we 








	   22	  
 
2.3.7.	  Module	  Preservability/Reproducibility	  
We downloaded and mapped genes from two microarray datasets of the bovine 9,11, and 
two RNA-seq datasets of the human and mouse 25, as well as our own to the orthologous gene 
database (http://www.ncbi.nlm.nih.gov/homologene/).  After identifying the commonly 
expressed orthologs, the preservability of a module was measured by the Z statistics 26, which 
characterizes the density and connectivity of genes within a module to those in the validation 
dataset.  The function, module Preservation, in the WGCNA package was used to calculate the Z 
statistics.  The categories of preservation were defined as strong if Z>10, weak to moderate if 
2<Z<10, and no evidence of preservation if Z<2, as suggested by an early simulation study 26. 
2.3.8.	  Cross-­‐Species	  Module	  Overlapping	  Analysis	  
To study if the development of functional modules conserves across species, we 
compared the gene co-expression modules of the bovine, mouse and human.  The same module 
detection analysis was performed on the human and mouse datasets by Xue et al. 25.  The number 
of overlapping genes in any two modules each from a different species was counted.  Fisher’s 
exact test was conducted to show whether or not the degree of overlapping was simply due to a 
random chance, which yielded a P-value reflecting the statistical significance of the overlap.    
2.3.9.	  Module	  Hub	  Gene	  Identification	  and	  Validation	  
The membership of a gene in a module was measured by the correlation between that 
gene and the eigengene of the module.  Genes in a module that are highly correlated with the 
module eigengene are defined as hub genes for the module.  We used all genes with correlation 
to their module eigengene of greater than 0.9 as the hub genes.  To explore the connections 
among hub genes, we examined the top 200 connections of the top 150 hubgenes for each stage 
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specific module and visualized them in VisANT 27.  To validate the hub genes, we used the raw 
datasets from two previously published microarray studies in the bovine and one RNA-seq study 
in the human and mouse.  These data were subjected to WGCNA and stage-specific modules and 
lists of hub genes (kME > 0.9) were generated for each dataset.  We then determined the overlap 
of hub genes from each stage-specific module of the same developmental stage in different 
datasets. 
2.3.10.	  Gene	  Ontology	  Analysis	  
Functional annotation enrichment analysis for Gene Ontology (GO) was conducted by 
topGo package in R 28.  Database for Annotation, Visualization and Integrated Discovery 29 
Bioinformatics Resource 30 was used for pathway analyses.  We summarized all similar sub-GO 
terms and pathways into an overarching term, and P-values are shown for the representative 
terms. 
2.3.11.	  Validation	  of	  RNA-­‐seq	  Data	  
Quantitative real-time PCR (qRT-PCR) was performed to validate differential expression 
of 10 selected genes using embryos at the 4- and 8-cell stages (n = 3).  Among these, five genes 
(GATA6, GNB2L1, BAD, H2AFZ and NANOG) were up-regulated and five (GDP9, DNMT1, 
ZP2, STAT3 and OOER) were down-regulated between these two stages.  Amplified RNA from 
individual embryos was reverse transcribed to cDNA by SuperScript III Reverse Transcriptase 
(Invitrogen) and amplified with specific primers (Table S2).  The qRT-PCR was performed using 
SYBR Green PCR Master Mix (ABI) and the ABI 7500 Fast instrument.  Data were analyzed 
using the 7500 software version 2.0.2 provided with the instrument.  All values were normalized 
to the internal control, GAPDH.  The oocytes and embryos from 2-cell to blastocyst stages were 
pooled and used as the calibrator sample.  The relative gene expression values were calculated 
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using the 2-ΔΔCt method.  The mean for each stage was determined and compared for an overall 
fold change.  
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2.4.	  Results	  
2.4.1.	  Expression	  Profiles	  of	  Bovine	  In	  Vivo	  Matured	  Oocytes	  and	  Pre-­‐implantation	  Embryos	  
Using linearly amplified RNA from single oocytes/embryos, we obtained approximately 
430 million sequencing reads from duplicate samples of bovine in vivo pre-implantation 
embryos at 8 stages of development (Table S2.3). The raw FASTQ files and normalized read 
counts per gene are available at Gene Expression Omnibus (GEO) (www.ncbi.nlm.nih.gov/geo) 
under the accession number GSE59186.  High Pearson correlation coefficients were found 
among biological replicates of the same developmental stage (Figure 2.1A, Table S2.1), 
demonstrating the reproducibility of sample preparation and the sequencing technology.  Instead 
of hundreds of expressed genes reported earlier 8,11, the total numbers of detectable genes ranged 
from 11,488 to 12,729 from oocytes to blastocysts in our study with the use of RNA-seq (Table 
2.1 and Table S2.4).  For the first time, it is revealed that the bovine oocytes and early embryos 
expressed roughly 50% of the total estimated 22,000 genes in the bovine genome.   
Pearson correlation coefficients and principal component analyses (PCA) of all detected 
genes revealed two distinct segmentations of bovine pre-implantation development: the first 
from the oocyte to the 4-cell stage; and the second from the 8-cell to the blastocyst stage (Figure 
2.1A, B).  This segmentation demonstrated that EGA in bovine occurs between the 4- and 8-cell 
stages.  This timing concurred with the conclusion by Kues et al. 10,11 yet contrasted with those of 
all other studies 6-8,10.  Two additional segmentations were also worth-noting: the first from 
oocyte to 2-/4-cell stages, and the second from 8-cell/morula to the blastocyst stage (Figure 
2.1B). These divisions were likely results of dramatic degradation of maternal RNAs and early 
differentiation, respectively. 
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2.4.2.	  Differentially	  Expressed	  Genes	  during	  Bovine	  In	  Vivo	  Pre-­‐implantation	  Development	  
Although the total numbers of genes expressed by embryos of different stages did not 
vary much, the actual genes expressed during early development are dramatically different.  A 
total of 2,845 unique genes were identified to be differentially expressed between all consecutive 
stages of development (P < 0.05).  Similar to Pearson correlations on all detected genes, 
hierarchal clustering of the differentially expressed genes also partitioned pre-implantation 
development into two distinct clusters (Figure 2.1C), that from oocytes to 4-cell and from 8-cell 
to blastocysts, which confirms the timing of EGA.  The majority of the differentially expressed 
genes, 2,031, were found between the 4- to 8-cell stages, providing another confirmation that 
bovine EGA occurs at this transition.  Among these genes, 1,086 and 945 were down- and up-
regulated, respectively (Figure 2.1D).  The down-regulated genes are involved in reproduction, 
transcription and cell cycle regulations.  Conversely, the up-regulated genes, representing those 
transcribed from the embryonic genome, are involved in translation, ATP metabolic process as 
well as RNA processing (Table S2.5).  The second largest change in gene expression occurred 
from compact morula to blastocyst, with 829 genes differentially expressed (Figure 2.1D), 
suggesting that specific genes were necessary during the blastulation and early differentiation 
processes.  The biological processes significantly represented at this transition are including cell 
proliferation, transport and early differentiation (Table S2.6).  This burst of protein production 
and cell division may be necessary to prepare the blastocyst for the upcoming coordinated 
differentiation.   
Two minor EGA events were also identified in addition to the major EGA between the 4- 
and 8-cell stages: one from the oocyte to the 2-cell stage and the other from the 16-cell to the 
early morula stage, with 324 and 413 genes differentially expressed, respectively (Figure 2.1D).  
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Between the oocytes and the 2-cell embryos, 166 of the 324 differentially expressed genes were 
down-regulated.  These represent rapid degradation of the maternally stored transcripts.  Gene 
ontology analysis indicated significant over-representation of elements involved in cell cycle and 
mitosis II (Table S2.7), suggesting that the 2-cell embryos reprogrammed its cell cycle regulation 
from that of an arrested state to an active mode of cell division through changes of gene 
expression. The second minor EGA, between the 16-cell embryo and early morula, included 413 
differentially expressed genes (Figure 2.1D).  These genes may play important roles during the 
development of tight junctions and other processes of compaction.  Interestingly at this transition, 
we found a high enrichment of genes involved in stem cell maintenance and development, 
suggesting that genes for pluripotency are active long before the formation of the inner cell mass 
(Table S2.8).   
In spite of the aforementioned differences, there are also wide-spread similarities in the 
expression profiles between the 2- and 4-cell embryos, the 8- and 16-cell embryos, as well as the 
early and compact morulae (Figure 2.1D).  Specifically, only 97 genes were differentially 
expressed between the 2- and 4-cell embryos (Table S2.9).  Moreover, among the more than 
11,000 genes commonly expressed by both the 8- and 16-cell embryos, only 236 genes were 
differentially expressed (Table S2.10).  Likewise, as few as 187 differentially expressed genes 
were found among the 10,843 commonly expressed genes between the early and compact 
morulae (Table S2.11).   
To confirm the throughput results from RNA-seq, we performed quantitative real-time 
PCR (qRT-PCR) on 10 genes using in vivo embryos at the 4- and 8-cell stages (n = 3).  Among 
the selected genes, five (GATA6, GNB2L1, BAD, H2AFZ and NANOG) were up-regulated and 
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five (GDP9, DNMT1, ZP2, STAT3 and OOER) were down-regulated between these two stages.  
The qRT-PCR results substantiated those from RNA-seq (Table 2.2). 
2.4.3.	  Cluster	  Profiles	  of	  Differentially	  Expressed	  Genes	  
Although as many as 2,845 differentially expressed genes were identified, the pattern of 
their dynamic changes can be categorized into as few as 30 distinct clusters, labeled as Clusters 1 
to 30 (Figure S2.1; Table S2.12).  These clusters can be further assigned to four main groups of 
different dynamic patterns (Figure 2.2A).  The first group, including Clusters 1, 7, 9, 11, 13, 14, 
15, 17, 19, 22, 24, 27 and 29, represents genes that increased their expression levels during pre-
implantation.  All clusters in this group, with the exception of Clusters 11, 17 and 29 showed a 
dramatic increase at the 8-cell stage, indicating that they are transcribed from the embryonic 
genome.  Genes in these clusters include developmentally important ones such as GATA6, 
H2AFZ and NANOG.  Interestingly, genes in Clusters 11 and 29, including GATA3 and DSP, 
peaked at the blastocyst stage, suggesting their roles in blastocyst formation and early 
differentiation.  The second dynamic expression pattern, including Clusters 2, 5, 6, 8, 16, 18, 23, 
25, 26 and 28, represents genes that underwent an overall trend of decrease, suggesting 
continued degradation over the pre-implantation period.  Of special interest was a sharp decrease 
during the 4- to 8- cell transition in Clusters 6, 8 and 28, including oocyte-specific genes such as 
ZP2 and WEE2, demonstrating the lack of their involvement in embryo development.  The 
decrease of genes in this group may also be a pre-requisite for EGA.  The third expression 
pattern, including Clusters 4, 10, 20 and 21, contains genes that first increased and then 
decreased their expression levels.  Among these, Clusters 4 and 10 were up at the 8-cell stages 
and then declined, suggesting that these genes, such as BAD, APOPT1 and GNAT1, are only 
involved in the activation of the embryonic genome.  The last group, including Clusters 3, 12 and 
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30, represents genes that maintained relatively constant levels of expression throughout all stages 
studied.  Members from this group such as ATP1A1, ATP5F1 and RALB are involved in ion 
exchange, energy metabolism and signal transduction, suggesting their necessary roles during the 
entire process of pre-implantation development.  It is possible that some of the transcripts in this 
group were stable maternal RNAs that were never degraded while others were maintained by the 
early embryos.  Nonetheless, genes in this group are good loading control candidates for gene 
expression quantifications.   
In addition to the dynamic changes of gene expression, we also identified genes that are 
only enriched in one particular stage of development.  Specifically, a group of 119 genes were 
enriched only in the matured oocytes (Figure 2.2B, Table S2.13).  These transcripts were 
degraded after fertilization and remained suppressed during embryo development.  Apart from 
well-known/studied genes such as H1FOO, we identified many less known/not annotated genes 
such as LOC782175 and LOC536606.  These genes likely have limited roles in embryo 
development but are important in maintaining oocytes at the matured stage.  Further 
investigations into their roles in oocytes will enhance our understanding of the mechanism for 
meiotic arrest.  Another group of 234 genes, including DNMT3A, GATA3, CD9 and APOP1, 
were only enriched at the blastocyst stage (Figure 2.2B, Table S2.13).  Groups of genes were 
also found to be enriched in a short duration of development such as 310 during oocyte to 4-cell 
stage and 111 during 8-cell to blastocyst stage (Figure 2.2B, Table S2.13).   
2.4.4.	  Stage-­‐Specific	  and	  Cross-­‐Species	  Gene	  Expression	  Comparisons	  
In addition to analyzing changes of individual genes, we also examined gene-interactions 
by identifying modules of genes that were co-expressed.  Gene co-expression suggests their 
involvement in a common network of biological processes and functions 31.  Using weighted 
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gene co-expression network analysis (WGCNA) 21,22 we identified 17 distinct co-expression 
modules from 13,127 detected genes in our RNA-seq dataset (Figure 2.3A).  Twelve of these 
modules were stage-specific, i.e., these modules included genes that were overexpressed in a 
particular embryonic stage (Figure 2.3B, Table S2.14) and can be used to represent the 
corresponding stage of development.  Interestingly, analysis of the functions of genes in these 
modules revealed a sequential progression of stage-specific core gene networks.  It migrated 
from cell cycle in oocytes, to regulation of transcription in 4-cell embryos, to translation in 8-cell 
embryos, to stem cell development, maintenance and differentiation in morulae, and finally to 
cell proliferation and protein transport in blastocysts (Figure 2.3C).  Such coordinated changes of 
functional pathways are reflective of the little-known developmental programming.  
To explore the conservation and divergence of genes in the 12 stage-specific co-
expression modules within and across species, we downloaded the raw datasets from two 
previously published microarray studies of the bovine 9,11 and one recently published RNA-seq 
study of the human and mouse 25.  We then identified 8,103, 9,648 and 8,705 commonly 
expressed orthologs from bovine, humans and mice against our expression dataset.  The 
modulePreservation function of WGCNA was used to calculate the Z-statistics 32, which is a 
measure of the level and pattern of the connectivity of co-expressed genes.  As expected, the 12 
stage-specific modules were more significantly preserved within species than between species.  
Specifically, 5 out of the 12 bovine stage-specific modules were strongly (Z>10) preserved in the 
two published bovine microarray datasets of similar samples, another 5 were weak to moderately 
preserved (2<Z<10; Figure 4).  To date, there is only one published report 25 of cross-species 
comparisons using co-expression module data from human and mouse embryos.  Here we 
conducted the first study assessing the cross-species preservation using data from the three 
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available mammalian species, bovine, human and mouse.  Remarkably, most bovine stage-
specific modules were at least moderately preserved with those of the human but less with those 
of the mouse (Figure 2.4), suggesting that the human not only share more similarities with the 
bovine than with the mouse in genome sequences 33,34 but also in embryonic gene-expression 
patterns, and thus supporting the notion that bovine embryos are better models for human 
embryonic development than their mouse counterparts.   
To further characterize the conservation and variation of functional modules among 
species, we conducted module analysis using WGCNA on all detected genes, 14,766 and 13,879, 
respectively, from the RNA-seq datasets of the human and mouse [19].  We then compared the 
gene lists within the co-expressed modules of the three species.  Intriguingly, there are 
significant overlaps of genes in the bovine and human stage-specific modules (P<10-4; Figure 
2.5A, Table S2.15).  Of note, many genes in modules specific to the bovine oocyte, 4-cell, 8-cell 
and morula stages overlapped with those at the corresponding stages in humans.  For example, 
513 genes (P<10-60) overlapped between bovine and human oocytes alone.  These genes are 
involved in protein transport and cell cycle processes.  Similarly, highly significant overlap in 
module genes were observed during bovine and human late pre-implantation development (from 
8-cell to blastocyst) although some bovine stage-specific module genes can be found in multiple 
stages of human development, and vice versa (Figure 2.5A).  GO analysis of these overlapped 
module genes indicate significant over-representation of translation, RNA processing, generation 
of precursor metabolites and energy.  To our surprise, as many as 95 genes (P<10-9) in the bovine 
oocyte-specific module were found in the human 4-cell specific module, giving the apparent 
suggestion that the progression of embryo development in the bovine may be more rapid than 
that of humans.  This certainly contradicts with the established observations that bovine in vivo 
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embryo development is 8 days (oocytes to blastocysts) 35 while in humans it is 5 days 36.  One 
possible explanation to this is the diversity of embryonic programming, e.g., human embryos 
prepare for an invasive type of implantation while bovine embryos only attach to the uterus 37.  
Consistent with this possibility, GO analysis showed that these overlapped genes are related to 
signal transduction such as Ras and small GTPase signaling.  Together, these results suggested 
that bovine and humans share many core transcriptional programming, while differ in stage-
specificity and timing.  In the contrary, overlaps of genes between bovine and mouse stage-
specific modules were only observed before EGA and after morula formation (Figure 2.5B, 
Table S2.16).  For example, genes in the mouse oocyte-specific module overlapped significantly 
with those specific to bovine oocyte (P<10-10), 2-cell (P<10-2) and 4-cell stages (P<10-4).  
Meanwhile, genes specific to the mouse morula module significantly overlapped with those in 
the bovine 8-cell (P<10-3), compact morula (P<10-2) and blastocyst modules (P<10-12).  These 
results showed that mouse early and late pre-implantation genes are spread over a large period of 
the bovine development, consistent with the speed of embryo development in these two species. 
Collectively, our results show that the three mammalian species share more maternally 
deposited genes than those expressed after EGA.  Based on overlapped genes found in modules 
prior to EGA, bovine maternal detritus (RNA and protein) occurs later than that in the mouse but 
slightly earlier than that in the human, despite the longer bovine pre-implantation development. 
 
2.4.5.	  Identification,	  Visualization	  and	  Validation	  of	  Hub	  Genes	  
In order to identify genes that are central and highly-connected within the stage-specific 
modules, we conducted hub gene identification analysis.  Hub genes are highly correlated within 
the stage-specific modules and are conceptual and concrete representatives of the corresponding 
modules.  For each stage-specific module, we assigned all genes with Pearson correlation 
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coefficients greater than 0.9 as its hub genes (Table 2.3).  Furthermore, to explore the 
connections among hub genes, we examined the top 200 connections of the top 150 hub genes 
(highly correlated hub genes) for each stage-specific module and visualized them in VisANT 
(Table 2.4, Figure 2.6).  The full lists of these genes can be found in Table S16.  Although there 
are well-studied genes such as RALB in oocytes and DNMT3A in blastocysts, many of these 
genes are surprisingly either under-studied in embryonic development or un-annotated, and are 
thus less known/unknown in this process.  For example, LOC100137763 and LOC100849216 
were highly correlated, un-annotated hub genes in bovine mature oocytes and blastocysts, 
respectively (Table 2.4, Figure S2.2).  The highly correlated hub genes reported here are likely 
key players for their specific stage(s) of development and may function as “master regulators” of 
gene expression and stage transition in early development.  Further investigation into their 
identities and functions will greatly enhance our understanding of embryo development and our 
ability to manipulate embryos through biotechnologies. 
Cross-species analysis showed higher degrees of hub gene validation at the oocyte and 
blastocyst stages than at other stages.  For example, 32% (211 genes) and 48% (132 genes) of all 
hub genes in the oocyte_1 and blastocyst_1 modules, respectively, were validated in at least one 
dataset (Table 2.3, Table S2.16).  Fewer hub genes from the 2-cell to morula stage were 
successfully validated among species.  For example, only 4% and 8% of hub genes were 
validated at the 16-cell and 8-cell stages, respectively.  This low degree of validation reflected 
the divergence in the stage-specificity and timing of transcriptional programming.  Unexpectedly, 
we observed relatively low number/percentage of validated hub genes against the two previously 
published bovine datasets 9,11 (Table 2.3), likely because of the low coverage of microarray 
and/or the relatively low resolution of microarray data. 
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2.4.6.	  Pathways	  in	  Stage-­‐Specific	  Modules	  during	  Bovine	  Pre-­‐implantation	  Development	  
Pathway analysis revealed essential signaling and metabolic networks in embryonic 
development. We found more than 100 pathways involved in a sequential order relative to 
bovine pre-implantation development, most of which were represented in oocytes, major EGA 
transition (4-cell to 8-cell) and blastocysts (Table S2.17).  Components of cell cycle, RNA 
degradation and progesterone-mediated oocyte maturation pathways were highly enriched before 
the 4-cell stage, while ribosome, spliceosome and proteasome pathways were highly represented 
after the 8-cell stage.  Interestingly, pathways for oxidative phosphorylation, glycolysis, pyruvate 
metabolism, pentose phosphate and the citrate cycle (TCA cycle), which are critical not only for 
cell proliferation, but also for maintenance of pluripotency 38, were uniquely found in blastocysts.  
Additionally, many well-known pathways including MAPK, insulin, ErbB, Wnt, mTOR and 
TGF-beta signaling were operative in bovine before the 8-cell stage.  It is noteworthy that the 
most prominent changes in biological networks occurred from oocyte to 4-cell stage and 
blastocyst stage reflecting major functional transitions. 
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2.5.	  Discussion	  
The development of RNA sequencing technologies permits the study of gene regulation 
at an unprecedented level.  Here, we provide the first comprehensive description of gene 
activities during in vivo bovine embryonic development.  Most such studies had been conducted 
in the mouse 3,4,9,25,39.  However, mouse data have limited utility in human embryogenesis due to 
the large differences in gene expression and genome sequences as shown here and in earlier 
studies.  It is therefore important to establish the full expression profile database from an 
alternative species.  To date, all expression profile studies using bovine embryos were either 
conducted on in vitro embryos and/or using the microarray 8-13,40.  The few studies employing the 
RNA-seq technology involved blastocyst stage only 12,13,40 except for a recent RNA-seq study 
using in vitro embryos of multiple stages 10.  None of these reports, however, can be used as the 
complete “gold standards” for bovine embryo development because in vitro developed embryos 
have wide-spread gene expression anomalies and the DNA microarray technology limits gene 
detection to only those printed 8,11 in addition to variations from hybridization.  In this study, we 
applied the RNA-seq technology and revealed the transcriptomes of bovine in vivo pre-
implantation development in a very high-throughput and quantitative manner 14.  For the first 
time, the bovine matured oocytes and early embryos were shown to transcribe more than half of 
all bovine genes 34.   
 The timing of EGA in bovine has long been accepted to be between the 8- and 16-cell 
stages 6-8.  Using in vivo embryos and microarray containing approximately half of the bovine 
genome, Kues et al. proposed a new timing: between the 4- to 8-cell stage when the largest 
number of differentially expressed genes were found 11.  This result was confirmed in our study, 
also employing in vivo embryos but with all bovine expressed genes, and a more powerful 
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throughput technology, the RNA-seq.  However, two prior expression profile studies both using 
in vitro bovine embryos 8,10, maintained EGA at the 8- to 16-cell transition.  It has been shown 
through the use of RT-PCR that in vitro vs. in vivo embryos have step-wise differences in 
mRNA expression 41-43.  The difference in EGA timing among the aforementioned studies 
therefore further demonstrated that in vitro embryos are not suitable for establishing reference 
base of early development 44,45. 
Another important contribution of this study was the discovery of patterns of gene 
expression and their correlation to milestones of embryo development.  Four waves of 
transcriptional changes, between oocyte and 2-cell, between 4- and 8-cell, between 16-cell to 
early morula, and between compact morula to blastocyst, were each correlated to degradation of 
maternal RNA, major EGA, compaction and blastulation.  These, together with the identification 
of transient, stage-exclusive gene expression, provide directions of future research in 
embryogenesis.  
Also for the first time, we identified a number of stage-specific modules in bovine pre-
implantation development.  They not only represent the corresponding stage of embryogenesis, 
but reveal an interesting progression of core gene networks from cell cycle (oocyte), to 
regulation of transcription (4-cell), translation (8-cell), stem cell development, maintenance and 
differentiation (morula), and finally to cell proliferation and protein transport (blastocyst).  The 
identification of these orchestrated functional changes is among the first step to unveil the little-
known embryonic programming, and is important in enhancing our ability to improve assisted 
embryo biotechnologies such as embryo culture conditions.  For example, metabolic pathways 
unique to the bovine blastocysts, such as glycolysis, pyruvate metabolism and the pentose 
phosphate pathway, were identified.  Their presence is compatible with the “Warburg effect” 
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commonly found in cancer cells 46.  In this unique pattern of metabolism, glycolytic end products 
of glucose enter the pentose phosphate pathway instead of the TCA cycle 47.  Such variation 
from the somatic cells’ metabolism of the TCA cycle 47 not only allows for rapid cell 
proliferation, but also maintains the pluripotency of the bovine blastocyst 38.  Using this feature 
of the blastocyst, specific medium that encourages the pentose pathway may be developed to 
increase the proportion of good embryos in the in vitro production system.  
Our cross-species analysis demonstrated that human embryos share more similarity to 
those of the bovine than the mouse in transcriptomes during early embryonic development.  The 
expression profiles established in this report can therefore serve as a reference base for embryos 
from assisted technology from both cattle and humans.  Interestingly, gene expression profiles 
unveiled unique developmental programming of embryos in the three species analyzed.  At the 
superficial level differences in stage-specific modules appear to suggest that the bovine embryos 
progress slower than those of the mouse, but more rapid than those of the human.  While this is 
consistent with the in vivo embryo development between the mouse (3.5 days) 39 and the bovine 
(8 days) but not between the bovine and the human (5 days) 36.  The inconsistency of gene 
expression at similar stages of development between humans and bovine suggest that the early 
embryos employ different pathways to prepare themselves for the upcoming different process of 
implantation.  Moreover, our results showed that the three mammalian species share more 
maternally deposited genes than EGA-activated genes, concurring with the conclusion from a 
microarray study using the Bayesian clustering method 9 and again revealing species differences 
in the programming of embryo development.  
The cellular and molecular mechanisms governing mammalian pre-implantation 
development are still poorly understood.  Here we identified a number of hub genes that are 
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critical connectors to other expressed components within each embryonic stage of development 
in the bovine.  Their importance is “validated” by those that have been studied previously.  For 
example, RALB is a highly correlated hub gene in oocytes and has key roles in both bovine 48 and 
Xenopus embryo development 49.  It is also implicated in tumorigenesis and cell proliferation in 
mice 50.  Similarly, DNMT3A is a hub gene in blastocysts.  Studies in mice have demonstrated 
that DNMT3A is essential for de novo methylation and embryo development 51,52.  DNMT3A is 
also likely essential in the bovine blastulation process.  The observations that DNMT3A is 
significantly reduced in cloned bovine embryos 53 and that lower pregnancy/calving rates and 
abnormal development are commonplace in cloned fetuses are “functional validation” of the hub 
gene status for this important regulator of epigenetic modifications 54.   
Most identified hub genes, however, haven’t been studied or annotated, albeit their 
potential important roles in embryo development.  For example, LOC100137763 and 
LOC100849216 are highly correlated, yet un-annotated hub genes identified in oocytes and 
blastocysts, respectively.  The hub genes identified here represent the unprecedented 
opportunities and insights offered by the RNA-seq technology and bioinformatics.  Collectively, 
our inventories of all hub genes provide a valuable resource for further studies of the molecular 
mechanisms of pre-implantation development. 
Although we had to conduct linear RNA amplification in order to yield sufficient 
materials from single oocytes/embryos, the highly reproducible protocol employed here has been 
previously validated 18 and does not alter the abundance of RNA from the original samples 18.  
Readers are cautioned, however, that the in vivo oocytes/embryos used here were generated after 
superovulation treatment.  Although superovulation can affect gene expression of 
oocytes/embryos 55-58, it is frequently used in both research and production 59 because naturally 
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ovulated/developed oocytes/embryos from single-ovulatory, large animals such as cattle are not 
very feasible.  Nonetheless, the ultimate "gold standards" for gene expression during bovine pre-
implantation development can only be established using naturally ovulated/developed 
oocytes/embryos. 
Overall, this study provides comprehensive examinations of gene activities in in vivo 
bovine oocytes and pre-implantation embryos.  Cross-species analysis revealed that bovine pre-
implantation transcriptional profiles share more similarity to those of the human than the mice.  
The data presented here can be used to assess the impact of various assisted reproductive 
techniques in both bovine and human reproduction.   
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Table 2.1. The numbers of genes detected in bovine in vivo matured oocytes and each stage 















FPKM: fragments per kilobase of exon per million fragments mapped.  






Early morula 11670 
Compact morula 11910 
Blastocyst 11924 
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Table 2.2. Quantitative real-time RT-PCR (qRT-PCR) results of 10 selected genes between 
4- and 8-cell stage embryos. 
 
Comparison Gene symbol 
Log (fold change)  
RNA-Seq Expression 
Log (fold change)* 
qRT-PCR 
4- vs. 8-cell 
embryos 
GATA6 8.4 Up 10.6 
GNB2L1 8.2 Up 9.2 
BAD 6.4 Up 8.4 
H2AFZ 8.2 Up 10.3 
NANOG 11.5 Up 7.8 
GDP9 -3.8 Down -2.1 
DNMT1 -3.2 Down -2.6 
ZP2 -3.5 Down -4.4 
STAT3 -2.8 Down -2.3 
OOER -2.7 Down -2.0 
 
*Fold change is expressed as the ratios of the values of the 4-cell embryos (n=3) divided by 
those of the 8-cell embryos (n=3).  Real time RT-PCR results substantiated the differential 
gene expression patterns from RNA-seq.  
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Total No. of 
Genes 
/Module 
Total No. of 
Hub 
Genes/Module 
No. (%) Hub Genes 
(Validated in at 
Least One 
Dataset)* 
No. (%) Hub 
Genes (Validated 
in Kues et al. 
2008) 
Oocyte_1 2347 650 211 (32%) 117 (18%) 
Oocyte_2 815 125 24 (19%) 6 (5%) 
2-cell 444 112 12 (11%) 11 (10%) 
4-cell 1868 299 54 (18%) 19 (6%) 
8-cell_1 229 52 7 (13%) 5(10%) 
8-cell_2 640 172 14 (8%) 13 (8%) 
16-cell 247 27 1 (4%) 0 (0) 
Early morula 120 15 2 (13%) 2 (13%) 
Compact morula 311 41 7 (17%) 7 (17%) 
Blastocyst_1 1049 274 132 (48%) 116 (42%) 
Blastocyst_2 1366 366 59 (16%) 44 (12%) 
Blastocyst_3 1010 118 65 (55%) 44(37%) 
 
More than one modules were found for oocytes, 8-cell embryos and blastocysts. 
*: two bovine microarray 9,11, one human and one mouse RNA-seq datasets 25 were used.  
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Table 2.4. Highly correlated hub genes in bovine stage-specific modules.   
 
Stage-specific module Hub Genes 
Oocyte_1 SRPX, NAA30 
Oocyte_2 LOC100137763, PAX3, RALB, SMC1B, UNC13C, VANGL1 
2-cell CAPRIN2, LACC1, LOC616167, NLRP9, ZGLP1, POL 
4-cell CNTNAP2, TPM3 
8-cell LOC519952, LOC789391, LYSMD3, TBXAS1, THAP8 
16-cell ARL10, FAM84B, LOC790411, CCDC39 
Early morula LGALS9, STAC, LOC100140626 
Compact morula APOBR, GALNTL1, LRP8, PCDH10, RGS20, HOXA11, LOC781048 
Blastocyst_1 DNMT3A, ATP6V0A4, FAM115C, LGALS1, SLC9A3R1 
Blastocyst_2 BCAM, BPIFA1, LOC100849216, PLXNA3, SHROOM2, SLC16A7 
Blastocyst_3 EEF2, RPL10A, RPL38 
 
Multiple modules exist for oocytes and blastocysts.  
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Figure 2.1. Correlation and hierarchical analyses of transcriptomes of bovine in vivo developed 
oocytes and embryos. 
 (A). Heatmap of duplicate samples of the same stages of bovine embryonic 
development.  The color spectrum, ranging from red through white to blue, represents 
Pearson correlation coefficients ranging from 1 to 0.53, indicating high to low 
correlations.  All duplicate samples are highly correlated in Pearson coefficients 
demonstrating the reproducibility of the procedures. 
 (B). Principal component analysis (PCA) of the transcriptomes for seven stages of in 
vivo developed bovine embryos and oocytes.  Embryos from the same stage are shown 
by symbols of the same shape.  The arrows indicate the developmental direction of the 
embryos. PC1, PC2 and PC3 represent the top three dimensions of the differentially 
expressed genes among the preimplantation embryos.   
 (C). Hierarchical clustering of differentially expressed genes in in vivo developed bovine 
oocytes and embryos.  Two major clusters are shown, one consisted of the matured 
oocytes and embryos at the 2- and 4-cell stages.  The second cluster is consisted of 
embryos at the 8-, 16-cell, early morula, compact morula and blastocyst stages.  The clear 
separation of embryos into two groups demonstrated the timing of EGA in cattle at the 4- 
to 8-cell transition.  The color spectrum, ranging from red through yellow to blue, 
indicates normalized levels of gene expression. 
 (D). The numbers of differentially expressed genes in consecutive stages of bovine in 
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Figure 2.2. Distinct patterns and dynamics of gene expression during bovine in vivo pre-
implantation development. 
 (A). Representative clusters of expression dynamics during early development.  Genes 
were clustered to be increased (a), decreased (b), increased first and then decreased (c), 
and maintained relatively constant levels of expression (d). 
 (B). Identification of stage-specific/enriched genes by cluster analysis.  Groups of genes 
were found to be only expressed in oocytes and blastocysts, enriched in oocytes to 4-cell 
embryos, and 8-cell to blastocysts. The color spectrum, ranging from red to white, 
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Figure 2.3. Co-expression network analysis of bovine pre-implantation development. 
 (A). Hierarchical cluster tree showing modules of co-expressed genes identified by 
WGCNA.  A total of 17 co-expressed modules were found during bovine pre-
implantation development and were represented by branches and labeled by different 
colors to the right of the tree.  The height (X-axis) indicates levels of correlation. 
 (B). Heatmap of correlations (and corresponding P-values) between co-expressed 
modules and stage of development.  The color scheme, from blue through white to red, 
indicates the levels of correlation, from low to high.  The stage-specific modules 
identified are highly correlated (i.e. over-expressed) with distinct developmental stages 
(columns).  
 (C). Functional terms of stage-specific modules of co-expressed genes during bovine 
pre-implantation development.  A systematic and sequential changes in functions of co-
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Figure 2.4. Heatmap of module preservation of stage-specific gene co-expression among bovine, 
human and mouse oocytes and embryos.  Commonly expressed orthologs from the present study 
and those published previously as indicated on the X-axis, including two from bovine microarray 
studies 9,11 and an RNA-seq study in humans and mice 25 were identified and included.  The 
labels on the Y-axis are stage-specific modules of co-expressed genes.  The color scheme, from 
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Figure 2.5. Divergence of stage-specific gene co-expression among bovine, human and mouse 
oocytes and embryos. 
 (A). Heatmap of gene overlap between independently constructed bovine and human 
modules. The X- and Y-axes show human (n=9) and bovine stage-specific modules 
(n=12), respectively. Each cell contains the number of intersecting genes and the 
corresponding P-value (–log10) of the intersection.  Significant gene overlaps were found 
in nearly all stages of development between the human and bovine.  
 (B). Heatmap of gene overlap between independently constructed bovine and mouse 
modules. The X- and Y-axes show mouse (n=9) and bovine stage-specific modules 
(n=12), respectively. Each cell contains the number of intersecting genes and the 
corresponding P-value (–log10) of the intersection. Significant gene overlaps were only 
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Figure 2.6. Representative, highly correlated hub genes in bovine oocytes (NEAA30, SRFX) and 
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2.6.	  Supplementary	  Information	  
Table S2.1: Pearson correlation coefficients of duplicate bovine oocytes and embryos of the 








Table S2.2: Primers for real time qRT-PCR. 




(bp)	   Accession	  number	  
GATA6	   GAAGACCCAGGGAGAAGAGG	  
60	   152	   XM_002697727.1	  
	  
GCAGTTCTGGTTTCAGCACA	  
GNB2L1	   ATCTCACAACGGGCACTACC	  
60	   82	   XM_005209237.1	  
	  
CGGTTGTCAGAGGAGAAAGC	  
BAD	   GAGGATGAGCGACGAGTTTC	  
60	   119	   XM_005227186.1	  	  
	  
TCAACCAGGACTGGAGGAAG	  
H2AFZ	   GGTAAGGCTGGGAAGGACTC	  
60	   195	   NM_174809.2	  
	  
TTCAAGTACCTCTGCGGTGA	  
NANOG	   TAGGGAATCTTCACCCATGC	  
60	   204	   NM_001025344.1	  
	  
GGGACCGTCTCTTCCTTCTC	  
GDF9	   TCTGGTTCCAGCTTCATTCA	  
60	   200	   NM_174681.2	  
	  
CTGGAGAGCCATACCGATGT	  
DNMT1	   AGTGGGGGACTGTGTTTCTG	  
60	   199	   NM_182651.2	  
	  
CTGCATGTCCTCACACTCGT	  
ZP2	   ATGTATCTCCTGGGCAGACG	  
60	   200	   NM_173973.2	  
	  
GAGGCCATTTGCTATTTCCA	  
STAT3	   GGCCATCTTGAGCACTAAGC	   60	   206	   NM_001012671.2	  







Table S2.3: Summary of sequence read alignments to the reference genome. 
 
Stage Total reads Total mapped reads Mapped reads (%) Unmapped reads 
Oocyte #1 33,710,645 21,088,863 62.56 12,621,782 
Oocyte #2 27,340,216 19,042,322 69.65 8,297,894 
2-cell #1 24,604,359 12,271,310 49.87 12,333,049 
2-cell #2 48,722,568 27,125,963 55.67 21,596,605 
4-cell #1 25,442,215 13,834,869 54.38 11,607,346 
4-cell #2 35,703,218 19,172,270 53.70 16,530,948 
8-cell #1 18,788,513 12,270,210 65.31 6,518,303 
8-cell #2 21,290,475 14,667,771 68.89 6,622,704 
16-cell #1 29,993,256 18,528,062 61.77 11,465,194 
16-cell #2 13,799,407 7,732,281 56.03 6,067,126 
Early morula #1 23,813,659 15,778,377 66.26 8,035,282 
Early morula #2 32,821,097 21,557,091 65.68 11,264,006 
Compact Morula #1 20,822,446 12,464,723 59.86 8,357,723 
Compact Morula #2 26,674,386 17,364,014 65.10 9,310,372 
Blastocyst #1 23,772,162 15,102,607 63.53 8,669,555 
Blastocyst #2 21,989,584 13,098,519 59.57 8,891,065 






OOER	   AGGAATCCGCTGGTGTTCTT	  
60	   200	   NM_001077869.2	  
	  
TGGCTCAGAAGCACACTCTT	  
GAPDH	  4	   AGATGGTGAAGGTCGGAGTG	  
60	   117	   NM_001034034.2	  	  	   GAAGGTCAATGAAGGGGTCA	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Table S2.4: Normalized read counts (expression) of genes in bovine oocytes and embryos. 
http://www.ncbi.nlm.nih.gov/pubmed/25185836 
 
Table S2.5: Differentially expressed genes between the 4- and 8-cell embryos.  Spreadsheet 1: all 
differentially expressed genes; Spreadsheet 2: genes down-regulated; Spreadsheet 3: genes up-
regulated; Spreadsheet 4: GO analysis output of down-regulated genes; Spreadsheet 5: GO 
analysis output of up-regulated genes. 
http://www.ncbi.nlm.nih.gov/pubmed/25185836 
 
Table S2.6: Differentially expressed genes between compact morulae and blastocysts.  
Spreadsheet 1: all differentially expressed genes; Spreadsheet 2: genes down-regulated; 
Spreadsheet 3: genes up-regulated; Spreadsheet 4: GO analysis output of down-regulated genes; 
Spreadsheet 5: GO analysis output of up-regulated genes. 
http://www.ncbi.nlm.nih.gov/pubmed/25185836 
 
Table S2.7: Differentially expressed genes between oocytes and the 2-cell embryos.  Spreadsheet 
1: all differentially expressed genes; Spreadsheet 2: genes down-regulated; Spreadsheet 3: genes 
up-regulated; Spreadsheet 4: GO analysis output of down-regulated genes; Spreadsheet 5: GO 
analysis output of up-regulated genes. 
http://www.ncbi.nlm.nih.gov/pubmed/25185836 
 
Table S2.8: Differentially expressed genes between the 16-cell embryos and early morulae.   
Spreadsheet 1: all differentially expressed genes; Spreadsheet 2: genes down-regulated; 
Spreadsheet 3: genes up-regulated; Spreadsheet 4: GO analysis output of down-regulated genes; 
Spreadsheet 5: GO analysis output of up-regulated genes. 
http://www.ncbi.nlm.nih.gov/pubmed/25185836 
 
Table S2.9: Differentially expressed genes between the 2- and 4-cell embryos. Spreadsheet 1: all 
differentially expressed genes; Spreadsheet 2: genes down-regulated; Spreadsheet 3: genes up-
regulated; Spreadsheet 4: GO analysis output of down-regulated genes; Spreadsheet 5: GO 
analysis output of up-regulated genes. 
http://www.ncbi.nlm.nih.gov/pubmed/25185836 
 
Table S2.10: Differentially expressed genes between the 8- and 16-cell embryos.  Spreadsheet 1: 
all differentially expressed genes; Spreadsheet 2: genes down-regulated; Spreadsheet 3: genes 
up-regulated; Spreadsheet 4: GO analysis output of down-regulated genes; Spreadsheet 5: GO 
analysis output of up-regulated genes. 
http://www.ncbi.nlm.nih.gov/pubmed/25185836 
 
Table S2.11: Differentially expressed genes between the early and compact morulae.  
Spreadsheet 1: all differentially expressed genes; Spreadsheet 2: genes down-regulated; 
Spreadsheet 3: genes up-regulated; Spreadsheet 4: GO analysis output of down-regulated genes; 
Spreadsheet 5: GO analysis output of up-regulated genes. 
http://www.ncbi.nlm.nih.gov/pubmed/25185836 
 
Table S2.12: Distinct Clusters of gene expression patterns in bovine oocytes and embryos. 




Table S2.13: Stage-specific/enriched genes in bovine oocytes and pre-implantation embryos. 
http://www.ncbi.nlm.nih.gov/pubmed/25185836 
 
Table S2.14: Co-expressed genes in stage-specific modules of bovine oocytes and embryos. 
http://www.ncbi.nlm.nih.gov/pubmed/25185836 
 
Table S2.15: Gene expression overlap between species.  Spreadsheet 1: overlapped genes 




Table S2.16: All hub genes identified in bovine oocytes and pre-implantation embryos (genes in 
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Table S2.17: Functional pathways in stage-specific modules in bovine oocytes and embryos. 
 
Stage Pathways Count P Value 
Oocyte bta04520:Adherens junction 18 1.40E-04 
Oocyte hsa04360:Axon guidance 13 2.24E-04 
Oocyte bta04120:Ubiquitin mediated proteolysis 27 3.51E-04 
Oocyte bta04530:Tight junction 24 1.15E-03 
Oocyte bta04110:Cell cycle 24 1.29E-03 
Oocyte hsa05200:Pathways in cancer 20 1.74E-03 
Oocyte bta04012:ErbB signaling pathway 17 2.62E-03 
Oocyte bta04114:Oocyte meiosis 21 3.30E-03 
Oocyte bta03410:Base excision repair 9 6.07E-03 
Oocyte hsa04010:MAPK signaling pathway 16 7.13E-03 
Oocyte bta04540:Gap junction 16 7.49E-03 
Oocyte bta03018:RNA degradation 5 7.95E-03 
Oocyte bta04914:Progesterone-mediated oocyte maturation 16 9.45E-03 
Oocyte bta04320:Dorso-ventral axis formation 7 1.20E-02 
Oocyte bta05220:Chronic myeloid leukemia 14 2.29E-02 
Oocyte bta00130:Ubiquinone and other terpenoid-quinone biosynthesis 4 2.32E-02 
Oocyte hsa04510:Focal adhesion 12 2.41E-02 
Oocyte hsa05222:Small cell lung cancer 7 2.92E-02 
Oocyte bta04310:Wnt signaling pathway 22 2.98E-02 
Oocyte hsa04660:T cell receptor signaling pathway 8 3.06E-02 
Oocyte bta04722:Neurotrophin signaling pathway 19 3.23E-02 
Oocyte bta05216:Thyroid cancer 7 3.36E-02 
Oocyte bta05221:Acute myeloid leukemia 11 3.49E-02 
Oocyte hsa04810:Regulation of actin cytoskeleton 12 3.70E-02 
Oocyte bta05213:Endometrial cancer 10 3.71E-02 
Oocyte bta03420:Nucleotide excision repair 9 3.89E-02 
Oocyte bta05212:Pancreatic cancer 12 5.35E-02 
Oocyte bta04144:Endocytosis 25 5.81E-02 
Oocyte bta03020:RNA polymerase 3 5.96E-02 
Oocyte hsa04620:Toll-like receptor signaling pathway 7 6.23E-02 
Oocyte hsa04910:Insulin signaling pathway 8 8.24E-02 
Oocyte bta05211:Renal cell carcinoma 11 9.10E-02 
Oocyte bta00240:Pyrimidine metabolism 14 9.50E-02 
2-cell bta05014:Amyotrophic lateral sclerosis (ALS) 4 8.35E-02 
2-cell bta04810:Regulation of actin cytoskeleton 8 8.91E-02 
2-cell bta04621:NOD-like receptor signaling pathway 4 9.13E-02 
2-cell bta00534:Heparan sulfate biosynthesis 3 9.63E-02 
4-cell bta04320:Dorso-ventral axis formation 9 4.84E-05 
4-cell bta04120:Ubiquitin mediated proteolysis 22 3.51E-04 
4-cell bta04914:Progesterone-mediated oocyte maturation 16 4.07E-04 
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4-cell bta05215:Prostate cancer 16 6.09E-04 
4-cell bta05200:Pathways in cancer 37 9.98E-04 
4-cell bta04916:Melanogenesis 16 1.14E-03 
4-cell bta05210:Colorectal cancer 15 1.85E-03 
4-cell bta04910:Insulin signaling pathway 19 2.47E-03 
4-cell bta00230:Purine metabolism 14 3.76E-03 
4-cell bta04510:Focal adhesion 24 3.79E-03 
4-cell bta04144:Endocytosis 23 6.41E-03 
4-cell bta04150:mTOR signaling pathway 10 8.04E-03 
4-cell bta04114:Oocyte meiosis 16 8.42E-03 
4-cell bta04062:Chemokine signaling pathway 14 1.17E-02 
4-cell bta04664:Fc epsilon RI signaling pathway 12 1.19E-02 
4-cell bta04360:Axon guidance 16 1.26E-02 
4-cell bta05211:Renal cell carcinoma 11 1.40E-02 
4-cell bta04660:T cell receptor signaling pathway 15 1.40E-02 
4-cell bta04722:Neurotrophin signaling pathway 16 1.69E-02 
4-cell bta05213:Endometrial cancer 9 1.70E-02 
4-cell bta05212:Pancreatic cancer 11 1.71E-02 
4-cell bta04520:Adherens junction 11 1.71E-02 
4-cell bta04012:ErbB signaling pathway 12 1.90E-02 
4-cell bta04662:B cell receptor signaling pathway 11 2.08E-02 
4-cell bta05214:Glioma 10 2.25E-02 
4-cell bta04810:Regulation of actin cytoskeleton 22 2.37E-02 
4-cell bta04110:Cell cycle 16 2.39E-02 
4-cell bta04930:Type II diabetes mellitus 8 2.50E-02 
4-cell bta05217:Basal cell carcinoma 9 2.96E-02 
4-cell bta05221:Acute myeloid leukemia 9 3.60E-02 
4-cell bta04310:Wnt signaling pathway 17 3.85E-02 
4-cell bta04710:Circadian rhythm 4 4.67E-02 
4-cell bta05223:Non-small cell lung cancer 8 5.75E-02 
4-cell bta04070:Phosphatidylinositol signaling system 10 5.80E-02 
4-cell bta05410:Hypertrophic cardiomyopathy (HCM) 10 6.24E-02 
4-cell bta04370:VEGF signaling pathway 10 6.70E-02 
4-cell bta00562:Inositol phosphate metabolism 2 7.41E-02 
4-cell 
bta05412:Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) 2 8.86E-02 
4-cell bta03018:RNA degradation 8 8.06E-02 
4-cell bta04010:MAPK signaling pathway 25 8.74E-02 
4-cell bta04912:GnRH signaling pathway 11 9.13E-02 
4-cell bta05410:Hypertrophic cardiomyopathy (HCM) 2 9.77E-02 
4-cell bta04350:TGF-beta signaling pathway 10 9.90E-02 
8-cell bta03010:Ribosome 50 3.03E-42 
8-cell bta05016:Huntington's disease 30 1.11E-08 
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8-cell bta05012:Parkinson's disease 24 1.30E-07 
8-cell bta03050:Proteasome 14 2.21E-07 
8-cell bta05010:Alzheimer's disease 24 6.19E-06 
8-cell bta03040:Spliceosome 16 1.74E-03 
8-cell bta04260:Cardiac muscle contraction 11 2.74E-03 
8-cell bta03420:Nucleotide excision repair 10 9.53E-03 
8-cell bta00900:Terpenoid backbone biosynthesis 4 3.44E-02 
8-cell bta04320:Dorso-ventral axis formation 6 3.58E-02 
8-cell bta00970:Aminoacyl-tRNA biosynthesis 5 4.15E-02 
8-cell bta03020:RNA polymerase 5 5.13E-02 
8-cell bta04310:Wnt signaling pathway 20 5.24E-02 
8-cell bta04120:Ubiquitin mediated proteolysis 5 5.45E-02 
8-cell bta05213:Endometrial cancer 9 6.39E-02 
8-cell bta04623:Cytosolic DNA-sensing pathway 5 7.69E-02 
16-cell bta00280:Valine, leucine and isoleucine degradation 4 1.38E-02 
16-cell bta00330:Arginine and proline metabolism 4 2.47E-02 
16-cell bta05221:Acute myeloid leukemia 4 2.86E-02 
16-cell bta00471:D-Glutamine and D-glutamate metabolism 2 3.60E-02 
16-cell bta04640:Hematopoietic cell lineage 4 6.04E-02 
16-cell bta05322:Systemic lupus erythematosus 4 6.26E-02 
16-cell bta05200:Pathways in cancer 8 7.24E-02 
16-cell bta04810:Regulation of actin cytoskeleton 6 7.95E-02 
16-cell bta04512:ECM-receptor interaction 4 8.65E-02 
16-cell bta00072:Synthesis and degradation of ketone bodies 2 9.93E-02 
Early Morula bta00051:Fructose and mannose metabolism 2 9.85E-02 
Early Morula bta05211:Renal cell carcinoma 3 9.67E-02 
Early Morula bta04810:Regulation of actin cytoskeleton 7 3.85E-03 
Early Morula bta04660:T cell receptor signaling pathway 4 5.23E-02 
Early Morula bta04530:Tight junction 4 7.50E-02 
Compact 
Morula bta04530:Tight junction 5 8.63E-02 
Blastocyst bta03010:Ribosome 51 7.22E-40 
Blastocyst bta00190:Oxidative phosphorylation 57 9.83E-13 
Blastocyst bta05012:Parkinson's disease 48 2.78E-08 
Blastocyst bta03040:Spliceosome 26 7.95E-08 
Blastocyst bta05010:Alzheimer's disease 52 8.68E-07 
Blastocyst bta05016:Huntington's disease 54 2.20E-06 
Blastocyst bta04142:Lysosome 37 5.75E-05 
Blastocyst bta00510:N-Glycan biosynthesis 18 1.67E-04 
Blastocyst bta00520:Amino sugar and nucleotide sugar metabolism 16 2.46E-03 
Blastocyst bta00480:Glutathione metabolism 6 3.92E-03 
Blastocyst bta00970:Aminoacyl-tRNA biosynthesis 15 4.21E-03 
Blastocyst bta00563:Glycosylphosphatidylinositol(GPI)-anchor biosynthesis 10 4.55E-03 
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Blastocyst bta03050:Proteasome 15 1.08E-02 
Blastocyst bta00150:Androgen and estrogen metabolism 6 1.47E-02 
Blastocyst bta00010:Glycolysis / Gluconeogenesis 17 1.66E-02 
Blastocyst bta01040:Biosynthesis of unsaturated fatty acids 9 1.66E-02 
Blastocyst bta03410:Base excision repair 11 2.11E-02 
Blastocyst bta00020:Citrate cycle (TCA cycle) 11 2.66E-02 
Blastocyst bta03440:Homologous recombination 10 2.81E-02 
Blastocyst bta00140:Steroid hormone biosynthesis 6 5.09E-02 
Blastocyst bta00310:Lysine degradation 12 5.29E-02 
Blastocyst bta04260:Cardiac muscle contraction 18 5.59E-02 
Blastocyst bta00514:O-Mannosyl glycan biosynthesis 3 7.58E-02 
Blastocyst bta00980:Metabolism of xenobiotics by cytochrome P450 4 7.63E-02 
Blastocyst bta00620:Pyruvate metabolism 11 8.13E-02 
Blastocyst bta00983:Drug metabolism 10 9.10E-02 
Blastocyst bta04020:Calcium signaling pathway 8 9.29E-02 
Blastocyst bta02010:ABC transporters 11 9.45E-02 
Blastocyst bta00030:Pentose phosphate pathway 8 9.58E-02 
Blastocyst bta00750:Vitamin B6 metabolism 4 9.87E-02 
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Scripts for Bovine RNA-Seq Analysis: 
 
1. Data trimming and quality control 
1) Extract .fastq files from the solid raw files 
a. In the SOLiD output files, each lane contain (lane1 to 6) a .sqx file that needs to be decompress.  
Each lane subfolder also has a multiplex_x.txt file that list which samples are in that lane.  For this 
example, that data was present in lane 5 and 6.  And each of the samples, for example B2D, has a 
read file for lane 5 and for lane 6. 
b. To decompress the data, I used xsqtools that can be downloaded here: 
http://www.lifetechnologies.com/us/en/home/technical-resources/software-downloads/xsq-
software.html.  To decompress a lane, type ‘convertFromXSQ.sh -c 
/scratch/solid_data/lane5/Run6_ZJ_YT_rnaSEQ_2013_01_17_1_05.xsq`.  A few files will be 
extracted, but what we need from now on is the .fastq filed for each replicates.  You should also 
rename each files to a more convenient filename.  For example for B2D, I renamed the .fastq files 
from lane 5 and 6 to B2D_05.fastq and B2D_06.fastq. 
2) Quality filtering and adapter trimming 
a. For this, you need ‘cutadapt’ (http://code.google.com/p/cutadapt/) and ‘fastq_quality_trimmer’ 
(http://hannonlab.cshl.edu/fastx_toolkit/). 
b. To cut the universal adapter, type ‘cutadapt -a CGCCTTGGCCGTACAGCAG -n 4 B2D_05.fastq 
> tmp1.fastq’ 
c. To cut the 5’ primer, type ‘cutadapt -g 
CCACTACGCCTCCGCTTTCCTCTCTATGGGCAGTCGGTGAT -n 4 tmp1.fastq > tmp2.fastq’ 
d. To filter out  low quality bases, type ‘fastq_quality_trimmer -Q 33 -v -t 20 -l 30 -i tmp2.fastq -o 
B2D_05_filtered.fastq’ 
e. You can check the quality of your reads after filtering unsing ‘fastQC’ 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) 
3) Download and index (if needed) reference genomes (Bos Taurus version Baylor Btau_4.6.1/bostau7)) 
a. Because the cow genome was not indexed.  I downloaded the full genome from 
http://hgdownload.cse.ucsc.edu/goldenPath/bosTau7/bigZips/bosTau7.fa.gz.  Decompress the file 
and to index the genome with bowtie2 (see previous link), type ‘bowtie2-build bosTau7.fa BT7’.  
BT7 will be the name of the index. 
b. You will also need the gene model file (.gtf) file.  You will need also the gene model file (.gtf 
file).  These can be found on the UCSC web server under the 'Table' browser -> your organism 
build -> refseq track -> table refgene -> output .gtf format 
c. To map the genomes, I used ‘tophat2’ with the following command line (both lane 5 and 6 are 
mapped together.: tophat2 -G BT7.gtf -o tophat2_B2D /ref_genomes/BT7 B2D_05_filtered.fastq, 
B2D_06_filtered.fastq 
d. Repeat for all samples. 
4) Differential expression calculation with cuffdiff: 
a. cuffdiff mm10.gtf -o cuffdiff/ tophat2_B2D/accepted_hits.bam,/tophat2_A1D/accepted_hits.bam 
tophat2_B2J/accepted_hits.bam,/tophat2_A1J/accepted_hits.bam 
All these can be performed on Galaxy web server (https://main.g2.bx.psu.edu/).  Tutorial for RNAseq on galaxy 
here:  https://docs.uabgrid.uab.edu/wiki/UAB_Galaxy_RNA_Seq_Step_by_Step_Tutorial 
 
2. Mapping 
RNA-Seq reads were mapped to Btau 4.6.1 assembly by using Tophat. 





3. Transcriptome structure assembly 
Individual mapped bam files are feed to Cufflinks to construct transcriptome models with the guidiance (-g option in 
Cufflinks) of Btau 4.6.1 NCBI bovine gene model. 
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Example command line: cufflinks -p 16 -g 
/home/jol/igenomes/Bos_taurus/NCBI/Btau_4.6.1/Annotation/Genes/genes.gtf -N -o /home/jol/JZL_RNA-
Seq/cow/00C/1/ -L 00C_1 /home/jol/JZL_RNA-Seq/cow/00C/1/accepted_hits.bam 
The results of each of these Cufflinks runs will contain a transcript.gtf file, which records all known genes and 
transcripts from NCBI gene model as well as novel genes and transcripts Cufflinks builds. These individual 
transcript.gtf files (16 in total) are used to converge to a master gene model in the next step. 
 
4. Converge transcriptome structure from all replicates from all cell stages 
Cuffmerge was used to converge individual transcript.gtf files to a master gene/transcript model/ 
Example command line: cuffmerge -s 
/home/jol/igenomes/Bos_taurus/NCBI/Btau_4.6.1/Sequence/WholeGenomeFasta/genome.fa -g 
/home/jol/igenomes/Bos_taurus/NCBI/Btau_4.6.1/Annotation/Genes/genes.gtf -p 16 ./assemblies.txt 
The output of this Cuffmerge step is a merged.gtf file containing all known genes from NCBI as well as novel genes 
and transcripts built from the RNA-Seq data. 
Then genes and transcrips mapped to uncertain chromosomes and contigs (i.e. chrUN) are filered out. The results 
are stored in filtered_merged.gtf after this filtering. 
 
5. Quantify gene expression levels 
The merged gene model and mapping result bam files from each RNA-Seq libraries are used to quantify the 
expression level of all genes (on gene level). This is achieved by using a Python package called HTSeq (http://www-
huber.embl.de/users/anders/HTSeq/doc/count.html#count). 
Example command line: python -m HTSeq.scripts.count -m intersection-nonempty -i gene_id /home/jol/JZL_RNA-
Seq/cow/00C/1/accepted_hits.sam filtered_merged.gtf > 00C_1_merged_gn_readCounts.txt 
 
6. Differential gene expression analyses 
The files containing read counts for genes were used as input to DESeq (a R package) to perform differential gene 
expression analysis. Detailed procedures are recorded in the R log file. Please note, a number of DE analyses were 
performed by using appropriate read counts files depending on the compared cell stages, and in each comparison, 
only genes with sum of expression across all compared samples greater than 25% percentile were used in the 




rna_exp <- read.table(file = 'E:/project/embryo_develop/expr/data/bull_expression.txt', header = TRUE, sep = '\t') 
datExpr1 <- cbind(data.frame(gene = rna_exp$gene_name), rna_exp[, 2:(ncol(rna_exp) - 1)]) # 27393 
datExpr2 <- datExpr1 
# remove genes that had no expression at any stage 
datExpr2 <- datExpr2[apply(datExpr2[, 2:ncol(datExpr2)], 1, function(x){if(length(which(x == 0)) == length(x)) 
return(FALSE) else return(TRUE)}), ] # 18318 genes 
datExpr3 <- t(datExpr2[, 2:ncol(datExpr2)]) 
pca_rs <- prcomp(datExpr3, scale = T) 
color <- c("blue4", "blue4", "chartreuse4", "chartreuse4", "firebrick1", "firebrick1", "darkviolet", "darkviolet", 
"lightgreen", "lightgreen", "deeppink", "deeppink", "burlywood4", "burlywood4", "darkgreen", "darkgreen") 
pch <- c(15, 15, 16, 16, 17, 17, 18, 18, 15, 15, 16, 16, 17, 17, 18, 18) 
scatterplot3d(pca_rs$x[, 1:3], color = color, pch = pch) 
legend(x=-2,y=5,c("Oocyte","2-cell","4-cell", "8-cell", "16-cell", "32-cell", "Compact Morula", 
"Blastocyst"),cex=.8, pch=pch[c(1, 3, 5, 7, 9, 11, 13, 15)], col=color[c(1, 3, 5, 7, 9, 11, 13, 15)]) 
pc1 <- pca_rs$x[, 1] 
pc2 <- pca_rs$x[, 2] 
plot(pc1, pc2, col="white", xlab="PC1", ylab="PC2") 
points(pc1[1:2], pc2[1:2], col="blue4", pch=15) 
points(pc1[3:4], pc2[3:4], col="chartreuse4", pch=16) 
points(pc1[5:6], pc2[5:6], col="firebrick1", pch=17) 
points(pc1[7:8], pc2[7:8], col="darkviolet", pch=18) 
points(pc1[9:10], pc2[9:10], col="lightgreen", pch=15) 
points(pc1[11:12], pc2[11:12], col="deeppink", pch=16) 
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points(pc1[13:14], pc2[13:14], col="burlywood4", pch=17) 
points(pc1[15:16], pc2[15:16], col="darkgreen", pch=18) 
legend(x=-50,y=130,c("Oocyte","2-cell","4-cell", "8-cell", "16-cell", "32-cell", "Compact Morula", 




library(DESeq), library(ggplot2), library("RColorBrewer"), library("gplots"), library(reshape), library(pheatmap), 
library(cluster) 
read.table("geneIDTogeneName_uniq.txt", sep=" ", header=F) -> gene.name 
rownames(gene.name) <- gene.name$V1 
Take Comparison 1 as example. 




comparison1.conditions <- c("00C","00C","2C","2C") 
comparison1.sample <- data.frame(cbind(comparison1.sampleID, comparison1.files, comparison1.conditions)) 
comparison1.cds <- newCountDataSetFromHTSeqCount(comparison1.sample, ".") 
use <- (rowSums(counts(comparison1.cds)) >= 1) 
comparison1.cds <- comparison1.cds[use, ] 
use <- (rowSums(counts(comparison1.cds)) > quantile(rowSums(counts(comparison1.cds)), probs=0.25)) 
comparison1.cds <- comparison1.cds[use, ] 
comparison1.cds <- estimateSizeFactors(comparison1.cds) 
comparison1.cds <- estimateDispersions(comparison1.cds) 
plotDispEsts(comparison1.cds) 
comparison1.res <- nbinomTest(comparison1.cds, "00C", "2C") 
plotMA(comparison1.res) 
hist(comparison1.res$pval, breaks=100, col="skyblue", border="slateblue", main="") 
colnames(comparison1.res) <- c("id", "baseMean", "00C", "2C", "foldChange", "log2FoldChange", "pval", "padj") 
comparison1.DE <- comparison1.res[comparison1.res$pval <= 0.05, ] 
comparison1.DE$gene.name <- gene.name[as.vector(comparison1.DE$id), 2] 
write.table(comparison1.DE, "comparison1_DE.txt", quote=F, sep="\t", row.names=F) 
comparison1.vsd <- varianceStabilizingTransformation(comparison1.cds) 
select <- which(comparison1.res$pval <= 0.05) 
hmcol = colorRampPalette(brewer.pal(9, "GnBu"))(100) 
heatmap.2(exprs(comparison1.vsd)[select,], col = hmcol, trace="none", margin=c(10, 6)) 













total.sample <- data.frame(cbind(total.sampleID, total.files, total.conditions)) 
total.cds <- newCountDataSetFromHTSeqCount(total.sample, "./") 
use <- (rowSums(counts(total.cds)) > quantile(rowSums(counts(total.cds)), probs=0.25)) 
#total.cds <- total.cds[use, ] 
total.cds <- estimateSizeFactors(total.cds) 
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cor(counts(total.cds, normalized=T)) -> m pheatmap(m, color = colorRampPalette(c("navy", "white", 
"firebrick3"))(50), fontsize=14) counts(total.cds, normalized=T) -> total.expression 










total.conditions <- c("00C","00C","2C","4C","4C","8C","8C","16C","16C","32C","32C","CM","CM","BL","BL") 
total.sample <- data.frame(cbind(total.sampleID, total.files, total.conditions)) 
total.cds <- newCountDataSetFromHTSeqCount(total.sample, "./") 
use <- (rowSums(counts(total.cds)) > quantile(rowSums(counts(total.cds)), probs=0.25)) 
#total.cds <- total.cds[use, ] 
total.cds <- estimateSizeFactors(total.cds) 
cor(counts(total.cds, normalized=T)) -> m 
pheatmap(m, color = colorRampPalette(c("navy", "white", "firebrick3"))(50), fontsize=14) 
counts(total.cds, normalized=T) -> total.expression 
total.expression.df <- data.frame(total.expression) 
colnames(total.expression.df) <- total.sampleID 
total.expression.df$gene_name <- gene.name[rownames(total.expression.df), 2] 
write.table(total.expression.df, "Total_expression.txt", sep="\t", row.names=T, col.names=T, quote=F) 













total.sample <- data.frame(cbind(total.sampleID, total.files, total.conditions)) 
total.cds <- newCountDataSetFromHTSeqCount(total.sample, "./") 
#use <- (rowSums(counts(total.cds)) > quantile(rowSums(counts(total.cds)), probs=0.25)) 
#total.cds <- total.cds[use, ] 
# Variance Stablization Transformation 
total.cds.blind <- estimateSizeFactors(total.cds) 
total.cds.blind <- estimateDispersions(total.cds.blind, method="blind") 
pairs(counts(total.cds.blind, normalized=T), upper.panel=panel.cor) 
pairs(log10(counts(total.cds.blind, normalized=T)+1), upper.panel=panel.cor) 
total.vsd.blind <- varianceStabilizingTransformation(total.cds.blind) 
select <- order(rowMeans(counts(total.cds.blind)), decreasing=T)[1:300] 
hmcol = colorRampPalette(c("Green","black","red"))(100) 
pheatmap(exprs(total.vsd.blind)[select, ], color=hmcol) 
pairs(exprs(total.vsd.blind), upper.panel=panel.cor) 
#dists <- as.matrix(dist(t(exprs(total.vsd.blind)))) 
#pheatmap(1-dists, color = colorRampPalette(c("navy", "white", "firebrick3"))(50), fontsize=14) 
#pheatmap(cor(exprs(total.vsd.blind)), color = colorRampPalette(c("navy", "white", "firebrick3"))(50), fontsize=14) 
# Focus on DE genes in 00C, 2C, 4C, 8C, CM and BL 
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t <- 
unique(sort(c(as.vector(comparison1.DE$id),as.vector(comparison2.DE$id),as.vector(comparison3.DE$id),as.vecto
r(comparison6.DE$id),as.vector(comparison7.DE$id)))) # length of t is 2952 
pheatmap(exprs(total.vsd.blind)[t, ], color = colorRampPalette(c("navy", "white", "firebrick3"))(50), fontsize=14) 
pheatmap(exprs(total.vsd.blind)[t, c(1:8,13:16)], color = colorRampPalette(c("navy", "white", "firebrick3"))(50), 
fontsize=14) 




colnames(m) <- c("00C", "2C", "4C", "8C", "16C", "32C", "CM", "BL") 
pheatmap(cor(m), color = colorRampPalette(c("navy", "white", "firebrick3"))(50), fontsize=14) # This heatmap 
makes best sense 
pheatmap(m[t, ], color = colorRampPalette(c("navy", "white", "firebrick3"))(50), fontsize=14) 
pheatmap(m[t, c(1,2,4,7,8)], color = colorRampPalette(c("navy", "white", "firebrick3"))(50), fontsize=14) 
# Try hclust, maybe should use pam() 
# hc <- hclust(dist(d)) 
# clusters <- cutree(hc, k=30) 
# mat <- melt(d) 
# Cluster.ID <- factor(rep(as.vector(clusters), 5), levels=as.character(1:max(clusters))) 
# mat <- cbind(mat, Cluster.ID) 
# ggplot(mat, aes(X2, value, group=X1, color=Cluster.ID)) + geom_line() + 
scale_x_discrete(limits=c("00C","2C","8C","CM","BL")) + xlab("") + ylab("expression") + 
scale_color_discrete(name="Cluster", breaks=as.character(1:30)) + facet_wrap(~Cluster.ID, nrow=5) 
# ggplot(mat, aes(X2, value, group=X1, color=Cluster.ID)) + geom_line() + stat_summary(aes(x=X2, y=value, 
group=1), fun.data=mean_cl_boot, color="black", fill="black", alpha=0.2, size=1.1, geom="smooth") + 
scale_x_discrete(limits=c("00C","2C","8C","CM","BL")) + xlab("") + ylab("expression") + 
scale_color_discrete(name="Cluster", breaks=as.character(1:30)) + facet_wrap(~Cluster.ID, nrow=5) 
# Now try to cluster the 2952 DE genes 
d <- m[t, c(1,2,3,4,7,8)] 
#kmeans(d, centers=30, iter.max=100) -> k 
pam(d, k=30) -> k # this is a better clustering algorithm 
mat <- melt(d) 
Cluster.ID <- factor(rep(as.vector(k$cluster), 6), levels=as.character(1:max(k$cluster))) 
mat <- cbind(mat, Cluster.ID) 
ggplot(mat, aes(X2, value, group=X1, color=Cluster.ID)) + geom_line() + stat_summary(aes(x=X2, y=value, 
group=1), fun.data=mean_cl_boot, color="black", fill="black", alpha=0.2, size=1.1, geom="smooth") + 
scale_x_discrete(limits=c("00C","2C","4C","8C","CM","BL")) + xlab("") + ylab("expression") + 
scale_color_discrete(name="Cluster", breaks=as.character(1:30)) + facet_wrap(~Cluster.ID, nrow=5) 
 
9. GO enrichment anaylses for each cluster (30 clusters in total) 
library(topGO) 
library(Rgraphviz) 
# Prepare gene universe and GO annotation relationship 
symbol2go <- read.table("symbol2go_cow.txt", header=F, sep="\t") 
symbol2go$V1 <- as.character(symbol2go$V1) 
symbol2go$V2 <- as.character(symbol2go$V2) 
aggregate(symbol2go, by=list(symbol2go$V1), FUN=c) -> symbol2go.list 
background.genes <- as.vector(unique(gene.name[names(k$cluster), 2])) 
symbol2go.list[,c(1,3)] -> symbol2go.list 
rownames(symbol2go.list) <- symbol2go.list$Group.1 
colnames(symbol2go.list) <- c("gene", "go_id") 
symbol2go.list <- symbol2go.list[background.genes, ] 
gene2go <- as.list(symbol2go.list$go_id) 
names(gene2go) <- symbol2go.list$gene 
## For 1 cluster 
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# No test can be done for cluster 17 
for(x in c(1:16,18:30)){ 
    print(c("Cluster", x)) 
    names(which(k$cluster==x)) -> tracking.ids 
    test.genes <- as.vector(unique(gene.name[tracking.ids, 2])) 
    geneList <- factor(as.integer(background.genes %in% test.genes)) 
    #geneList <- factor(as.integer(names(gene2go) %in% test.genes)) 
    names(geneList) <- names(gene2go) 
    GOdata.BP <- new("topGOdata", ontology = "BP", allGenes = geneList, annot = annFUN.gene2GO, gene2GO = 
gene2go) 
test.stat <- new("classicCount", testStatistic = GOFisherTest, name = "Fisher test") 
resultFisher <- getSigGroups(GOdata.BP, test.stat) 
    GenTable(GOdata.BP, classic=resultFisher, topNodes=1000, numChar=500) -> BP.result 
    BP.result <- BP.result[BP.result$classic <= 0.01, ] 
    significant.genes <- vector() 
        for(i in 1:dim(BP.result)[1]){ 
            term <- BP.result[i, "GO.ID"] 
            annotated <- genesInTerm(GOdata.BP, term)[[1]] 
            significant <- intersect(annotated, test.genes) 
            significant.genes[i] <- paste(significant, collapse=",") 
        } 
    cbind(BP.result, significant.genes) -> BP.result 
    #BP.result <- BP.result[which(p.adjust(BP.result[,"classic"],method="bonferroni")<=0.05),] 
    #ggplot(BP.result, aes(Term, -log10(as.numeric(BP.result$classic)))) + geom_bar(stat="identity") + 
theme(axis.text.x  = element_text(angle=90, vjust=0.5)) + scale_y_continuous(name="-log10(P-value)") + 
scale_x_discrete(limits=BP.result$Term) 
    prefix <- paste("Cluster", x, sep="_") 
    printGraph(GOdata.BP, resultFisher, firstSigNodes = 30, fn.prefix = prefix, useInfo = "def", pdfSW = TRUE) 
    fn <- paste(x, "Cluster_GO.txt", sep="_") 
    write.table(BP.result, file=fn, quote=F, row.names=F, sep="\t") 
} 
# Get genes in each cluster and their expression levels 
for(x in 1:30){ 
counts(total.cds.blind, normalized=T)[names(which(k$cluster==x)),] -> count.table 
cbind(as.vector(gene.name[names(which(k$cluster==x)),2]), count.table) -> count.table 
colnames(count.table)[1] <- "gene" 
fn <- paste(x, "Cluster_expression.txt", sep="_") 
write.table(count.table, file=fn, quote=F, row.names=T, sep="\t") 
} 
# Without VST 
total.cds <- estimateSizeFactors(total.cds) 
counts(total.cds, normalized=T) -> total.expression 
cbind(apply(total.expression[,1:2], 1, mean),apply(total.expression[,3:4], 1, mean),apply(total.expression[,5:6], 1, 
mean),apply(total.expression[,7:8], 1, mean),apply(total.expression[,9:10], 1, mean),apply(total.expression[,11:12], 
1, mean),apply(total.expression[,13:14], 1, mean),apply(total.expression[,15:16], 1, mean)) -> total.expression 
colnames(total.expression) <- c("00C", "2C", "4C", "8C", "16C", "32C", "CM", "BL") 
cor(total.expression) -> m 
pheatmap(m, color = colorRampPalette(c("navy", "white", "firebrick3"))(50), fontsize=14) 




b <- c("2C vs 00C", "4C vs 2C", "8C vs 4C", "16C vs 8C", "32C vs 16C", "CM vs 32C", "BL vs CM") 
data.frame(a,b) -> d 
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ggplot(d, aes(factor(b), a)) + geom_bar(stat="identity", width=0.6, fill="skyblue") + scale_x_discrete(limits=d$b, 
name="Developmental stages compared") + scale_y_continuous(name="No. of differentially expressed genes (P-
value <= 0.05)") + theme_bw() 
# t <- 
unique(sort(c(as.vector(comparison1.DE$id),as.vector(comparison3.DE$id),as.vector(comparison6.DE$id),as.vecto
r(comparison7.DE$id)))) 
# total.expression[t, ] -> total.DE 
# total.DE <- total.DE[, c(1,2,4,7,8)] 
# rownames(comparison1.res) <- comparison1.res$id 
# rownames(comparison2.res) <- comparison2.res$id 
# rownames(comparison3.res) <- comparison3.res$id 
# rownames(comparison4.res) <- comparison4.res$id 
# rownames(comparison5.res) <- comparison5.res$id 
# rownames(comparison6.res) <- comparison6.res$id 
# rownames(comparison7.res) <- comparison7.res$id 
# common.tested <- intersect(intersect(intersect(comparison1.res$id, comparison3.res$id), comparison6.res$id), 
comparison7.res$id) 
# common.DE <- intersect(common.tested, t) 
# common.foldchange <- cbind(comparison1.res[common.DE, 6], comparison3.res[common.DE, 6], 
comparison6.res[common.DE, 6], comparison7.res[common.DE, 6]) 
# rownames(common.foldchange) <- common.DE 
# colnames(common.foldchange) <- c("2C vs 00C", "8C vs 4C", "CM vs 32C", "BL vs CM") 
# common.foldchange[intersect(which(is.infinite(common.foldchange)), which(common.foldchange > 0))] <- 10 
# common.foldchange[intersect(which(is.infinite(common.foldchange)), which(common.foldchange < 0))] <- -10 
# pheatmap(common.foldchange, cluster_cols=F) 
# kmeans(total.DE, centers=16, iter.max=50) -> k 
# total.DE[names(k$cluster[order(k$cluster)]),] -> reorder 
# pheatmap(log10(reorder+0.1), cluster_rows=F, cluster_cols=F, show_rownames=F, color = 
colorRampPalette(c("green", "black", "red"))(50)) 
# m <- melt(log10(total.DE+0.1)) 
# Cluster.ID <- factor(rep(as.vector(k$cluster), 5), levels=as.character(1:max(k$cluster))) 
# m <- cbind(m, Cluster.ID) 
# ggplot(m, aes(X2, value, group=X1, color=Cluster.ID)) + geom_line() + 
scale_x_discrete(limits=c("00C","2C","8C","CM","BL")) + xlab("") + ylab("log10(expression)") + 
scale_color_discrete(name="Cluster", breaks=as.character(1:20)) 
# ggplot(m, aes(X2, value, group=X1, color=Cluster.ID)) + geom_line() + 
scale_x_discrete(limits=c("00C","2C","8C","CM","BL")) + xlab("") + ylab("log10(expression)") + 
scale_color_discrete(name="Cluster", breaks=as.character(1:20)) + facet_wrap(~Cluster.ID, nrow=4) 
Gene ontology enrichment analysis, using all GO annotated genes as background 
library(topGO) 
library(Rgraphviz) 
# Prepare gene universe and GO annotation relationship 
symbol2go <- read.table("symbol2go_cow.txt", header=F, sep="\t") 
symbol2go$V1 <- as.character(symbol2go$V1) 
symbol2go$V2 <- as.character(symbol2go$V2) 
aggregate(symbol2go, by=list(symbol2go$V1), FUN=c) -> symbol2go.list 
symbol2go.list[,c(1,3)] -> symbol2go.list 
colnames(symbol2go.list) <- c("gene", "go_id") 
gene2go <- as.list(symbol2go.list$go_id) 
names(gene2go) <- symbol2go.list$gene 
 
## For comparison 1 up and down regulated genes 
test.genes.up <- as.vector(comparison1.DE[comparison1.DE$log2FoldChange >= 0, "gene.name"]) 
geneList <- factor(as.integer(names(gene2go) %in% test.genes.up)) 
names(geneList) <- names(gene2go) 
	   67	  
GOdata.BP <- new("topGOdata", ontology = "BP", allGenes = geneList, annot = annFUN.gene2GO, gene2GO = 
gene2go) 
test.stat <- new("classicCount", testStatistic = GOFisherTest, name = "Fisher test") 
resultFisher <- getSigGroups(GOdata.BP, test.stat) 
GenTable(GOdata.BP, classic=resultFisher, topNodes=38, numChar=500) -> BP.result 
#BP.result <- BP.result[which(p.adjust(BP.result[,"classic"],method="bonferroni")<=0.05),] 
ggplot(BP.result, aes(Term, -log10(as.numeric(BP.result$classic)))) + geom_bar(stat="identity") + theme(axis.text.x  
= element_text(angle=90, vjust=0.5)) + scale_y_continuous(name="-log10(P-value)") + 
scale_x_discrete(limits=BP.result$Term) 
printGraph(GOdata.BP, resultFisher, firstSigNodes = 20, fn.prefix = "Comparison1_up_BP", useInfo = "def", 
pdfSW = TRUE) 
write.table(BP.result, file="Comparison1_up_BP.txt", quote=F, row.names=F, sep="\t") 
test.genes.down <- as.vector(comparison1.DE[comparison1.DE$log2FoldChange < 0, "gene.name"]) 
geneList <- factor(as.integer(names(gene2go) %in% test.genes.down)) 
names(geneList) <- names(gene2go) 
GOdata.BP <- new("topGOdata", ontology = "BP", allGenes = geneList, annot = annFUN.gene2GO, gene2GO = 
gene2go) 
test.stat <- new("classicCount", testStatistic = GOFisherTest, name = "Fisher test") 
resultFisher <- getSigGroups(GOdata.BP, test.stat) 
GenTable(GOdata.BP, classic=resultFisher, topNodes=46, numChar=500) -> BP.result 
#BP.result <- BP.result[which(p.adjust(BP.result[,"classic"],method="bonferroni")<=0.05),] 
ggplot(BP.result, aes(Term, -log10(as.numeric(BP.result$classic)))) + geom_bar(stat="identity") + theme(axis.text.x  
= element_text(angle=90, vjust=0.5)) + scale_y_continuous(name="-log10(P-value)") + 
scale_x_discrete(limits=BP.result$Term) 
printGraph(GOdata.BP, resultFisher, firstSigNodes = 20, fn.prefix = "Comparison1_down_BP", useInfo = "def", 
pdfSW = TRUE) 





# The following setting is important, do not omit. 
options(stringsAsFactors = FALSE); 
# Allow multi-threading within WGCNA. This helps speed up certain calculations. 
# At present this call is necessary for the code to work. 
# Any error here may be ignored but you may want to update WGCNA if you see one. 
enableWGCNAThreads() 
rna_exp <- read.table(file = 'D:/other_people/jiang/bull_expression.txt', header = TRUE, sep = '\t') 
datExpr1 <- cbind(data.frame(gene = rna_exp$gene_name), rna_exp[, 2:(ncol(rna_exp) - 1)]) # 27393 
datExpr2 <- datExpr1 
# remove genes that had no expression at any stage 
datExpr2 <- datExpr2[apply(datExpr2[, 2:ncol(datExpr2)], 1, function(x){if(length(which(x == 0)) == length(x)) 
return(FALSE) else return(TRUE)}), ] # 18318 genes 
# collapse same gene 
row.names(datExpr2) <- 1:nrow(datExpr2) 
datExpr2_colps <- collapseRows(datExpr2[, 2:ncol(datExpr2)], datExpr2$gene, 1:nrow(datExpr2)) 
datExpr3 <- cbind(data.frame(gene = row.names(datExpr2_colps$datETcollapsed)), 
datExpr2_colps$datETcollapsed) 
row.names(datExpr3) <- 1:nrow(datExpr3) 
# remove the first 25% 
use <- (rowSums(datExpr3[, 2:ncol(datExpr3)]) > quantile(rowSums(datExpr3[, 2:ncol(datExpr3)]), probs=0.25)) 
datExpr3 <- datExpr3[use, ] # 13127 
write.csv(datExpr3, file = 'D:/other_people/jiang/bull_expression_collapsed.txt', row.names = FALSE) 
datExpr_merged <- data.frame(gene = datExpr3$gene) 
datExpr_merged <- cbind(datExpr_merged, ooc = apply(datExpr3[, 2:3], 1, mean)) 
datExpr_merged <- cbind(datExpr_merged, c2 = apply(datExpr3[, 4:5], 1, mean)) 
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datExpr_merged <- cbind(datExpr_merged, c4 = apply(datExpr3[, 6:7], 1, mean)) 
datExpr_merged <- cbind(datExpr_merged, c8 = apply(datExpr3[, 8:9], 1, mean)) 
datExpr_merged <- cbind(datExpr_merged, c16 = apply(datExpr3[, 10:11], 1, mean)) 
datExpr_merged <- cbind(datExpr_merged, c32 = apply(datExpr3[, 12:13], 1, mean)) 
datExpr_merged <- cbind(datExpr_merged, CM = apply(datExpr3[, 14:15], 1, mean)) 
datExpr_merged <- cbind(datExpr_merged, BL = apply(datExpr3[, 16:17], 1, mean)) 
datExpr <- t(datExpr3[, 2:ncol(datExpr3)]) 
tom <- TOMsimilarity((0.5 + 0.5 * cor(datExpr, use = 'p')) ^ 12) 
tree <- flashClust(as.dist(1 - tom), method = 'average') 
unmergedLabels = cutreeDynamic(dendro = tree, distM = 1-tom, deepSplit = 2, cutHeight = NULL, minClusterSize 
= 30, pamRespectsDendro = FALSE );  
unmergedColors = labels2colors(unmergedLabels) 
sizeGrWindow(8,6) 
plotDendroAndColors(tree, unmergedColors, "Dynamic Tree Cut", dendroLabels = FALSE, hang = 0.03, addGuide 
= TRUE, guideHang = 0.05) 
# compute module eigengenes  
ME <- moduleEigengenes(datExpr, unmergedColors) 
cor_ME <- cor(ME$eigengenes, use = 'p') # correlation among modules 
# merge highly correlated modules 
merge = mergeCloseModules(datExpr, unmergedLabels, MEs = ME, cutHeight = 0.3, verbose = 3) 
# Numeric module labels 
moduleLabels = merge$colors; 
# Convert labels to colors 
moduleColors = labels2colors(moduleLabels) 
# label - color map 
unique_lbls <- unique(moduleLabels) 
lbl_clr_map <- data.frame(label = unique_lbls, color = rep('', length(unique_lbls))) 
for (iLbl in 1:length(unique_lbls)) { 
lbl_clr_map$color[iLbl] <- moduleColors[moduleLabels == unique_lbls[iLbl]][1] 
} 
sizeGrWindow(9,6) 
plotDendroAndColors(tree, moduleColors, "Merged", dendroLabels = FALSE, hang = 0.03, addGuide = TRUE, 
guideHang = 0.05) 
bovine_module <- list() 
bovine_module$unmergedLabels <- unmergedLabels 
bovine_module$unmergedColors <- unmergedColors 
bovine_module$tree <- tree 
bovine_module$moduleLabels <- moduleLabels 
bovine_module$moduleColors <- moduleColors 
bovine_module$lbl_clr_map <- lbl_clr_map 
bovine_module$merge <- merge 
save(bovine_module, file = 'D:/other_people/jiang/rs/modules/unmerged2/module_bovine.RData') 
oocyte_indicator <- c(rep(1, 2), rep(0, 14)) 
c2_indicator <- c(rep(0, 2), rep(1, 2), rep(0, 12)) 
c4_indicator <- c(rep(0, 4), rep(1, 2), rep(0, 10)) 
c8_indicator <- c(rep(0, 6), rep(1, 2), rep(0, 8)) 
c16_indicator <- c(rep(0, 8), rep(1, 2), rep(0, 6)) 
c32_indicator <- c(rep(0, 10), rep(1, 2), rep(0, 4)) 
CM_indicator <- c(rep(0, 12), rep(1, 2), rep(0, 2)) 
BL_indicator <- c(rep(0, 14), rep(1, 2)) 
bovine_module$mudule_sage_cor <- corAndPvalue(merge$newMEs, cbind(oocyte_indicator, c2_indicator, 
c4_indicator, c8_indicator, c16_indicator, c32_indicator, CM_indicator, BL_indicator)) 
save(bovine_module, file = 'E:/project/embryo_develop/expr/rs/modules/unmerged2/module_bovine.RData') 
sizeGrWindow(9,9) 
# plotCor(cor_stage, new = FALSE) 
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colnames(bovine_module$mudule_sage_cor$cor) <- c('Oocyte', '2-cell', '4-cell', '8-cell', '16-cell', 'Early Morula', 
'Compact Morula', 'Blastocyst') 
pheatmap(bovine_module$mudule_sage_cor$cor[c(3, 4, 1, 2, 6, 5, 14, 17, 15, 8, 10, 9), ], cluster_rows = FALSE, 
cluster_cols = FALSE,display_numbers = TRUE, number_format = "%.2f") 
write.csv(bovine_module$mudule_sage_cor$cor[c(3, 4, 1, 2, 6, 5, 14, 17, 15, 8, 10, 9), ], file = 
'E:/project/embryo_develop/expr/rs/modules/unmerged2/cor_r.csv') 
write.csv(bovine_module$mudule_sage_cor$p[c(3, 4, 1, 2, 6, 5, 14, 17, 15, 8, 10, 9), ], file = 
'E:/project/embryo_develop/expr/rs/modules/unmerged2/cor_pv.csv') 
plot_modules = c(1, 15, 12, 54, 34, 6, 39, 13, 17, 29, 35, 18, 2, 4, 23, 53) 
for (iM in 1:length(plot_modules)) { 
module_expr <- datExpr3[bovine_module$moduleLabels == plot_modules[iM], ] 
module_expr_merged <- datExpr_merged[bovine_module$moduleLabels == plot_modules[iM], ] 
rowsum1 <- rowSums(module_expr[, 2:ncol(module_expr)]) 
use1 <- rowsum1 > quantile(rowsum1, probs = 0.1) & rowsum1 < quantile(rowsum1, probs = 0.9) 
#write.csv(module1_expr, file = 'D:/other_people/jiang/rs/modules/unmerged2/module1_expr.csv', row.names = 
FALSE) 
jpeg(paste('Y:/other_people/jiang/rs/modules/unmerged2/module', plot_modules[iM], '_heatmap.jpeg', sep = '')) 
pheatmap(log10(t(module_expr[use1, 2:ncol(module_expr)]) + 1), cluster_rows = FALSE, cluster_cols = FALSE) 
dev.off() 
jpeg(paste('Y:/other_people/jiang/rs/modules/unmerged2/module', plot_modules[iM], '_boxplot.jpeg', sep = '')) 
boxplot(log10(module_expr_merged[use1, 2:ncol(module_expr_merged)] + 1)) dev.off() 
} 
# line plot 
#plot_modules <- c(1, 12, 54, 34, 29, 35, 18, 2) 
plot_modules <- c(1, 15, 12, 54, 34, 6, 29, 35, 18, 2, 4, 23) 
plot_value <- matrix(rep(NA, length(plot_modules) * (ncol(datExpr_merged) - 1)), nrow = length(plot_modules)) 
for (iM in 1:length(plot_modules)) { 
module_expr <- datExpr3[bovine_module$moduleLabels == plot_modules[iM], ] 
module_expr_merged <- datExpr_merged[bovine_module$moduleLabels == plot_modules[iM], ] 
rowsum1 <- rowSums(module_expr[, 2:ncol(module_expr)]) 
use1 <- rowsum1 > quantile(rowsum1, probs = 0.1) & rowsum1 < quantile(rowsum1, probs = 0.9) 
plot_value[iM,] <- log10(colMeans(module_expr_merged[use1, 2:ncol(module_expr_merged)])) 
} 
rownames(plot_value) <- plot_modules 
#write.table(plot_value, file = 'D:/other_people/jiang/rs/modules/unmerged2/line_plot_value.csv', sep = ',', 
row.names = FALSE, col.names = FALSE) 
write.table(plot_value, file = 'D:/other_people/jiang/rs/modules/unmerged2/line_plot_value_ex.csv', sep = ',', 
col.names = FALSE) 
par(col = 'black', mfrow = c(1, 1)) 
plot(c(1, (ncol(module_expr_merged) - 1)), range(plot_value), type = 'n',  
main = 'Gene expression profiles of stage specific modules across different stages', xlab = 'Developemental stage', 
xaxt = 'n', ylab = 'log10 of expression value') 
colors <- rainbow(length(plot_modules)) 
linetype <- c(1:length(plot_modules)) 
plotchar <- seq(15, 15 + length(plot_modules), 1) 
for (iM in 1:length(plot_modules)) { 
lines(1:(ncol(module_expr_merged) - 1), plot_value[iM, ], type = 'b', lwd = 3, lty = linetype[iM], col = colors[iM], 
pch = plotchar[iM], xlab = '', xaxt = 'n') 
} 
x_lbls <- c('Oocyte', '2-cell', '4-cell', '8-cell', '16-cell', 'Early Morula', 'Compact Morula', 'Blastocyst') 
axis(1, at = 1:(ncol(module_expr_merged) - 1), labels = FALSE) 
text(x = 1:(ncol(module_expr_merged) - 1), labels = x_lbls, par("usr")[3] - 0.1 , srt = 45, pos = 1, xpd = TRUE) 
# add a legend 
legend(1, max(plot_value), c('Oocyte', '2-cell', '4-cell', '8-cell', '16-cell', 'Early Morula', 'Compact Morula', 
'Blastocyst'), cex=0.8, col=colors, font = 24, pch=plotchar, lty=linetype, title="Modules") 
# module 1 
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module1_expr <- datExpr3[bovine_module$moduleLabels == 1, ] 
module1_expr_merged <- datExpr_merged[bovine_module$moduleLabels == 1, ] 
rowsum1 <- rowSums(module1_expr[, 2:ncol(module1_expr)]) 
use1 <- rowsum1 > quantile(rowsum1, probs = 0.1) & rowsum1 < quantile(rowsum1, probs = 0.9) 
#write.csv(module1_expr, file = 'D:/other_people/jiang/rs/modules/unmerged2/module1_expr.csv', row.names = 
FALSE) 
pheatmap(log10(t(module1_expr[use1, 2:ncol(module1_expr)]) + 1), cluster_rows = FALSE, cluster_cols = 
FALSE) 
jpeg('Y:/other_people/jiang/rs/modules/unmerged2/module1_boxplot.jpeg') 
boxplot(log10(module1_expr_merged[use1, 2:ncol(module1_expr_merged)] + 1)) 
dev.off() 
# module 15 
module1_expr <- datExpr3[bovine_module$moduleLabels == 1, ] 
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3.1.	  Abstract	  
Twenty-six confirmed imprinted genes in the bovine were quantified in in vivo produced 
oocytes and embryos.  Eighteen were detectable and their transcriptional abundance were 
categorized into five patterns: largely decreased (MEST and PLAGL1); first decreased and then 
increased (CDKN1C and IGF2R); peaked at a specific stage (PHLDA2, SGCE, PEG10 and 
PEG3); low until peaked in blastocysts (GNAS, MEG3, DGAT1, ASCL2, NNAT, and NAP1L5); 
and finally constant low (DIRAS3, IGF2, H19 and RTL1).  A number of genes were expressed at 
surprisingly high levels.  For instance, the mRNAs for the paternally expressed MEST, and to a 
lesser extent PLAGL1, were highly abundant in oocytes and could only be expressed from the 
maternal allele.  On the contrary, GNAS and MEG3, both maternally expressed, were barely 
detectable in bovine oocytes but highly expressed in blastocysts, suggesting that their genomic 
imprints were not established/recognized until much later in development.  Furthermore, we 
compared these genes to their counterparts in mice, humans and pigs.  We found differences in 
the imprinting status, levels and dynamics of gene expression among these four species.  The 
data presented here will serve as a reference base for expression profiles of imprinted genes by 
embryos produced from assisted reproductive biotechnologies.  
 
Key words: Imprinted genes, Pre-implantation development, Bovine, Mouse, Human, Pig  
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3.2.	  Introduction	  
Genomic imprinting is a series of precisely regulated epigenetic processes that cause 
genes to be expressed in a parental-origin-specific manner in mammals 1.  Proper allelic 
expression of imprinted genes plays important roles in embryonic and placental development as 
well as in maternal behavior 2.  The exact numbers of total imprinted genes and their roles in 
mammalian development remain as open questions.  It is estimated that approximately 150 and 
100 imprinted genes are present in the mouse and human, respectively 
(http://igc.otago.ac.nz/Search.html and http://www.mousebook.org/imprinting-gene-list).  The 
identification of imprinted genes in farm species, however, lags behind, with a total of 28, 17, 
and 10 confirmed, imprinted genes in cattle, pigs, and sheep, respectively 3.   
The specific genes imprinted in each species can also be very different.  For example, 50 
imprinted genes in the mouse overlap with those in humans, and numerous genes imprinted in 
the mouse and/or human are not imprinted in the other species or in farm animals 3.  Moreover, 
the timing of imprinting activation during development is also species- and developmental stage-
specific.  Genomic imprinting is seen in mouse embryos as early as the two-cell stage, and by the 
blastocyst stage, monoallelic expression of most imprinted genes is observed 4.  On the contrary, 
the allelic expression status of most imprinted genes is not known in human embryos 5. To date, 
the onset of monoallelic expression of imprinted genes in farm species has not been examined 
systematically but occurs much later than the blastocyst stage in the bovine, ovine and porcine 6-
10.  
The exact nature of genetic imprints is still relatively uncertain.  It is known that genomic 
imprinting is regulated through epigenetic mechanisms, including allele-specific DNA 
methylation at differentially methylated regions established during gametogenesis and 
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embryogenesis 11 and maintained in subsequent cell divisions during pre-implantation 
development 12.  Changes in global DNA methylation in zygotes and early embryos from several 
species have been studied and found to differ dramatically.  For example, the male pronucleus is 
nearly completely demethylated in the mouse and rat, partial demethylated in cattle and goats, 
and minimally demethylated in sheep and pigs 13.  In addition to DNA methylation, imprinting 
regulation likely involves other epigenetic modifications and mechanisms such as histone 
modifications, chromatin architecture, and non-coding RNAs 3,12.   
Because imprints are established during gametogenesis and embryo development 14, 
environmental factors such as in vitro culture and manipulations of oocytes and embryos could 
affect their expression and these changes can last through the entire life of the animals 15.  
Increased incidences of imprinting disorders including large offspring syndrome (LOS) in 
ruminants and Beckwith-Wiedemann Syndrome (BWS) in humans have been reported in 
assisted reproductive technologies (ART) where in vitro culture of oocytes/embryos are 
conducted 16-20.  Because in vitro and in vivo embryos have step-wise differences in 
transcriptomes 21, qualitative and quantitative expression profiles of imprinted genes from in 
vivo pre-implantation embryos are essential gold standards for embryos produced from 
biotechnologies. 
To date, the expression of only a selected few imprinted genes have been characterized 
and shown to be regulated in a tissue- and/or developmental stage-specific manner across species 
including humans 22, porcine 10 and bovine 6.  Benefited from the most comprehensive RNA 
sequencing (RNA-seq) profiles of pre-implantation embryos from the pig 23, cattle 24, mouse 25 
and human 25,26 , we set forth to analyze the expression of 26 bovine imprinted genes in cattle 
and compared them across these four species during oocyte and embryo development.  Our data 
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provide important evidence for stage- and species-specific regulation of imprinting during pre-
implantation development. 
  
	   80	  
3.3.	  Methods	  
The expression profiles of bovine in vivo derived oocytes and pre-implantation embryos 
were characterized by RNA-seq and published recently 21.  Briefly two biological replicates of in 
vivo produced bovine oocytes and embryos at the 2-, 4-, 8-, early morula, late morula and 
blastocyst stages were subjected to RNA-seq at the depth of approximately 30 million reads per 
sample.  To analyze species differences, three other RNA-seq datasets of pre-implantation 
development from the human, mouse and pig were downloaded from Gene Expression Omnibus 
(GEO) (www.ncbi.nlm.nih.gov/geo) under the accession numbers GSE44183 25, and SRA076823 
23.  All oocytes and embryos used in these studies were in vivo derived with the exception of 
those from humans (Table S3.1).  For each embryonic stage, data were normalized among the 
four species by transforming uniquely mapped reads to RPKM 27.  The 26 genes that have been 
confirmed to be imprinted in the bovine were examined in the bovine as well as in humans, mice 
and pigs regardless of their imprinting status in these species 3 (Table S3.2).  Expression profiles 
of these genes were searched against all four datasets and the RPKM values of each gene from 
the same developmental stage were averaged and analyzed among four species.  All genes with 
RPKM > 0.1 were defined as detectable.   
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3.4.	  Results	  
The total number of imprinted genes in the bovine genome is still unknown.  From the 28 
confirmed imprinted genes in the bovine, MAOA and XIST were excluded because they are only 
imprinted in the placenta.  The mRNA abundance of imprinted genes in MII oocytes and 
embryos were compared within and amongst four different species, bovine, humans, mice and 
pigs.  Overall, 18 of the 26 confirmed bovine imprinted genes were expressed in bovine in vivo 
oocytes and/or pre-implantation embryos (Table S3.3), while only 14, 12 and 9 of these were 
expressed in humans, mouse and pigs, respectively.  Among them, the levels of six genes, cyclin-
dependent kinase inhibitor 1C (CDKN1C), GNAS complex locus (GNAS), insulin-like growth 
factor 2 receptor (IGF2R), mesoderm specific transcript (MEST), pleckstrin homology-like 
domain, family A, member 2 (PHLDA2) and pleiomorphic adenoma gene-like 1 (PLAGL1), 
were highly expressed (RPKM > 10) in bovine oocytes or in at least one bovine embryonic 
stages (Table S3.3) while others are expressed at relatively low levels.   
The changes of the 18 expressed, imprinted genes were categorized into 5 different 
dynamic patterns according to their abundance.  The first group, including the paternally 
expressed MEST (also known as the paternally expressed gene 1 (PEG1)) and PLAGL1, 
represents genes that underwent an overall trend of decrease in expression levels during pre-
implantation development in the bovine.  Incidentally, the same trend was also seen in the other 
three species (Figure 3.1).  Specifically, MEST and PLAGL1 were high in oocytes, dramatically 
decreased from MII oocytes to the 8-cell stage and then maintained a low but detectable level up 
to the blastocyst stage.  While having an overall similar decrease trend, the transition to low 
expression occurred at different stages in the other species.  Specifically, the mouse and pig had 
earlier decreases at the 2- or 4- cell stage while the change in humans was similar to that in cattle 
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(8-cell).  Notably, MEST was the highest expressed gene among all genes studied in all four 
species.  PLAGL1 was also seen at relatively high levels in oocytes from all species examined.  
Among all the genes studied, these two genes were also consistent in their imprinting status 
among the four species.  Also interesting to note, these genes are paternally expressed, it is 
reasonable to expect that the maternal alleles of these genes in the oocytes carry expression-
inhibitory imprints established during gametogenesis and low levels of these genes should be 
seen in oocytes.  Therefore their high levels in the oocytes suggest that the genomic imprints of 
the maternal alleles of these genes are either not established or not recognized at this stage of 
development.   
The second dynamic expression pattern, including the maternally expressed CDKN1C 
and IGF2R, represents genes that first decreased and then increased their expression levels 
(Figure 3.2).  Interestingly, the expression dynamics of these two genes were different in the 
other three species studied.  In oocytes of the human, mouse and pig only low levels of CDKN1C 
and IGF2R were found.  The levels then increased and then decreased in the human and mouse 
but continued to increase in the pig.  Of further note, CDKN1C was no detectable in pig oocytes 
or embryos (Figure 3.2).  
The third group represents genes that first increased, then decreased and subsequently 
maintained a relatively constant level from oocytes to blastocysts in the bovine (Figure 3.3A, B).  
For example, the maternally expressed PHLDA2, the paternally expressed sarcoglycan epsilon 
(SGCE) and the paternally expressed gene 10 (PEG10) all peaked at the 2- to 4-cell stages, while 
the paternally expressed gene 3 (PEG3) peaked at the 8-cell stage.  Interestingly, members of 
this group were not expressed in other species.  For instance PHLDA2, PEG10, and PEG3 were 
not detectable in pigs, and PEG10 was not expressed in mice.  These and other drastically 
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different expression patterns shown in Fig. 3 suggest species variations of genetic imprinting 
during early embryo development. 
The fourth group, including the maternally expressed GNAS, maternally expressed gene 3 
(MEG3), diacylglycerol O-acyltransferase 1 (DGAT1), achaete-scute family bHLH transcription 
factor 2 (ASCL2), and the paternally expressed neuronatin (NNAT) as well as nucleosome 
assembly protein 1-like 5 (NAP1L5), contained genes that maintained relatively low expression 
levels until peaking at the morula or blastocyst stage in the bovine (Figure 3.4A, B).  Major 
species differences were also seen in the expression dynamics of these genes.  For example, 
DGAT1 peaked at the zygotic stage in humans and 4-cell stage in pigs.  The maternally 
expressed MEG3 and GNAS accumulated in the mature mouse oocytes yet barely detectable in 
the bovine oocytes.  This group also contained the most inconsistency in imprinting status among 
the four species.  For example, GNAS was not imprinted in either the human or pig and DGAT1 
is only imprinted in the bovine.  
The last group, including the paternally expressed DIRAS family, GTP-binding RAS-like 
3 (DIRAS3), insulin-like growth factor 2 (IGF2) and retrotransposon-like 1 (RTL1), as well as the 
maternally expressed and non-coding H19, included genes that maintained relatively constant 
low levels of expression throughout all stages studied in bovine oocytes and embryos (Figure 
3.5).  Interestingly, these genes were not as silent in other species.  For example, DIRAS3 had an 
extremely high expression level in the pig morulae and was relatively highly expressed in 
multiple stages of human early embryos.  High levels of the paternally expressed IGF2 was 
observed in the mouse oocytes yet complete absent in pigs.  Of note, neither H19 nor RTL1 were 
detected in the oocytes or embryos from the human, mouse and pig.  The near undetectable 
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levels of H19 in all stages of bovine embryos and absence from oocytes/embryos of other species 
are consistent with their absence in the gonads. 
In addition to these categories based on the bovine abundance patterns, eight genes that 
are imprinted and were expressed in other species were not detectable in the bovine 
oocytes/embryos.  Three, including small nuclear ribonucleoprotein polypeptide N (SNRPN), 
tumor suppressing subtransferable candidate 4 (TSSC4), ubiquitin specific peptidase 29 (USP29), 
and four, including SNRPN, TSSC4, USP29, antisense transcript gene of PEG3 (APEG3), were 
imprinted and expressed in human and mouse embryos (Table 3.1 and Table S3.4), respectively.  
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3.5.	  Discussion	  
Imprinted genes play critical roles in normal fetal and placental development.  
Interestingly, gene imprinting is not only developmental stage-specific, but also species-specific.  
Mammalian genomic imprinting has primarily been studied in mice and humans, while only 
limited information is available in livestock species.  Due to species variations, most information 
gained in the mouse/human cannot be extended to other species.  In this study, we provide the 
first comprehensive description of total transcript levels of currently known and confirmed 
bovine imprinted genes during in vivo embryonic development in the bovine and in three other 
mammalian species.  We showed that the profiles, number and identity of bovine imprinted 
genes that are expressed during pre-implantation may not be the same in embryos of other 
species.   
Using reverse transcription polymerase chain reaction (RT-PCR) and uniparental 
embryos, selected imprinted genes such as MEST, SGCE, and NNAT were found to be bi-
allelically expressed in bovine in vitro/vivo blastocysts 6,28.  These results were enhanced in our 
study by using a more powerful throughput technology, RNA-seq, which provides the 
quantitative expression of imprinted genes at multiple stages of in vivo development.  We found 
that MEST and GNAS are the most abundant genes in early oocytes/embryos across all species 
studied, suggesting their conserved roles in early development.  Although we were not able to 
distinguish the specific parental alleles from which the genes were expressed, the fact that none 
of the bovine imprinted gene studied to date establishes mono-allelic expression by the 
blastocyst stage suggest that the gene expression we quantified was a combination of 
accumulation from the maternal allele in the oocytes and from both parental alleles in early 
embryos.  The counter-intuitive levels of several genes, such as MEST and PLAGL1, both 
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paternally expressed yet highly abundant in bovine oocytes; and PHLDA2, GNAS, MEG3, 
DGAT1 and ASCL2, all maternally expressed yet barely detectable in bovine oocytes, are 
intriguing.  They suggest either the lack of genomic imprints on the maternal alleles of these 
genes or that these imprints are not recognized.  Indeed, differential methylation at the imprinting 
control region of several genes including those characterized here, PLAGL1 and PEG3, were not 
established during gametogenesis in non-human primates 29.  The late onset of mono-allelic 
expression of imprinted genes in cattle suggests that genomic imprints may also be established 
post-fertilization.  
All 18 expressed bovine imprinted genes had developmental stage-specific patterns of 
expression.  Their unique dynamics may provide insights into their specific roles in the 
developing embryos.  For example, MEST and PLAGL1 were highly expressed early in 
development and then decreased, indicating potential roles in oocytes, fertilization, or initial 
cleavage events.  PHLDA2 peaked between 2- and 4-cell stages and decreased subsequently.  
Although the exact role of PHLDA2 during embryo development is unclear, when siRNA 
specific to PHLDA2 was injected into bovine zygotes a substantial increase in blastocyst 
development was resulted 30.  These observations, together with ours suggest that PHLDA2 may 
inhibit embryonic development during the later pre-implantation period and is therefore 
selectively down-regulated.  CDKN1C is another imprinted gene whose expression in pre-
implantation development in cattle was confirmed by functional studies.  Injection of CDKN1C-
specific siRNA into one-cell zygotes resulted in a 45% reduction in blastocyst development 30, 
an observation consistent with our finding that it was up-regulated starting from the 16-cell stage 
after the initial degradation from the levels in the oocytes.  The decrease in PHLDA2 and 
increase in CDKN1C thus ensure proper blastocyst development. 
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A relatively large number of the bovine genes studied, 8 out of 18, either peaked or 
increased at the blastocyst stage.  These include the maternally expressed CDKN1C, IGF2R, 
GNAS, MEG3, DGAT1, ASCL2 and the paternally expressed NNAT and NAP1L5 31-33.  As we 
found previously 21 a wave of increased gene expression occurs during the morula to blastocyst 
transition in the bovine.  These eight genes may be up-regulated to prepare the bovine embryos 
to undergo differentiation and further development.  Interestingly, these genes have very 
different expression dynamics among different species.  These patterns may reflect the 
differences in the speed of development and the timing of maternal-zygotic transition and 
differentiation among the species studied. 
Eight bovine imprinted genes were not detectable in bovine oocytes or pre-implantation 
embryos while being expressed at relatively high levels in certain stages in other species.  For 
example, SNRPN, TSSC4 and USP29, were both imprinted and expressed in human and mouse 
pre-implantation embryos.  Because monoallelic expression of imprinted genes is tissue- and 
developmental stage-specific 4,12,34, these genes may not play a role in bovine pre-implantation 
development yet are important in other species at these stages.  
Lastly, we also noted differences in gene expression between in vivo and in vitro 
produced embryos.  For example, SNRPN and TSSC4 were undetectable here but detected in 
bovine in vitro embryos 24.  H19, IGF2 and PEG10 were undetectable in in vivo embryos in pigs, 
however, expression of these genes has been observed in pig in vitro blastocysts 10.  Evidences 
have also been shown that in vitro culture and somatic cell nuclear transfer affect the 
establishment of SNRPN imprinting 9.  These differences further demonstrate the notion that 
culture conditions can induce anomalies in genomic imprinting and the need that in vivo 
embryos should be used for establishment of gold standards of expression dynamics.   
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In summary, we provide here a reference base for the expression levels of imprinted 
genes in bovine in vivo produced oocytes and early embryos and contrasted these patterns with 
those in other species.  The exact nature of genetic imprints and the timing of their establishment 
during early development are yet to be examined systematically.  The connection between 
genomic imprints and mono-allelic expression will be of major focus for our future studies. 
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Table 3.1. Imprinting status in humans, mice and pigs for the eight genes that are imprinted but 
undetectable in bovine oocytes and embryos. 
 
Bovine imprinted genes Human Mouse Pig 
APEG3 Not imprinted Imprinted Not imprinted 
SNRPN Imprinted Imprinted Not imprinted 
TSSC4 Imprinted Imprinted Not imprinted 
USP29 Imprinted Imprinted Not imprinted 
NESP55 Not imprinted Not imprinted - 
MAGEL2 - - Not imprinted 
KCNQ1OT1 - - Not imprinted 
MIMT1 - Not imprinted Not imprinted 
             “ – ”: Information on imprinting status is not available. 
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Figure 3.1. Levels of transcriptional expression of bovine imprinted genes that continuously 
decreased during pre-implantation development.  Paternally expressed genes are labeled in blue. 




Figure 3.2. Transcriptional expression of bovine imprinted genes that were decreased first and 
then increased during bovine pre-implantation development.  Maternally expressed genes are 
labeled in pink and genes that are not imprinted in a particular species are labeled in black.  The 
lack of a graph indicates that the gene was not detected in that species. 
 
Fig. 3.2  
 
Figure 3.3. Transcriptional expression of bovine imprinted genes that increased first and then 
decreased at the 2- or 4-cell stage (A), or at the 8-cell stage (B). Maternally and paternally 
expressed genes are labeled in pink and blue, respectively.  Genes that are not imprinted in a 
particular species are labeled in black. The lack of a graph indicates that the gene was not 
detected in that species. 
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Fig. 3.3B  
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Figure 3.4. Transcriptional expression of bovine imprinted genes that maintained relatively low 
expression and then peaked at blastocysts to high (A) or low levels (B).  Maternally and 
paternally expressed genes are labeled in pink and blue, respectively.  Genes that are not 
imprinted in a particular species are labeled in black. The lack of a graph indicates that the gene 
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Figure 3.5. Transcriptional expression of imprinted genes that maintained low expression during 
pre-implantation development.  Maternally and paternally expressed genes are labeled in pink 
and blue, respectively.  Genes that are not imprinted in a particular species are labeled in black. 
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3.6.	  Supplementary	  Information	  Table	  S3.1.	  Summary	  of	  the	  numbers	  of	  biological	  replicates	  	  used	  in	  the	  four	  datasets	  of	  this	  study.	  	  
	  
 *Single	  oocyte/embryo	  per	  biological	  replicate	  was	  used	  in	  the	  studies	  of	  cattle,	  mice	  and	  humans.	  	  All	  oocytes/embryos	  were	  in	  vivo	  produced	  with	  the	  exception	  of	  the	  humans.	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Table S3.2. The names, parental expression patterns and chromosomal locations of confirmed 
imprinted genes in cattle  
        
Symbol Gene Name Expressed allele Chromosome 
APEG3 antisense transcript gene of PEG3 P 18 
ASCL2 achaete-scute family bHLH transcription factor 2 M 29 
CDKN1C cyclin-dependent kinase inhibitor 1C M 29 
DGAT1 diacylglycerol O-acyltransferase 1 M 14 
DIRAS3 DIRAS family, GTP-binding RAS-like 3 P 3 
GNAS GNAS complex locus M 13 
H19 H19 M 29 
IGF2 insulin-like growth factor 2 P 29 
IGF2R insulin-like growth factor 2 receptor  M 9 
KCNQ1OT1 KCNQ1 opposite strand/antisense transcript 1 P 29 
MAGEL2 MAGE-like 2 P 21 
MEG3 maternally expressed 3 M 21 
MEST mesoderm specific transcript P 4 
MIMT1 MER1 repeat containing imprinted transcript 1 P 18 
NAP1L5 nucleosome assembly protein 1-like 5 P 6 
NESP55 Neuroendocrine secretory protein-55 M 13 
NNAT neuronatin P 13 
PEG10 paternally expressed 10 P 4 
PEG3 paternally expressed 3  P 18 
PHLDA2 pleckstrin homology-like domain, family A, member 2 M 29 
PLAGL1 pleiomorphic adenoma gene-like 1 P 9 
RTL1 retrotransposon-like 1 P 21 
SGCE sarcoglycan, epsilon P 4 
SNRPN small nuclear ribonucleoprotein polypeptide N M 21 
TSSC4 tumor suppressing subtransferable candidate 4 M 29 
USP29 ubiquitin specific peptidase 29 P 18 
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Table S3.3. Spreadsheet 1. Expression levels of imprinted genes in bovine in vivo oocytes and pre-
implantation embryos 





ASCL2 Imprinted M 0.22 0.32 0.14 0.03 0.00 0.00 0.04 4.19 
CDKN1C Imprinted M 12.72 2.34 1.56 0.36 0.50 2.78 1.57 3.71 
DGAT1 Imprinted M 1.66 1.30 0.96 1.20 0.79 3.17 3.86 5.64 
DIRAS3 Imprinted P 0.10 0.00 0.00 0.03 0.28 0.02 0.11 0.16 
GNAS Imprinted M 7.58 12.85 11.48 59.18 43.11 25.72 66.07 202.81 
H19 Imprinted M 0.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
IGF2 Imprinted P 0.08 0.10 0.02 0.06 0.00 0.01 0.00 0.00 
IGF2R Imprinted M 9.80 2.65 2.02 1.93 6.34 3.02 6.25 7.96 
MEG3 Imprinted M 0.03 0.16 0.04 0.15 1.64 0.01 0.19 25.28 
MEST Imprinted P 220.15 102.98 59.87 4.47 1.14 4.49 1.16 0.27 
NAP1L5 Imprinted P 0.00 0.00 0.00 0.10 0.03 0.10 0.00 0.44 
NNAT Imprinted P 0.00 0.10 0.00 0.27 0.05 0.18 0.05 2.37 
PEG10 Imprinted P 0.22 1.20 0.95 0.33 0.00 0.00 0.00 0.00 
PEG3 Imprinted P 0.00 0.02 0.28 0.58 0.01 0.00 0.00 0.00 
PHLDA2 Imprinted M 4.29 25.91 24.82 6.26 8.31 8.99 7.84 4.51 
PLAGL1 Imprinted P 49.28 20.63 12.39 0.54 0.51 1.17 0.70 0.01 
RTL1 Imprinted P 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.04 
SGCE Imprinted P 0.71 5.20 6.15 0.55 0.01 0.07 0.09 0.12 
  Genes in shades have high levels of expression (RPKM>1) in at least one stage of development.	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Table S3.3. Spreadsheet 2. Imprinting status and levels in human in vitro oocytes and embyros for 
genes that are imprinted in the bovine.   
          Gene 
Name Status 
Expressed 
allele Oocyte Pronuclear Zygote 2-cell 4-cell 8-cell 
Morul
a 
ASCL2 Not imprinted Biallelic 0.01 0.00 0.00 0.00 0.03 1.69 0.18 
CDKN1C Imprinted M 0.42 1.21 0.31 0.22 0.11 7.99 0.00 
DGAT1 Not imprinted Biallelic 0.92 6.86 7.85 1.32 3.72 3.04 3.53 
DIRAS3 Imprinted P 2.49 15.72 4.68 11.21 1.77 5.60 0.03 
GNAS Imprinted 
Isoform 
dependent 3.86 10.62 12.03 20.25 58.96 19.04 22.03 
H19 Imprinted M ND ND ND ND ND ND ND 
IGF2 Imprinted P 0.01 0.24 0.00 0.05 0.09 2.21 0.03 
IGF2R Imprinted Biallelic 3.09 1.91 1.88 1.57 3.02 3.64 0.38 
MEG3 Imprinted M ND ND ND ND ND ND ND 
MEST Imprinted P 439.80 199.68 294.27 110.77 88.72 24.19 75.57 
NAP1L5 Imprinted P 0.01 0.00 0.00 0.00 0.03 4.54 1.66 
NNAT Imprinted P ND ND ND ND ND ND ND 
PEG10 Imprinted P 3.57 0.48 0.67 0.52 3.02 0.13 0.12 
PEG3 Imprinted P 0.04 0.00 0.06 0.11 0.03 0.61 0.58 
PHLDA2 Imprinted M 0.01 0.00 0.00 0.00 0.03 17.38 2.53 
PLAGL1 Imprinted P 17.48 5.00 5.09 3.09 9.82 0.12 0.13 
RTL1 Imprinted P ND ND ND ND ND ND ND 
SGCE Imprinted P 7.57 1.49 1.06 2.65 0.81 0.07 1.35 	  
*ND: Genes with RPKM < 0.1 are defined not detected (ND). 
Genes in shades have high levels of expression (RPKM>1) in at least one stage of development.	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Table S3.3. Spreadsheet 3. Imprinting status and levels in mouse in vivo oocytes and embyros for 
genes that are imprinted in the bovine.   
         Gene 
Name Status 
Expressed 
allele Oocyte Pronuclear 2-cell 4-cell 8-cell Morula 
ASCL2 Imprinted M 0.30 0.03 0.13 0.83 0.00 0.00 
CDKN1C Imprinted M 3.25 3.30 6.20 8.30 4.30 0.77 
DGAT1 Not imprinted Biallelic 0.75 1.70 2.13 4.43 2.87 24.27 
DIRAS3 Not imprinted Biallelic ND ND ND ND ND ND 
GNAS Imprinted M 27.60 33.73 4.67 7.43 8.70 47.67 
H19 Imprinted M ND ND ND ND ND ND 
IGF2 Imprinted P 4.95 0.90 0.10 0.27 0.00 0.00 
IGF2R Imprinted M 12.15 0.80 36.33 35.57 31.00 21.37 
MEG3 Imprinted M 2.15 0.23 0.07 0.00 0.00 0.20 
MEST Imprinted P 210.65 127.77 34.90 5.43 2.20 0.47 
NAP1L5 Imprinted P ND ND ND ND ND ND 
NNAT Imprinted P ND ND ND ND ND ND 
PEG10 Imprinted P ND ND ND ND ND ND 
PEG3 Imprinted P 1.55 1.10 0.27 0.23 0.10 0.30 
PHLDA2 Imprinted M 28.70 10.83 18.47 5.57 12.27 3.57 
PLAGL1 Imprinted P 2.70 1.20 3.20 0.00 0.00 0.03 
RTL1 Imprinted P ND ND ND ND ND ND 
SGCE Imprinted P 0.00 0.00 0.07 3.43 4.37 2.67 
 
*ND: Genes with RPKM < 0.1 are defined not detected (ND). 
Genes in shades have high levels of expression (RPKM>1) in at least one stage of development.  
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Table S3.3. Spreadsheet 4. Imprinting status and levels in pig in vivo oocytes and embyros for 
genes that are imprinted in the bovine.   
         Gene 
Name Status 
Expressed 
allele Oocyte 2-cell 4-cell 8-cell morula Blastocyst 
ASCL2 Not imprinted Biallelic ND ND ND ND ND ND 
CDKN1C Not imprinted Biallelic ND ND ND ND ND ND 
DGAT1 Not imprinted Biallelic 36.70 2.44 38.59 3.95 18.77 7.33 
DIRAS3 Not imprinted Biallelic 0.02 0.07 0.26 140.46 1991.18 147.92 
GNAS Not imprinted Biallelic 10.65 11.47 2.58 1.82 28.05 43.02 
H19 Imprinted M ND ND ND ND ND ND 
IGF2 Imprinted P ND ND ND ND ND ND 
IGF2R Not imprinted Biallelic 0.75 0.46 0.89 0.05 1.95 3.24 
MEG3 Imprinted M ND ND ND ND ND ND 
MEST Imprinted P 626.02 344.67 104.35 144.00 17.66 76.66 
NAP1L5 Imprinted P 0.00 0.10 0.34 0.33 0.33 0.64 
NNAT Imprinted P 0.11 0.29 0.13 0.04 0.04 0.11 
PEG10 Imprinted P ND ND ND ND ND ND 
PEG3 Imprinted P ND ND ND ND ND ND 
PHLDA2 Imprinted M ND ND ND ND ND ND 
PLAGL1 Imprinted P 7.51 5.23 0.08 0.10 0.02 0.02 
RTL1 Not imprinted Biallelic ND ND ND ND ND ND 
SGCE Imprinted P 16.19 86.98 4.47 52.31 0.08 0.11 
*ND: Genes with RPKM < 0.1 are defined not detected (ND). 
    Genes in shades have high levels of expression (RPKM>1) in at least one stage of development. 
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Table S3.4. Spreadsheet 1. The eight confirmed bovine imprinted genes that were not detected in 













Table S3.4. Spreadsheet 2. The expression levels in human oocytes and embryos for the genes 
that are undetected in bovine oocytes or embryos. 
  
      
  
  Oocyte Pronuclear Zygote 2-cell 4-cell 8-cell Morula 
SNRPN 11.12 11.87 5.57 6.37 17.46 13.56 8.83 
TSSC4 0.26 5.00 2.41 8.09 2.04 22.17 30.74 






Table S3.4. Spreadsheet 3. Expression levels in mouse oocytes and embryos for the genes that 
are undetected in bovine oocytes or embryos. 
  
     
  
  Oocyte Pronuclear 2-cell 4-cell 8-cell Morula 
SNRPN 16.55 8.83 7.73 22.97 34.83 44.07 
TSSC4 12.00 8.00 7.33 4.80 15.63 13.63 
USP29 10.80 13.30 45.13 21.47 11.40 0.67 
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4.1.	  Abstract	  
High Hydrostatic Pressure (HHP) has been used to enhance stress tolerance and to 
promote survival of embryos before they are subjected to insults such as cryopreservation.  
However, the molecular mechanisms of the beneficial effects of HHP are poorly understood.  
Here we found re-expansion rates of bovine blastocysts after vitrification-warming were 
significantly (P < 0.05) higher in embryos treated with 40 MPa or 60 MPa than controls, 
demonstrating that the application of HHP promotes the in vitro developmental competence of 
vitrified bovine embryos.  However, 80 MPa resulted in significantly reduced re-expansion rates, 
suggesting that this pressure started to be lethal to bovine blastocysts.  Microarray analysis 
revealed a total of 399 differentially expressed transcripts, representing 254 unique genes, among 
different treatment groups. Gene ontology analysis revealed that HHP at 40 MPa and 60 MPa 
promoted embryo competence through down-regulation of genes involved in cell death and 
apoptosis, and up-regulation of RNA processing, cellular growth and proliferation.  In contrast 
80 MPa up-regulated expression of genes for apoptosis, and down-regulated genes for protein 
folding and cell cycle. These may explain why 80 MPa-treated embryos stopped developing.  
Moreover, gene expression was also changed by the length of the recovery time after HHP.  The 
significantly over-represented groups are apoptosis and cell death in the 1h group, and protein 
folding, response to unfolded protein and cell cycle in the 2h group. Taken together, these data 
suggest that HHP induces specific responses in vitrified bovine blastocysts and promotes their 
developmental competence through modest transcriptional reprogramming.  
Keywords: bovine, vitrified blastocysts, HHP, recovery time, microarray, transcriptional profiles  
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4.2.	  Introduction	  
In vitro maturation, culture and cryopreservation of gametes and embryos require 
meticulously adjusted conditions to avoid or minimize detrimental stress of osmotic, oxidative, 
cold/heat shock, nutritional and mechanic nature.  Eustress can improve protein conformation, 
maintain cellular homeostasis as well as stabilize membrane structures, while distress will cause 
apoptotic cell death 1-4.  Recent studies indicate that stress from a well-defined and properly 
applied sub-lethal high hydrostatic pressure (HHP) may induce general adaptation and increase 
tolerance to various in vitro procedures 5.  For example, HHP treatment has been shown to 
improve the survival rates, fertilizing ability and development competence of cryopreserved 
oocytes 6,7, sperm 8,9, embryos 10-12 and embryonic stem cells 13.  Applying a HHP of 60 MPa for 
1 hour (h) could increase the ICM cell numbers of bovine blastocysts 12.  Furthermore, re-
expansion and hatching rates after vitrification-warming were also found to be affected by the 
duration of the recovery time, the period between the termination of HHP treatment and the 
initiation of vitrification.  HHP followed by 1h of recovery proved to be superior with regards to 
both re-expansion and hatching rates 11,14.  Upon further fine-tuning, this invention can be 
applied to improve in vitro embryo biotechnologies in various species including humans. 
A transcriptional effect is believed to be involved in the elevated stress tolerance induced 
by HHP.  Previous studies on mouse embryos evaluated candidate genes from pressure-related 
functional groups.  The expression of the antizyme inhibitor 1 (AZIN1), the mitochondrial 
superoxide dismutase 2 (SOD2) and the gamma growth arrest and DNA-damage-inducible 
(GADD45G) are found to be significantly up-regulated by HHP treatment 10.  Further 
investigations revealed that pressure can change protein structures and enhance the production of 
heat shock proteins (HSP) 15,16 such as HSP70 12.  In bovine blastocysts, several candidate stress 
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genes have also been examined.  These include stress related genes SOD2, glutathione 
peroxidase 4 (GPX4) and heat shock 70kDa protein 1A (HSPA1A).  None of the evaluated genes, 
however, were significantly changed by the 60 MPa HHP treatment 11.  Therefore, the molecular 
mechanisms for the beneficial effects of HHP are yet to be ascertained.  
Without many known definitive candidate genes, genome-wide expression profiling by 
DNA microarray is highly effective in throughput examinations of transcriptomes.  Accordingly, 
the aim of the present study is to evaluate the effects of HHP treatments at three different levels 
with different recovery times on the transcriptomes of bovine in vitro produced (IVP) vitrified 
blastocysts.  To our knowledge, this is the first transcriptional profiling of bovine blastocysts 
treated by HHP.  Pathways such as apoptosis, protein folding, cell cycle regulation, RNA 
processing and translation were found to be affected by HHP.   
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4.3.	  Materials	  and	  Methods	  
4.3.1.	  	  Microarray	  Design	  and	  Annotation	  	  
The Cattle Array-Ready oligonucleotides were designed at the University of Illinois at 
Urbana-Champaign and described in detail by Everts et al 17.  The microarray contained 13,254 
70-mer oligonucleotide probes that were synthesized at Illumina (www.illumina.com, San Diego, 
CA, USA).  All probes were printed in duplicates on glass slides at Microarrays Inc. (Nashville, 
TN, USA).  In total, these oligonucleotide probes represent 10,991 unique genes.  
4.3.2.	  	  Collection	  of	  IVP	  blastocysts	  
In vitro bovine blastocysts were produced as described previously 11,18.  Briefly, in vitro 
fertilization (Day 0) was performed using abattoir bovine oocytes and embryos were 
immediately placed in CR1aa medium supplemented with BSA for Days 1 and 2 of culture.  
Cleaved embryos were transferred to CR1aa + 10 % FBS and cultured at 38.5 °C in 5 % CO2 in 
humidified air until Day 7/expanded blastocyst stage.  Embryos were examined and staged under 
light microscopy and only morphologically intact embryos meeting the standards of Grade 1 by 
the International Embryo Transfer Society (IETS) were used in the following experiments.   
4.3.3.	  	  High	  Hydrostatic	  Pressure	  Treatment	  of	  Bovine	  IVP	  Blastocysts	  
Blastocysts were randomly distributed into the control and HHP treated groups as shown 
in Fig. 4.1.  To apply HHP, groups of embryos were transferred to 0.25 ml straws in embryo 
holding medium (TCM-199; Gibco, Grand Island, NY, USA) without air bubbles.  Straws were 
sealed by plastic plugs and were then placed into a pre-warmed stainless steel pressure machine 
(HHP machine 100; Cryo-Innovation, Budapest, Hungary) filled with water as the pressure 
medium.  The following treatments were included (Fig. 4.1): (1) Control embryos were left 
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unaffected in the incubator (one atmospheric pressure or 0.1 MPa); (2) treatment groups were 
assigned to 40, 60 and 80 MPa HHP for 1h at either 25 °C (room temperature) or 37 °C (body 
temperature), followed by three different recovery time periods (0, 1 and 2h) post-HHP in the 
holding medium before the embryos were vitrified using the Solid Surface Vitrification (SSV) 
method 19.  The cryopreserved blastocysts were then thawed by immersing the straws into 0.5 M 
sucrose solution for 5 min at 39 °C, after which the blastocysts were transferred into TCM-199 
medium and cultured in an incubator at 39 °C, 5% CO2 and humidified air.  The re-expansion 
rates of embryos given 2h of recovery were evaluated for morphological survival 24h after 
warming.  Then pools of 5 embryos from each treatment were washed twice in D-PBS and stored 
in RNAlater (Ambion, Grand Island, NY, USA) in liquid nitrogen.  All treatments were repeated 
three times (n = 3). 
The re-expansion rates were analyzed using One Way ANOVA with Tukey’s multiple 
comparisons, or the Student’s t-test.  Figures were presented as mean ± standard deviation (SD).  
A P-value < 0.05 (*) or < 0.01 (**) was considered statistically significant. 
4.3.4.	  	  RNA	  Isolation,	  Linear	  Amplification,	  Labeling	  and	  Microarray	  Hybridization	  
Following the reproducible procedures of RNA extraction and linear amplification from 
our previous study 18, we isolated total RNA from each pool of 5 blastocysts using TRIzol 
reagent (Invitrogen, Grand Island, NY) and precipitated the RNA with linear acrylamide 
(Ambion, Grand Island, NY).  The quality of the total RNA was examined with the Aglient RNA 
6000 Pico kit (Aglient Technologies, Santa Clara, CA) using the Aglient Bioanalyzer 2100.  
RNA was then amplified twice using the TargetAmp 2-round aminoallyl-aRNA amplification kit 
1.0 (Epicentre, Madison, WI) according to the manufacturer’s instructions.  From 5 blastocysts, 
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we were able to generate an average of 60 µg of amplified RNA after two rounds of 
amplification.  Amplified RNA was stored at -80 °C until utilization on the microarray.  
The reference microarray design, in which the embryonic expression profiles were 
compared to a standard reference RNA, was used.  The reference RNA was isolated from brain, 
kidney, liver and lung tissues of a naturally reproduced heifer and pooled at an equal proportion.  
More than 90 % of the genes on the microarray were lit up by the standard reference.  Two 
microgram of amplified RNA from each sample and the reference were reverse transcribed, 
labeled, and hybridized to each microarray as previously described for single embryos 18.  In 
total, 144 microarrays were used including dye-swap hybridizations.   
4.3.5.	  	  Microarray	  Data	  Analysis	  
The microarrays were scanned with GenePix 400B (Molecular Devices, Union City, CA, 
USA) and normalization of fluorescence intensities was accomplished by using the GenePix Pro 
6.0 scanning software (Axon Instruments, Union City, CA, USA).  Each scanned image was 
examined thoroughly and dust particles and spots with high background were flagged and 
removed from analysis.  The background and standard deviation were calculated for each raw 
data file after scanning, and only those spots with intensities three standard deviations above 
background were considered “expressed” and loaded into Genespring 12.1 (Agilent 
Technologies Palo Alto, CA, USA).  Loess normalization was applied to all microarrays before 
statistical comparisons.  In the analysis, each probe was considered individually.   
In the evaluations of post-normalization of the probes in the microarrays, 12,274 
transcripts present in either the standard reference or sample on 90% of the microarrays 
underwent further analysis.  A SAS model with covariates being pressure, recovery time and 
temperature were considered.  We looked at two metrics, firstly the number of genes for which 
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we find that factor significant using a significance level of 0.01 and secondly the sum of the P-
values for all probes.  Based on these two measures, we ranked HHP as the most significant 
factor, followed by recovery time, and lastly temperature, which confirmed our observation that 
no significant differences were found between 25 °C and 37 °C on the re-expansion rates by 
HHP.  We therefore combined the data from the two temperatures to increase the statistical 
power.  The SAS model was then evaluated to identify the genes differentially expressed 
between treated and control blastocysts.  Genes were deemed differentially expressed if they 
showed a Benjamini Hochberg procedure controlling for false discovery rate (FDR) at P-value < 
0.05.  Hierarchical clusters were generated by using Genespring GX 12.1 with the K-means 
clustering algorithm.  Heatmaps and Venn diagrams of the summary of differentially expressed 
genes were developed with R. 
4.3.6.	  	  Gene	  Ontology	  Analysis	  
Functional annotation enrichment analysis for Gene Ontology (GO) was conducted using 
DAVID 20.  GO terms shown in this study summarized all similar sub-terms into an overarching 
term, and Benjamani-Hochberg adjusted P-values are shown for the representative term. 
4.3.7.	  	  Quantitative	  Real	  Time-­‐Reverse	  Transcription	  Polymerase	  Chain	  Reaction	  (qRT-­‐PCR)	  
Analysis	  
qRT-PCR was performed to validate differential expression of eight selected genes using 
amplified RNA.  Amplified RNA was reverse transcribed to cDNA by SuperScript III Reverse 
Transcriptase (Invitrogen) and amplified with specific primers designed by using Primer 3.0 
(Table S4.1).  The qRT-PCR was performed using SYBR Green PCR Master Mix (ABI) and an 
ABI 7500 Fast instrument.  The data were analyzed using the 7500 software version 2.0.2 
provided with the instrument.  All values were normalized to the internal control, β-ACTIN.  The 
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efficiency of each primer pair was calculated over a 3.5 log dilution range and the relative gene 
expression values were calculated using the 2-△△Ct method.  Expression levels that were relative 
to those in the standard reference were calculated and the mean for each group was determined 
and compared for an overall fold change.  Data from qRT-PCR were analyzed as described 
above for re-expansion rates.  
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4.4.	  Results	  
4.4.1.	  	  The	  Effect	  of	  HHP	  on	  Re-­‐expansion	  Rates	  of	  Cryopreserved	  Bovine	  IVP	  Blastocysts	  
Blastocyst re-expansion is a predictive value for implantation of frozen-thawed 
blastocysts.  We first investigated the post-thaw survival of vitrified IVP bovine blastocysts.  
Because comparisons of 0 and 1h recovery time had been studied previously 11, only 2h recovery 
was included here.  Re-expansion rates were significantly affected by HHP and recovery but not 
by temperature.  Therefore data for the two temperatures were combined.  Application of 
appropriate HHP (40 or 60 MPa) followed by 2h of recovery proved to be superior with regard to 
re-expansion. Specifically, re-expansion rates were significantly (P < 0.05) higher in the 40-MPa 
(90 %) and 60-MPa (87 %) groups than the controls (63.5 %) (Fig. 4.2).  These data 
demonstrated that application of HHP stress promoted the in vitro developmental competence of 
vitrified bovine embryos.  However, HHP treatment at 80 MPa resulted in significantly reduced 
re-expansion rates (43.5 %) compared to controls (63.5 %; Fig. 4.2), suggesting that 80 MPa is 
starting to be lethal to bovine blastocysts.  
4.4.2.	  	  Hierarchical	  Clustering	  of	  Expression	  Profiles	  of	  Pressure-­‐Treated	  and	  Cryopreserved	  
Bovine	  IVP	  blastocysts	  
Building upon the previous notion and our observation that vitrified embryos re-
expanded better when appropriate HHP treatment is combined with a short recovery period, a 
comprehensive genome-wide transcriptomic investigation was conducted.  The “ranking” of the 
most significant factors was pressure, then recovery time and lastly temperature, which is 
consistent with our observation that re-expansion rates were not significantly affected by 
temperature.  Expression data were also combined for the two temperatures.  Hierarchical 
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clustering of all treatments based on 12,274 analyzed transcripts clearly showed a tendency for 
different expression profiles (Fig. 4.3A).  Specifically, the 40- and 60-MPa groups were 
separated from the 80-MPa and control groups (Fig. 4.3A).  Within each HHP level, 1h and 2h 
clustered together and separated from 0h with the exception in 80-MPa group (Fig. 4.3A).  This 
overall clustering pattern in gene expression is consistent with the re-expansion results.   
A total of 399 transcripts (254 unique genes) were identified as differentially expressed 
among different treatment groups (P < 0.05) (Table S4.2).  The hierarchical clustering of all 
differentials (Fig. 4.3B) was again based on pressure, further suggesting that pressure played a 
significant role in gene expression changes.   
4.4.3.	  	  Effects	  of	  HHP	  on	  Gene	  Expression	  
Among the 399 total differentially expressed transcripts, 340 were caused by HHP while 
59 were not related to pressure changes.  Of the 340, 83 and 182, 84 and 44, were down- and up-
regulated in cryopreserved embryos treated with 40 MPa or 60 Mpa HHP, respectively (Fig. 
4.4A, Table S4.3).  The common down-regulated transcripts in both the 40 MPa and 60 MPa 
HHP-treated embryos were involved in the cell death and apoptosis (Table 4.1), among these 
were heat shock 22kDa protein 8 (HSPB8), death inducer-obliterator 1 (DIDO1), meuroepithelial 
cell-transforming gene 1 (NET1), coagulation factor III (F3) and caspase 7 (CASP7).  
Interestingly, CASP7, a protein of the caspase family and considered to be an important 
executioner protein of apoptosis, and HSPB8, a common heat shock protein involved in 
regulation of cell proliferation and apoptosis, were both down-regulated upon HHP treatment 
(Fig. 4.5).  Moreover, DIDO1 and NET1, both activated early in apoptosis (pro-apoptotic) were 
also down-regulated by HHP (Fig. 4.5).  The expression changes of these genes upon 40 and 60 
MPa HHP are in agreement with the higher survival rates of these groups.  Conversely, the up-
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regulated transcripts, such as serine/arginine-rich splicing factor 7 (SFRS7), SFRS9, DNA-
directed RNA polymerase II subunit G (POLR2G), POLR2F, POLR2L, small nuclear 
ribonucleoprotein D3 (SNRPD3), SNRPD2, eukaryotic translation initiation factor 4B (EIF4B), 
ribosomal protein L38 (RPL38) and mitochondrial ribosomal protein L43 (MRPL43) (Table 4.1), 
are involved in RNA processing and transcription, as well as regulations of protein synthesis, and 
likely promoted embryo survival.  Collectively, these results suggested that stress caused by 
elevated HHP induced embryos to degrade apoptotic transcripts and increase RNA transcription 
and translation.  These effects, while not necessarily specific for pressure resistance or cryo-
tolerance, prepared the embryos to resist insults and survive better.  However, when pressure was 
further increased to 80 MPa, 25 and 92 transcripts were down- and up-regulated, respectively 
(Fig. 4.4A, Table S4.3).  The biological processes significantly represented among down-
regulated transcripts included protein folding and cell cycle, which including BAG family 
molecular chaperone regulator 4 (BAG4), DBF4 zinc finger A (DBF4), mitogen-activated protein 
kinase phosphatase 1 (DUSP1), and serine/threonine-protein kinase SNK (PLK2; Table 4.1), 
while the up-regulated transcripts significantly over-represented cell death, apoptosis, and 
chromatin assembly/disassembly, such as EIF4B, hexokinase 1 (HK1), histone cluster 1, H1e 
(HIST1H1E) and histone deacetylase 8 (HDAC8; Table 4.1).  Some of these changes are opposite 
to those seen at 40 or 60 MPa.  These results suggested that over exerting HHP would disturb 
cell structure and proliferation and therefore be detrimental to bovine embryos.  
Among genes up- and down-regulated at each pressure level, 136, 21 and 39 transcripts 
were uniquely differentially expressed in the 40-, 60- or 80-MPa treated groups compared to the 
controls, respectively (Fig. 4.4B, Table S4.4).  Additionally, 66 transcripts uniquely overlapped 
in the comparisons between the 40- or 60-MPa treated embryos and controls (Fig. 4.4B, Table 
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S4.5).  These include down-regulated transcripts, NET1, which is involved in cell death and 
apoptosis, and up-regulated transcripts, SFRS7, SFRS9, POLR2G, POLR2F, POLR2L, SNRPD2 
and amyloid beta (A4) precursor-like protein 1 (APLP1), which are involved in RNA processing 
and translation.  Twenty-six transcripts were differentially expressed in all pressure treated 
groups compared to un-pressured controls.  These include DIDO1, HSPH1, HSPB8, HK1 and 
EIF4B (Fig. 4.4B, Table S4.6) and may represent essential genes responding to pressure stress.  
4.4.4.	  	  Effects	  of	  Different	  Recovery	  Time	  on	  Gene	  Expression	  
The duration of the recovery period is particularly interesting because HHP induces gene 
changes in cellular metabolism and functions and time is needed for the synthesis of special 
RNA and proteins.  In a previous study, allowing bovine embryos to recover for 1h after HHP 
was found to further increase embryo survival compared to 2h or HHP alone without recovery 11.  
Here, we compared gene expression at these three time points.  Among the total of 399 
differentially expressed transcripts, 167 were caused by recovery.  We identified 49 and 98 
down-regulated, and 16 and 33 up-regulated transcripts at 1h and 2h compared to controls (0h), 
respectively (Fig. 4.6A, Table S4.7).  Gene ontology analysis of the down-regulated transcripts 
revealed apoptosis, proteolysis and phosphate metabolic process in the 1h group, and protein 
folding, cell cycle and cell death in the 2h group as significantly overrepresented (Table 4.2).  
Up-regulated transcripts were involved in cellular growth and proliferation, cell morphology, and 
cellular function and maintenance in the 1h group, cellular growth and proliferation, DNA 
replication and G1/S transition of mitotic cell cycle in the 2h group (Table 4.2).  Of special 
interest was the dramatically higher number of differentially expressed transcripts in the 0 vs. 2h 
comparison than that of the 0 vs. 1h comparison, suggesting that 2h of recovery allowed more 
changes of gene expression to occur.  Among the differentials unique to the 0 vs. 1h and 0 vs. 2h 
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comparisons, 20 and 41 transcripts were revealed, respectively (Fig. 4.6B, Table S4.8).  A total 
of 42 transcripts were common differentials in both the 0 vs. 1h and 0 vs. 2h comparisons (Fig. 
4.6B, Table S4.9), including CASP7, DUSP1 and F3, which are involved in apoptosis and cell 
death.  
It is noteworthy that although a 2h recovery induced more gene expression changes, it did 
not promote better embryo re-expansion than 1h.  The additional changes in gene expression 
during the second hour of recovery may have corrected changes already taken place during the 
first hour, thereby canceling some of the changes needed to resist insults from the subsequent 
cryopreservation. 
4.4.5.	  	  Confirmation	  of	  Microarray	  Data	  by	  Real	  Time	  qRT-­‐PCR	  
To confirm the throughput results of microarray, we performed qRT-PCR on eight genes, 
namely CASP7, NET1, APLP1, EIF4B, HSPH1, HSPB8, DIDO1 and F3, which were 
significantly affected by HHP treatments and play crucial roles in cell death and apoptosis.  In 
nearly all cases, the qRT-PCR detected bigger fold changes and substantiated results from 
microarray (Fig. 4.7A, B). 
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4.5.	  Discussion	  
In the bovine embryo transfer industry, vitrification is the most common method to 
cryopreserve IVP embryos 21.  Sublethal HHP was reported to enhance stress tolerance and 
increase post-thaw survival of sperm, embryos or stem cells after cryopreservation in murine, 
porcine and bovine 10.  Different HHP conditions (pressure level, recovery time and temperature) 
have been explored on gametes and embryos subjected to various assisted reproductive 
technology procedures 22.  HHP at 60 MPa for 1h have been shown to increase the in vitro 
development of bovine blastocysts 11,12.  In the present study, we extended previous findings by 
testing 40 and 80 MPa and found that 80 MPa is not well-tolerated.  Additionally we also found 
that HHP at 40 prior to vitrification gave a higher re-expansion rate than the previously tested 60 
MPa and non-treated group.  The results in the bovine are also in accordance with previous 
reports that in the mouse and ovine 13.    
Despite advances in morphological studies, limited information on the molecular 
mechanisms of the positive effect of HHP is available.  Without clear candidates, comparing the 
entire transcriptomes of the treated and controls was the approach of choice.  Interestingly, 
changes of transcriptomes were reflective of the re-expansion data that the best treatment 
condition, 40 MPa, elicited the most changes in gene expression compared to controls.  Most of 
the down-regulated genes in the beneficial levels of HHP, 40 and 60 MPa, belonged to cell death 
and apoptosis, up-regulated genes were involved in RNA processing, cellular growth and 
proliferation, while some of these changed in the opposite direction by the harmful level of HHP 
at 80 MPa.  The majority of the genes reported here are newly identified for HHP-treated, 
vitrified embryos.  Collectively, it appears that while the embryos responded to HHP stress by 
changing gene expression, these events prepared them for the upcoming insult of vitrification.  
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However, when too much stress was given (80 MPa for bovine blastocysts), embryo lethality 
occurred.  By the candidate approach it was previously reported that sublethal stress such as heat, 
affects the embryos through apoptosis 2,3,23 by influencing the expression of development- 24 and 
stress-related genes 25,26.  In this study, the same pathways were revealed for HHP stress.  It 
appears that cells have limited pathways to resist stress and use the same mechanisms for 
different external insults.  
Because a short recovery period after HHP was shown to be beneficial for cell/embryo 
survival 6,11,27, we also determined genes that were affected by different lengths of recovery.  
Similarly to pressure, genes involved in regulation of cell death, apoptosis and protein folding 
were down-regulated, while up-regulated genes belonged to cell morphology, DNA replication 
and cellular growth and proliferation after either a 1h or 2h recovery.  HHP and recovery seem to 
affect the same developmental pathways because alleviating cell death is essential for embryonic 
development. 
In addition to the well-known apoptotic events induced by stress, we also identified many 
new pathways involved in the protection mechanisms.  These include RNA processing, 
translation, cell cycle, oxidative phosphorylation and cellular growth and proliferation.  A closer 
look at the gene lists revealed members of the above-mentioned pathways such as CASP7, 
DIDO1, NET1, HSPH1, and HSPB8, which may be responsible for the possible protection 
mechanisms induced by HHP.  Particularly, CASP7, a member of caspase family, HSPH1 and 
HSPB8, members from the heat shock gene family, DIDO1 and NET1 were down-regulated by 
HHP (40 and 60 MPa).  CASP7 has been shown to be an important executioner protein of 
apoptosis 28,29.  HSPH1 has been shown to prevent the aggregation of denatured proteins in cells 
under severe stress 30,31.  HSPB8 belongs to the superfamily of small heat-shock proteins and 
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involved in regulation of cell proliferation and apoptosis through the activation of transforming 
growth factor-β activated kinase 1 (TAK1) 32.  In addition, DIDO1 and NET1 were activated 
early in apoptosis through regulation of BCL-2 33,34.  Sequential activation of these essential 
genes to respond to pressure stress plays a central role in improving the stress tolerance of 
vitrified bovine embryos.  Furthermore, EIF4B was up-regulated in bovine blastocysts by HHP.  
EIF4B is required for cell proliferation and survival through regulation of protein synthesis 35-37.  
Its up-regulation suggests that 40- and 60-MPa requires the formation of new proteins to promote 
embryo survival.  However, the well-known HSP70 (HSPA1A in our microarray) which was 
induced by sublethal pressures in microorganism 38 was not significantly regulated by HHP in 
our study, an observation consistent with a previous report employing the candidate approach 11.  
It is possible that, instead of the HSP70, the bovine embryos activate alternative proteins such as 
HSPH1 and HSPB8, to respond to pressure stress.   
This is the first throughput study on HHP-treated and cryopreserved blastocysts.  It 
should be noted that our microarray represents 10,991 genes, about half of the bovine expressed 
genome 39.  Of the approximately 12,000 genes expressed by the bovine blastocysts, 6,086 were 
represented in the microarray used.  Therefore, half of the blastocyst’s transcriptomes is not 
studied here.  However, we were able to identify multiple HHP-induced pathways and some 
were common to those cells used to resist other stresses such as heat.  These data suggest that the 
cells are limited to only a number of pathways to counteract external stress and it is therefore 
likely that this throughput study identified all pathways, albeit not all genes, involved in HHP 
stress resistance.  Application of the more powerful RNA-seq technology may help to identify 
additional differentially expressed genes, but it is unlikely that pathways additional to those 
found here will be revealed.   
	   121	  
Previous studies mainly focused on the development of embryos from HHP-treated 
oocytes as well as gene expression of treated oocytes 5-7,10-12,27.  These studies together with ours 
revealed that only a moderate number of genes was changed by HHP.  Changes at the protein 
level such as folding,  post-translation modifications 15 and protein levels likely represent major 
responses induced by HHP.  To date, proteomic analysis has only been applied to HHP-treated 
microorganisms 40.  Such study on embryos, however, is currently unfeasible due to small 
sample sizes and high expenses.   
In summary, our results showed 1) bovine cryopreserved embryos exhibit higher 
developmental competance after treatment of HHP at 40 or 60 MPa, 80 MPa, however, is not 
well-tolerated; 2) HHP treatments induced a modest transcriptional reprogramming in bovine 
embryos; and 3) HHP affected expression of genes involved in cell death and survival, RNA 
processing, as well as cell cycle and cell proliferation.  
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Table 4.1.  Representative functional groups of differentially expressed genes affected by HHP 
treatments. 
Treatment Change GO terms P-value Genes 
0 vs. 40 
Down-
regulated 
Cell death 1.27E-04 DOCK1, HSPB8, F3, CASP7, RFFL, DIDO1, TOP2A, NET1 
Apoptosis 2.55E-04 DOCK1, F3, CASP7, RFFL, DIDO1, TOP2A, NET1 
Transition metal ion 
transport 3.04E-02 ATP2C1, SLC39A9 
Up-
regulated 
RNA processing 1.16E-06 
POLR2G, POLR2F, POLR2L, SNRPD2, SART3, 
SF3B5, APLP1, SMNDC1, SFRS7, RBPMS, PPP1R8, 
SFRS9, U2AF1, DDX51 
Translation 2.82E-02 EIF4B, MRPL10, RPL15, RPL36, RPL38, MRPL43 
Oxidative phosphorylation 1.42E-02 NDUFA3, NDUFB10, NDUFB8, NDUFC2 
0 vs. 60 
Down-
regulated 
Cell Death 5.47E-05 BAG4, CASP7, DUSP6, F3, GADD45B, HK1, HSPB8, IGFBP3, DIDO1 
Apoptosis 4.35E-02 BAG4, GADD45B, DIDO1, NET1 
Transition metal ion 
transport 3.04E-02 ATP2C1, SLC39A9 
Up-
regulated 
RNA processing 7.45E-06 SFRS7, POLR2G, POLR2F, PRPF4B, POLR2L, SNRPD3, SFRS9, TFB2M, SNRPD2, APLP1 
Transcription, DNA-
dependent 6.58E-03 POLR2G, BGLAP, POLR2F, POLR2L, TFB2M 
Translation 4.34E-02 EIF4B, RPL36, RPL38, MRPL43 
0 vs. 80 
Down-
regulated 
Protein folding 1.53E-02 BAG4, DNAJC10, DNAJA1, DNAJB6 
Response to unfolded 
protein 1.86E-02 HSPH1, DNAJA1, DNAJB6 
Cell cycle 2.53E-02 PLK2, DUSP1, DBF4, NSL1, ANXA1, BANP, RAD54B 
Up-
regulated 
Chromatin assembly or 
disassembly 1.38E-05 HIST1H1E, HDAC8 
Apoptosis and Cell Death 3.38E-05 AP2A2, EIF4B, HK1 
Cellular Assembly and 
Organization 1.17E-02 HDAC8 
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Table 4.2.  Representative functional groups of differentially expressed genes affected by HHP 
recovery time. 
Treatment Change GO terms P-value Genes 
0 vs. 1h 
Down-
regulated 
Apoptosis 1.27E-02 F3, CASP7, MDM4, GADD45B, DIDO1 
Proteolysis 2.02E-02 WSB1, UHRF2, F3, CASP7, YOD1, CNOT4 
Phosphate metabolic 
process 5.97E-02 PRPF4B, DUSP1, GADD45B, IGFBP3, DUSP6 
Up-
regulated 
Cellular growth and 
proliferation 2.64E-03 DBF4 
Cell Morphology 1.74E-03 CNTNAP1 
Cellular Function and 
Maintenance 1.39E-02 NDUFA3 
0 vs. 2h 
Down-
regulated 
Protein folding 1.53E-02 BAG4, DNAJC10, DNAJA1, DNAJB6, HSPH1 
Cell cycle 2.53E-02 FAM83D, UHRF2, PLK2, DUSP1, BANP, BIRC5, CABLES1 
Cell death 5.92E-02 BAG4, HSPB8, F3, CASP7, BIRC5, APLP1 
Up-
regulated 
Cellular Growth and 
Proliferation 6.24E-05 APLN 
DNA replication 1.18E-02 DBF4, WRNIP1, TOP2A 
G1/S transition of mitotic 
cell cycle 4.86E-02 BCAT1, DBF4 
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Figure 4.1.  Experiment design of high hydrostatic pressure (HHP) treatment on cryopreserved 




Figure 4.2.  Re-expansion rates (mean + SD) of vitrified and thawed bovine IVP blastocysts 
upon different HHP treatments with a 2h recovery time. (**: P-value < 0.01, *: P-value <0.05; n 
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Figure 4.3.  (A). Hierarchical clustering of all 12,274 analyzed transcripts among different HHP 
treatments and recovery times.  Clear separations by HHP levels (0, 40, 60 and 80 MPa) were 
seen, demonstrating that pressure is the more significant factor than recovery time.  (B).  
Heatmap of differentially expressed genes among different HHP treatments. The color spectrum, 
ranging from red to green, indicates normalized levels of gene expression from .   
 
 
Figure 4.4.  (A). The numbers of differentially expressed genes between HHP-treated embryos 
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Figure 4.5. Modified apoptotic pathways in HHP-treated embryos. Genes in the green and red 
boxes were down- and up-regulated in both the 40- and 60-MPa treated groups (P-value < 0.05), 





Figure 4.6.  (A). The numbers of differentially expressed genes between embryos allowed 
recovery time and controls.  (B) Venn diagram shows the number of differentially genes specific 
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Figure 4.7. Comparisons of microarray and quantitative real-time RT-PCR (qRT-PCR) results of 
8 selected genes from 40 and 60 MPa treated embryos.  Fold change (mean ± SD) was expressed 
as the ratios of the levels of the 40 or 60 MPa treated embryos (n=3) to those of the controls (0.1 
MPa) (n=3).  In all cases, real time RT-PCR results substantiated the differential gene expression 
patterns from microarray. 
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4.6.	  Supplementary	  Information	  
Table S4.1: Primers for real time qRT-PCR. 
Genes Primers sequences (5' - 3') Annealing temperature (°C) 
Fragment 
size (bp) Accession number 
HSPB8 
ACGACTTGACTGCCTCTTGG 
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Table S4.2: List of all differentially expressed genes in bovine IVP embryos affected by HHP 
treatments. 
Probe UniGene ID Gene Name Product P-value 
4927 Bt.55759 DKFZp434K181
5 
hypothetical protein DKFZp434K1815 6.86E-08 
3757 Bt.2005 LSM1 LSM1 homolog, U6 small nuclear RNA associated (S. 
cerevisiae) 
1.50E-07 
6288 Bt.13965 CNTNAP1 contactin associated protein 1 2.48E-07 
8731 Bt.27784 PPP1R10 protein phosphatase 1, regulatory (inhibitor) subunit 10 4.21E-07 
2287 Bt.27376 Bag4 BCL2-associated athanogene 4 4.25E-07 
2719 Bt.75092 DIDO1 death inducer-obliterator 1 4.49E-07 
6779 Bt.90151 LOC100008589 28S ribosomal RNA 8.45E-07 
2380 Bt.23564 C6orf120 chromosome 6 open reading frame 120 1.02E-06 
8859 Bt.27784 PPP1R10 protein phosphatase 1, regulatory (inhibitor) subunit 10 1.13E-06 
3495 Bt.8279 C3orf60 chromosome 3 open reading frame 60 1.30E-06 
9586 Bt.88378 KIAA1303 raptor 1.52E-06 
6419 Bt.13965 CNTNAP1 contactin associated protein 1 1.56E-06 
288 Bt.28094 CASP7 caspase 7, apoptosis-related cysteine peptidase 1.68E-06 
3623 Bt.8279 C3orf60 chromosome 3 open reading frame 60 1.85E-06 
9896 Bt.58080 ZNF3 zinc finger protein 3 1.85E-06 
10009 Bt.48940 PPAP2B phosphatidic acid phosphatase type 2B 1.96E-06 
2357 Bt.5184 Ankrd40 ankyrin repeat domain 40 2.39E-06 
2263 Bt.23564 C6orf120 chromosome 6 open reading frame 120 2.66E-06 
6641 Bt.90151 LOC100008589 28S ribosomal RNA 2.96E-06 
1090 Bt.7391 APLP1 amyloid beta (A4) precursor-like protein 1 3.84E-06 
1536 Bt.66354 POLR2L polymerase (RNA) II (DNA directed) polypeptide L, 
7.6kDa 
6.22E-06 
9438 Bt.88378 KIAA1303 raptor 6.94E-06 
2402 Bt.7873 BCAM basal cell adhesion molecule (Lutheran blood group) 6.99E-06 
9762 Bt.58080 ZNF3 zinc finger protein 3 7.52E-06 
6978 Bt.22374 MGC137396 similar to CG9339-PF 9.39E-06 
3888 Bt.2005 LSM1 LSM1 homolog, U6 small nuclear RNA associated (S. 
cerevisiae) 
9.51E-06 
1895 Bt.42858 ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 5 
1.02E-05 
2285 Bt.7873 BCAM basal cell adhesion molecule (Lutheran blood group) 1.10E-05 
3093 Bt.53211 LOC615039 hypothetical LOC615039 1.14E-05 
1662 Bt.66354 POLR2L polymerase (RNA) II (DNA directed) polypeptide L, 
7.6kDa 
1.19E-05 
3177 Bt.48951 ASB11 ankyrin repeat and SOCS box-containing 11 1.21E-05 
747 Bt.28249 SEC24A SEC24 related gene family, member A (S. cerevisiae) 1.53E-05 
2575 Bt.2041 AP2A2 adaptor-related protein complex 2, alpha 2 subunit 1.71E-05 
9020 Bt.4586 GNG2 guanine nucleotide binding protein (G protein), gamma 
2 
1.81E-05 
1477 Bt.12399 NEU1 sialidase 1 (lysosomal sialidase) 1.84E-05 
6849 Bt.22374 MGC137396 similar to CG9339-PF 1.89E-05 
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8159 Bt.89557 NA Transcribed locus 1.96E-05 
4237 Bt.87845 COX5B cytochrome c oxidase subunit Vb 2.00E-05 
4305 Bt.89659 FKBP9L FK506 binding protein 9-like 2.02E-05 
8416 Bt.21965 ZNF358 zinc finger protein 358 2.10E-05 
1767 Bt.42858 ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 5 
2.23E-05 
5625 Bt.45080 LRRC45 leucine rich repeat containing 45 2.36E-05 
8432 Bt.5633 TMEM129 transmembrane protein 129 2.38E-05 
7909 Bt.64563 RFFL ring finger and FYVE-like domain containing 1 2.54E-05 
5766 Bt.65363 C16orf69 chromosome 16 open reading frame 69 2.56E-05 
5328 Bt.55867 HSPC152 hypothetical protein HSPC152 2.62E-05 
320  TMEM121 transmembrane protein 121 2.64E-05 
8747 Bt.23521 DUSP26 dual specificity phosphatase 26 (putative) 2.74E-05 
2441 Bt.2041 AP2A2 adaptor-related protein complex 2, alpha 2 subunit 3.05E-05 
8883 Bt.4586 GNG2 guanine nucleotide binding protein (G protein), gamma 
2 
3.28E-05 
11924 Bt.37906 YOD1 YOD1 OTU deubiquinating enzyme 1 homolog (S. 
cerevisiae) 
3.39E-05 
893 Bt.59331 UAP1 UDP-N-acteylglucosamine pyrophosphorylase 1 3.55E-05 
1897 Bt.12732 NYREN18 NEDD8 ultimate buster-1 3.57E-05 
2569 Bt.7562 FLJ41352 FLJ41352 protein 3.66E-05 
4162 Bt.89659 FKBP9L FK506 binding protein 9-like 3.78E-05 
5332 Bt.12314 PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 3.97E-05 
904 Bt.7418 ANKH ankylosis, progressive homolog (mouse) 4.40E-05 
4243 Bt.6710 LOC440330 hypothetical LOC440330 4.50E-05 
4349 Bt.66386 WRNIP1 Werner helicase interacting protein 1 4.59E-05 
4380 Bt.87845 COX5B cytochrome c oxidase subunit Vb 4.62E-05 
8808 Bt.53659 ABHD13 abhydrolase domain containing 13 4.64E-05 
3287 Bt.48951 ASB11 ankyrin repeat and SOCS box-containing 11 4.73E-05 
1436 Bt.6451 HIST1H1E histone cluster 1, H1e 4.92E-05 
1603 Bt.12399 NEU1 sialidase 1 (lysosomal sialidase) 5.03E-05 
8644 Bt.8738 HSPH1 heat shock 105kDa/110kDa protein 1 5.51E-05 
10144 Bt.48940 PPAP2B phosphatidic acid phosphatase type 2B 5.70E-05 
5355 Bt.269 ATP2C1 ATPase, Ca++ transporting, type 2C, member 1 5.96E-05 
2339 Bt.52556 RCP9 calcitonin gene-related peptide-receptor component 
protein 
6.21E-05 
781 Bt.7418 ANKH ankylosis, progressive homolog (mouse) 6.37E-05 
1841 Bt.12138 RP11-413M3.2 similar to CG12379-PA 6.48E-05 
4205 Bt.66386 WRNIP1 Werner helicase interacting protein 1 6.48E-05 
586 Bt.12578 ORC5L origin recognition complex, subunit 5-like (yeast) 6.51E-05 
5212 Bt.12314 PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 6.60E-05 
770 Bt.59331 UAP1 UDP-N-acteylglucosamine pyrophosphorylase 1 6.66E-05 
8983 Bt.45485 KLF9 Kruppel-like factor 9 6.68E-05 
1685 Bt.77469 KCTD20 potassium channel tetramerisation domain containing 
20 
6.84E-05 
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967 Bt.73261 LOC513955 hypothetical LOC513955 6.85E-05 
8617 Bt.23521 DUSP26 dual specificity phosphatase 26 (putative) 6.93E-05 





hypothetical protein DKFZp434K1815 7.42E-05 
4386 Bt.6710 LOC440330 hypothetical LOC440330 7.53E-05 
10996 Bt.22526 HSPB8 heat shock 22kDa protein 8 7.83E-05 
8250 Bt.22175 KCNT1 potassium channel, subfamily T, member 1 7.92E-05 
9907 Bt.59214 FGD5 FYVE, RhoGEF and PH domain containing 5 8.01E-05 
9654 Bt.46839 SNRPD2 small nuclear ribonucleoprotein D2 polypeptide 
16.5kDa 
8.10E-05 
4144 Bt.49595 TMEM111 transmembrane protein 111 8.44E-05 
8544 Bt.21965 ZNF358 zinc finger protein 358 8.87E-05 
4834 Bt.8545 MRPL43 mitochondrial ribosomal protein L43 9.09E-05 
5208 Bt.55867 HSPC152 hypothetical protein HSPC152 9.14E-05 
9121 Bt.45485 KLF9 Kruppel-like factor 9 9.23E-05 
8774 Bt.8738 HSPH1 heat shock 105kDa/110kDa protein 1 9.29E-05 
3089 Bt.22538 FZD8 frizzled homolog 8 (Drosophila) 9.71E-05 
2133 Bt.4185 NHP2L1 NHP2 non-histone chromosome protein 2-like 1 (S. 
cerevisiae) 
1.01E-04 
5945 Bt.26976 COX11 COX11 homolog, cytochrome c oxidase assembly 
protein (yeast) 
1.02E-04 
5154 Bt.52786 LOC100008588 18S ribosomal RNA 1.03E-04 
2970 Bt.53211 LOC615039 hypothetical LOC615039 1.03E-04 
1968 Bt.53760 LOC728216 similar to ubiquitin specific peptidase 18 1.05E-04 
5262 Bt.8206 SFRS7 splicing factor, arginine/serine-rich 7, 35kDa 1.05E-04 
7305 Bt.89284 LOC100008589 28S ribosomal RNA 1.06E-04 
2404 Bt.27376 Bag4 BCL2-associated athanogene 4 1.06E-04 
7223 Bt.500 HK1 hexokinase 1 1.09E-04 
3865 Bt.52937 hCG_20417 mitochondrial ribosomal protein L20 1.09E-04 
403 Bt.28094 CASP7 caspase 7, apoptosis-related cysteine peptidase 1.13E-04 
1769 Bt.12732 NYREN18 NEDD8 ultimate buster-1 1.13E-04 
5768 Bt.49597 LOC528919 similar to F-box and WD-40 domain protein 12 1.13E-04 
3414 Bt.61384 UNC84B unc-84 homolog B (C. elegans) 1.16E-04 
2079 Bt.53760 LOC728216 similar to ubiquitin specific peptidase 18 1.17E-04 
7060 Bt.11280 BANP BTG3 associated nuclear protein 1.22E-04 
6385 Bt.9092 POLR2G polymerase (RNA) II (DNA directed) polypeptide G 1.23E-04 
3885 Bt.51520 C14orf94 chromosome 14 open reading frame 94 1.24E-04 
4656 Bt.32544 NVL nuclear VCP-like 1.28E-04 
7185 Bt.11280 BANP BTG3 associated nuclear protein 1.32E-04 
9205 Bt.21568 FAM118B family with sequence similarity 118, member B 1.32E-04 
1402 Bt.4279 SHC1 SHC (Src homology 2 domain containing) 
transforming protein 1 
1.35E-04 
8583 Bt.52379 QRICH1 glutamine-rich 1 1.37E-04 
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7986 Bt.66 NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 3, 9kDa 
1.38E-04 
3733 Bt.52937 hCG_20417 mitochondrial ribosomal protein L20 1.40E-04 
2027 Bt.10259 PLK2 polo-like kinase 2 (Drosophila) 1.47E-04 
4986 Bt.89574 KIAA0182 KIAA0182 1.50E-04 
9829 Bt.27267 TMEM4 transmembrane protein 4 1.51E-04 
6659 Bt.3196 STRA6 stimulated by retinoic acid gene 6 homolog (mouse) 1.52E-04 
5633 Bt.2568 ADFP adipose differentiation-related protein 1.57E-04 
123 Bt.64291 H3F3A H3 histone, family 3A 1.58E-04 
5025 Bt.52786 LOC100008588 18S ribosomal RNA 1.61E-04 
393 Bt.58700 C9orf58 chromosome 9 open reading frame 58 1.67E-04 
9501    1.69E-04 
11807 Bt.37906 YOD1 YOD1 OTU deubiquinating enzyme 1 homolog (S. 
cerevisiae) 
1.70E-04 
870 Bt.28249 SEC24A SEC24 related gene family, member A (S. cerevisiae) 1.74E-04 
10034 Bt.7363 LOC789389 similar to Wolf-Hirschhorn syndrome candidate 2 
protein 
1.75E-04 
7097 Bt.500 HK1 hexokinase 1 1.87E-04 
3739 Bt.28081 POGZ pogo transposable element with ZNF domain 1.89E-04 
89 Bt.32543 IPO8 importin 8 1.91E-04 
3754 Bt.51520 C14orf94 chromosome 14 open reading frame 94 1.92E-04 
2654 Bt.4298 GPR172B G protein-coupled receptor 172B 1.94E-04 
626 Bt.38424 DST dystonin 1.99E-04 
5818 Bt.26976 COX11 COX11 homolog, cytochrome c oxidase assembly 
protein (yeast) 
2.01E-04 
5495 Bt.2568 ADFP adipose differentiation-related protein 2.03E-04 
1640 Bt.49587 GPI glucose phosphate isomerase 2.07E-04 
7811 Bt.39540 IL15RA interleukin 15 receptor, alpha 2.07E-04 
7448 Bt.89284 LOC100008589 28S ribosomal RNA 2.08E-04 
3263 Bt.37779 BPHL biphenyl hydrolase-like (serine hydrolase; breast 
epithelial mucin-associated antigen) 
2.11E-04 
9186 Bt.65788  Transcribed locus 2.14E-04 
2167 Bt.20080 WSB1 WD repeat and SOCS box-containing 1 2.15E-04 
9208 Bt.26958 LOC788996 similar to Potassium/sodium hyperpolarization-
activated cyclic nucleotide-gated channel 2 (Brain 
cyclic nucleotide-gated channel 2) (BCNG-2) 
2.16E-04 
6252 Bt.9092 POLR2G polymerase (RNA) II (DNA directed) polypeptide G 2.21E-04 
1401 Bt.3199 RUSC1 RUN and SH3 domain containing 1 2.21E-04 
2193 Bt.52796 COPS6 COP9 constitutive photomorphogenic homolog subunit 
6 (Arabidopsis) 
2.25E-04 
7856 Bt.66 NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 3, 9kDa 
2.26E-04 
5236 Bt.269 ATP2C1 ATPase, Ca++ transporting, type 2C, member 1 2.29E-04 
8035 Bt.38851 RHPN2 rhophilin, Rho GTPase binding protein 2 2.30E-04 
2807 Bt.64366 NDUFC2 NADH dehydrogenase (ubiquinone) 1, subcomplex 
unknown, 2, 14.5kDa 
2.41E-04 
2521 Bt.4298 GPR172B G protein-coupled receptor 172B 2.52E-04 
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11261 Bt.9525 RNF113A ring finger protein 113A 2.58E-04 
5727 Bt.70 NDUFB10 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 10, 22kDa 
2.60E-04 
5271 Bt.4908 RBBP7 retinoblastoma binding protein 7 2.66E-04 
5894 Bt.65363 C16orf69 chromosome 16 open reading frame 69 2.71E-04 
5840 Bt.1658 DUSP1 dual specificity phosphatase 1 2.76E-04 
2986 Bt.27527 STXBP3 syntaxin binding protein 3 2.78E-04 
9337 Bt.26958 LOC788996 similar to Potassium/sodium hyperpolarization-
activated cyclic nucleotide-gated channel 2 (Brain 
cyclic nucleotide-gated channel 2) (BCNG-2) 
2.80E-04 
2223 Bt.52556 RCP9 calcitonin gene-related peptide-receptor component 
protein 
2.81E-04 
12100 Bt.30953 DOCK1 dedicator of cytokinesis 1 3.01E-04 
6155 Bt.7804 GYG1 glycogenin 1 3.01E-04 
7816 Bt.6438 TGFB2 transforming growth factor, beta 2 3.05E-04 
1560 Bt.77469 KCTD20 potassium channel tetramerisation domain containing 
20 
3.11E-04 
6408 Bt.52209 RAD54B RAD54 homolog B (S. cerevisiae) 3.16E-04 
2274 Bt.44330 LRP10 low density lipoprotein receptor-related protein 10 3.17E-04 
4802 Bt.22766 SART3 squamous cell carcinoma antigen recognized by T cells 
3 
3.23E-04 
5966 Bt.5519 TncRNA trophoblast-derived noncoding RNA 3.28E-04 
1689 Bt.39564 LOC506268 similar to C2orf29 protein 3.33E-04 
8404 Bt.76983 BIRC5 Baculoviral IAP repeat-containing 5 (survivin) 3.43E-04 
8640 Bt.44264 LTF lactotransferrin 3.51E-04 
5165 Bt.2056 APEH N-acylaminoacyl-peptide hydrolase 3.57E-04 
3375 Bt.37779 BPHL biphenyl hydrolase-like (serine hydrolase; breast 
epithelial mucin-associated antigen) 
3.58E-04 
2830 Bt.75092 DIDO1 death inducer-obliterator 1 3.64E-04 
11731 Bt.22575 TMEM167 transmembrane protein 167 3.68E-04 
506 Bt.6024 POLR3K polymerase (RNA) III (DNA directed) polypeptide K, 
12.3 kDa 
3.70E-04 
8460 Bt.5530 DHRS3 dehydrogenase/reductase (SDR family) member 3 3.77E-04 
8533 Bt.76983 BIRC5 Baculoviral IAP repeat-containing 5 (survivin) 3.79E-04 
8128 Bt.33726 NPY neuropeptide Y 3.89E-04 
385 Bt.36587 APLN apelin, AGTRL1 ligand 3.91E-04 
4066 Bt.73096 CTH cystathionase (cystathionine gamma-lyase) 4.04E-04 
7061 Bt.42818 POLR3B polymerase (RNA) III (DNA directed) polypeptide B 4.06E-04 
1273 Bt.4279 SHC1 SHC (Src homology 2 domain containing) 
transforming protein 1 
4.09E-04 
758 Bt.21023 AS3MT arsenic (+3 oxidation state) methyltransferase 4.10E-04 
3541 Bt.61384 UNC84B unc-84 homolog B (C. elegans) 4.17E-04 
3518 Bt.28502 FAM83D family with sequence similarity 83, member D 4.18E-04 
281 Bt.9783 DDX3X DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-
linked 
4.21E-04 
2111 Bt.9186 FBXL3 F-box and leucine-rich repeat protein 3 4.28E-04 
8679 Bt.53659 ABHD13 abhydrolase domain containing 13 4.32E-04 
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2240 Bt.5184 Ankrd40 ankyrin repeat domain 40 4.36E-04 
9071 Bt.66625 CNOT4 CCR4-NOT transcription complex, subunit 4 4.38E-04 
2887 Bt.61617 UHRF2 ubiquitin-like, containing PHD and RING finger 
domains, 2 
4.40E-04 
2559 Bt.64693 Dnaja1 DnaJ (Hsp40) homolog, subfamily A, member 1 4.42E-04 
42 Bt.34521 RBM12 RNA binding motif protein 12 4.53E-04 
6830 Bt.52335 IFT57 intraflagellar transport 57 homolog (Chlamydomonas) 4.55E-04 
8292 Bt.89557  Transcribed locus 4.63E-04 
11028 Bt.30639 CNOT2 CCR4-NOT transcription complex, subunit 2 4.67E-04 
7556 Bt.63484 SURF2 surfeit 2 4.67E-04 
1307 Bt.6451 HIST1H1E histone cluster 1, H1e 4.71E-04 
13 Bt.64291 H3F3A H3 histone, family 3A 4.71E-04 
708 Bt.732  Transcribed locus 4.72E-04 
3393 Bt.28502 FAM83D family with sequence similarity 83, member D 4.74E-04 
11811 Bt.625 C6orf106 hypothetical protein LOC617655 4.75E-04 
1858 Bt.62530 ITPK1 inositol 1,3,4-triphosphate 5/6 kinase 4.83E-04 
4505 Bt.15915 IPO11 importin 11 4.89E-04 
437  TMEM121 transmembrane protein 121 4.92E-04 
1019 Bt.9195 SIVA1 SIVA1, apoptosis-inducing factor 4.93E-04 
4043    5.09E-04 
4008 Bt.26835 RANGNRF RAN guanine nucleotide release factor 5.11E-04 
5896 Bt.49597 LOC528919 similar to F-box and WD-40 domain protein 12 5.15E-04 
10194 Bt.62845 ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1 5.18E-04 
6897 Bt.21510 GPR107 G protein-coupled receptor 107 5.28E-04 
3939 Bt.73096 CTH cystathionase (cystathionine gamma-lyase) 5.28E-04 
3585 Bt.26997 Ptpmt1 protein tyrosine phosphatase, mitochondrial 1 5.31E-04 
1794 Bt.64539 QSCN6 quiescin Q6 5.35E-04 
538 Bt.13737 GALK2 galactokinase 2 5.44E-04 
1290 Bt.63116 AKR1B1 aldo-keto reductase family 1, member B1 (aldose 
reductase) 
5.50E-04 
4532 Bt.4949 SF3B5 splicing factor 3b, subunit 5, 10kDa 5.53E-04 
4001 Bt.26739 TOMM40L translocase of outer mitochondrial membrane 40 
homolog (yeast)-like 
5.57E-04 
1109 Bt.17683 DBF4 DBF4 homolog (S. cerevisiae) 5.60E-04 
6960 Bt.52335 IFT57 intraflagellar transport 57 homolog (Chlamydomonas) 5.75E-04 
7496 Bt.10332 Cramp1l Crm, cramped-like (Drosophila) 5.81E-04 
4952 Bt.2642 ZNF706 zinc finger protein 706 5.94E-04 
2391 Bt.44330 LRP10 low density lipoprotein receptor-related protein 10 6.03E-04 
779 Bt.90218 TES testis derived transcript (3 LIM domains) 6.11E-04 
5487 Bt.45080 LRRC45 leucine rich repeat containing 45 6.11E-04 
10232 Bt.1858 C20orf108 chromosome 20 open reading frame 108 6.16E-04 
971 Bt.7391 APLP1 amyloid beta (A4) precursor-like protein 1 6.19E-04 
8117 Bt.22175 KCNT1 potassium channel, subfamily T, member 1 6.19E-04 
5040 Bt.1786 YME1L1 YME1-like 1 (S. cerevisiae) 6.20E-04 
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11140 Bt.9525 RNF113A ring finger protein 113A 6.29E-04 
9841 Bt.87389 GAPDH glyceraldehyde-3-phosphate dehydrogenase 6.29E-04 
8877 Bt.48519 RBPMS RNA binding protein with multiple splicing 6.31E-04 
1902 Bt.12743 ABCD4 ATP-binding cassette, sub-family D (ALD), member 4 6.35E-04 
10681 Bt.59095 C9orf97 chromosome 9 open reading frame 97 6.48E-04 
279 Bt.58700 C9orf58 chromosome 9 open reading frame 58 6.48E-04 
1514 Bt.49587 GPI glucose phosphate isomerase 6.52E-04 
5186 Bt.57711 NDUFB8 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 8, 19kDa 
6.55E-04 
4400 Bt.49192 RPL15 ribosomal protein L15 6.58E-04 
2020 Bt.4185 NHP2L1 NHP2 non-histone chromosome protein 2-like 1 (S. 
cerevisiae) 
6.65E-04 
1419 Bt.63116 AKR1B1 aldo-keto reductase family 1, member B1 (aldose 
reductase) 
6.78E-04 
2471 Bt.49501 C15orf40 chromosome 15 open reading frame 40 6.81E-04 
8041 Bt.64563 RFFL ring finger and FYVE-like domain containing 1 6.96E-04 
4274 Bt.11909 DUSP6 dual specificity phosphatase 6 7.01E-04 
5773 Bt.38862 RALA v-ral simian leukemia viral oncogene homolog A (ras 
related) 
7.03E-04 
4027 Bt.11096 KPNA4 karyopherin alpha 4 (importin alpha 3) 7.04E-04 
2112 Bt.44470 SATB1 SATB homeobox 1 7.05E-04 
4931 Bt.27370 HEATR3 HEAT repeat containing 3 7.07E-04 
5036 Bt.2056 APEH N-acylaminoacyl-peptide hydrolase 7.16E-04 
6501 Bt.48788 RAB30 RAB30, member RAS oncogene family 7.18E-04 
5382 Bt.8206 SFRS7 splicing factor, arginine/serine-rich 7, 35kDa 7.25E-04 
10097 Bt.1858 C20orf108 chromosome 20 open reading frame 108 7.25E-04 
519 Bt.49151 LOC729046 similar to 60S ribosomal protein L17 (L23) 7.50E-04 
11849 Bt.9469 DNAJC10 DnaJ (Hsp40) homolog, subfamily C, member 10 7.59E-04 
6124 Bt.43820 RPL36 ribosomal protein L36 7.60E-04 
1818 Bt.62762 LOC124446 hypothetical protein BC017488 7.64E-04 
2435 Bt.7562 FLJ41352 FLJ41352 protein 7.64E-04 
4263 Bt.23076 C1orf93 chromosome 1 open reading frame 93 7.65E-04 
636 Bt.6024 POLR3K polymerase (RNA) III (DNA directed) polypeptide K, 
12.3 kDa 
7.67E-04 
2709 Bt.21070 MRPL10 mitochondrial ribosomal protein L10 7.69E-04 
5854 Bt.70 NDUFB10 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 10, 22kDa 
7.71E-04 
4257 Bt.49192 RPL15 ribosomal protein L15 7.74E-04 
4914 Bt.64707 LOC146346 hypothetical protein LOC146346 7.76E-04 
4406 Bt.23076 C1orf93 chromosome 1 open reading frame 93 7.84E-04 
7684 Bt.39540 IL15RA interleukin 15 receptor, alpha 7.85E-04 
265 Bt.20277 TOP2A topoisomerase (DNA) II alpha 170kDa 7.86E-04 
4018 Bt.49595 TMEM111 transmembrane protein 111 7.88E-04 
4665 Bt.4949 SF3B5 splicing factor 3b, subunit 5, 10kDa 7.98E-04 
8266 Bt.16440 USP6NL USP6 N-terminal like 8.00E-04 
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5987 Bt.13810 U2AF1 U2 small nuclear RNA auxiliary factor 1 8.16E-04 
8588 Bt.5530 DHRS3 dehydrogenase/reductase (SDR family) member 3 8.16E-04 
5 Bt.29924 MDM4 Mdm4, transformed 3T3 cell double minute 4, p53 
binding protein (mouse) 
8.25E-04 
6339 Bt.44021 WDR8 WD repeat domain 8 8.30E-04 
2053 Bt.20080 WSB1 WD repeat and SOCS box-containing 1 8.32E-04 
1886 Bt.76825 LOC789371 hypothetical protein LOC789371 8.34E-04 
395 Bt.9783 DDX3X DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-
linked 
8.36E-04 
942 Bt.6650 GGH gamma-glutamyl hydrolase (conjugase, 
folylpolygammaglutamyl hydrolase) 
8.42E-04 
1782 Bt.53344 ARHGAP21 Rho GTPase activating protein 21 8.51E-04 
3806 Bt.25997 CABLES1 Cdk5 and Abl enzyme substrate 1 8.53E-04 
10961 Bt.20683 TP53INP2 tumor protein p53 inducible nuclear protein 2 8.75E-04 
4345 Bt.17589 DMTF1 cyclin D binding myb-like transcription factor 1 8.80E-04 
2992 Bt.18512 ASF1A ASF1 anti-silencing function 1 homolog A (S. 
cerevisiae) 
8.81E-04 
289 Bt.21926 LOC508142 similar to translocase of outer mitochondrial membrane 
34 
8.82E-04 
4418 Bt.11909 DUSP6 dual specificity phosphatase 6 8.90E-04 
2776 Bt.61617 UHRF2 ubiquitin-like, containing PHD and RING finger 
domains, 2 
9.04E-04 
6018 Bt.7804 GYG1 glycogenin 1 9.06E-04 
3472 Bt.49273 POLR2F polymerase (RNA) II (DNA directed) polypeptide F 9.07E-04 
7594 Bt.11282  Transcribed locus 9.17E-04 
2877 Bt.30434 SFRS9 splicing factor, arginine/serine-rich 9 9.18E-04 
884 Bt.49509 LZTFL1 leucine zipper transcription factor-like 1 9.19E-04 
10764    9.47E-04 
3054 Bt.43655 MGC152057 hypothetical LOC507084 9.47E-04 
11275 Bt.2988 GNG11 guanine nucleotide binding protein (G protein), gamma 
11 
9.47E-04 
11761 Bt.17953 FOXP1 forkhead box P1 9.56E-04 
564 Bt.28460 SNRPD3 small nuclear ribonucleoprotein D3 polypeptide 18kDa 9.71E-04 
7968 Bt.49157 APOA1 apolipoprotein A-I 9.73E-04 
3701 Bt.24435 SYNCRIP synaptotagmin binding, cytoplasmic RNA interacting 
protein 
9.75E-04 
3833 Bt.24435 SYNCRIP synaptotagmin binding, cytoplasmic RNA interacting 
protein 
9.81E-04 
2634 Bt.90254 HDAC8 histone deacetylase 8 9.81E-04 
5114 Bt.89574 KIAA0182 KIAA0182 9.88E-04 
10059 Bt.62845 ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1 9.96E-04 
2555 Bt.5528 SLC7A5 solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 5 
1.01E-03 
8529 Bt.7930 NUCB1 nucleobindin 1 1.01E-03 
2422 Bt.5528 SLC7A5 solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 5 
1.01E-03 
1116 Bt.25186 BCAT1 branched chain aminotransferase 1, cytosolic 1.01E-03 
10864 Bt.22526 HSPB8 heat shock 22kDa protein 8 1.02E-03 
	   137	  
7027 Bt.21510 GPR107 G protein-coupled receptor 107 1.03E-03 
8133 Bt.16440 USP6NL USP6 N-terminal like 1.05E-03 
6908 Bt.2453 POLR2H polymerase (RNA) II (DNA directed) polypeptide H 1.05E-03 
4183 Bt.89506 NSL1 NSL1, MIND kinetochore complex component, 
homolog (S. cerevisiae) 
1.05E-03 
2934 Bt.17132 KRIT1 KRIT1, ankyrin repeat containing 1.06E-03 
3818 Bt.22310 ARIH2 ariadne homolog 2 (Drosophila) 1.07E-03 
10834 Bt.18408 CCDC117 coiled-coil domain containing 117 1.07E-03 
1731 Bt.62530 ITPK1 inositol 1,3,4-triphosphate 5/6 kinase 1.07E-03 
4884  SEMA3G sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3G 
1.08E-03 
3736 Bt.49705 PRDX6 peroxiredoxin 6 1.09E-03 
3794 Bt.44982 CHRNA10 cholinergic receptor, nicotinic, alpha 10 1.09E-03 
3045 Bt.36226 SMNDC1 survival motor neuron domain containing 1 1.10E-03 
9773 Bt.59214 FGD5 FYVE, RhoGEF and PH domain containing 5 1.10E-03 
3140 Bt.56130 SIAHBP1 fuse-binding protein-interacting repressor 1.11E-03 
11668 Bt.49238 HPRT1 hypoxanthine phosphoribosyltransferase 1 (Lesch-
Nyhan syndrome) 
1.12E-03 
6217 Bt.11128 MGC140717 similar to uracil-DNA glycosylase isoform UNG2 1.13E-03 
2865 Bt.89629 EIF4B eukaryotic translation initiation factor 4B 1.14E-03 
4134 Bt.26835 RANGNRF RAN guanine nucleotide release factor 1.17E-03 
3109 Bt.27527 STXBP3 syntaxin binding protein 3 1.18E-03 
3671 Bt.27129 SLC39A9 solute carrier family 39 (zinc transporter), member 9 1.18E-03 
11544 Bt.49238 HPRT1 hypoxanthine phosphoribosyltransferase 1 (Lesch-
Nyhan syndrome) 
1.21E-03 
5839 Bt.5519 TncRNA trophoblast-derived noncoding RNA 1.21E-03 
9706 Bt.87389 GAPDH glyceraldehyde-3-phosphate dehydrogenase 1.22E-03 
3017 Bt.56130 SIAHBP1 fuse-binding protein-interacting repressor 1.22E-03 
989 Bt.17683 DBF4 DBF4 homolog (S. cerevisiae) 1.23E-03 
11879 Bt.17953 FOXP1 forkhead box P1 1.23E-03 
7513 Bt.63820 LOC517063 similar to adenylate kinase isoenzyme 4, mitochondrial 1.23E-03 
3868 Bt.49705 PRDX6 peroxiredoxin 6 1.24E-03 
4707 Bt.46116 MXRA7 matrix-remodelling associated 7 1.25E-03 
2672 Bt.6612 DDX51 DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 1.26E-03 
6997 Bt.15697 PER2 period homolog 2 (Drosophila) 1.26E-03 
4711 Bt.8545 MRPL43 mitochondrial ribosomal protein L43 1.26E-03 
8090 Bt.14027 DDX23 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23 1.27E-03 
10966 Bt.18408 CCDC117 coiled-coil domain containing 117 1.27E-03 
874 Bt.22035 C5orf14 chromosome 5 open reading frame 14 1.28E-03 
7621 Bt.9482 LOC504245 similar to Rho GTPase activating protein 17 1.29E-03 
1806 Bt.51523 TBC1D14 TBC1 domain family, member 14 1.31E-03 
1607 Bt.4371 GADD45B growth arrest and DNA-damage-inducible, beta 1.31E-03 
7122 Bt.22 PPP1R8 protein phosphatase 1, regulatory (inhibitor) subunit 8 1.32E-03 
3543 Bt.4055 BGLAP bone gamma-carboxyglutamate (gla) protein 
(osteocalcin) 
1.32E-03 
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2425 Bt.64693 Dnaja1 DnaJ (Hsp40) homolog, subfamily A, member 1 1.32E-03 
5988 Bt.43820 RPL36 ribosomal protein L36 1.33E-03 
9334 Bt.21568 FAM118B family with sequence similarity 118, member B 1.33E-03 
5079 Bt.2642 ZNF706 zinc finger protein 706 1.34E-03 
5169 Bt.1786 YME1L1 YME1-like 1 (S. cerevisiae) 1.34E-03 
5967 Bt.1658 DUSP1 dual specificity phosphatase 1 1.34E-03 
3900 Bt.11096 KPNA4 karyopherin alpha 4 (importin alpha 3) 1.35E-03 
1923 Bt.64539 QSCN6 quiescin Q6 1.35E-03 
10650 Bt.16032 ANXA1 annexin A1 1.36E-03 
4566 Bt.6431 PCAF p300/CBP-associated factor 1.38E-03 
9151 Bt.77424 Fubp1 far upstream element (FUSE) binding protein 1 1.39E-03 
7717 Bt.11282  Transcribed locus 1.39E-03 
4322 Bt.13666 ATP5S ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit s (factor B) 
1.40E-03 
7815 Bt.6432 FAM44B family with sequence similarity 44, member B 1.40E-03 
11164 Bt.7658 RPL38 ribosomal protein L38 1.40E-03 
1947 Bt.62762 LOC124446 hypothetical protein BC017488 1.41E-03 
10742 Bt.89587 USP37 ubiquitin specific peptidase 37 1.42E-03 
5381 Bt.6330  Transcribed locus 1.42E-03 
7352 Bt.10332 Cramp1l Crm, cramped-like (Drosophila) 1.43E-03 
11069 Bt.15722 FBL fibrillarin 1.43E-03 
3598 Bt.49273 POLR2F polymerase (RNA) II (DNA directed) polypeptide F 1.43E-03 
5344 Bt.39475  Transcribed locus 1.44E-03 
8654 Bt.13784 TIMM10 translocase of inner mitochondrial membrane 10 
homolog (yeast) 
1.44E-03 
8474 Bt.89593 PRPF4B PRP4 pre-mRNA processing factor 4 homolog B 
(yeast) 
1.44E-03 
7456 Bt.46948 LRRFIP2 leucine rich repeat (in FLII) interacting protein 2 1.45E-03 
3189 Bt.44977 SLC4A1AP solute carrier family 4 (anion exchanger), member 1, 
adaptor protein 
1.45E-03 
7204 Bt.65398  Transcribed locus 1.45E-03 
3871 Bt.28081 POGZ pogo transposable element with ZNF domain 1.46E-03 
2415 Bt.46615 MGC138967 similar to CG10809-PA 1.48E-03 
7833 Bt.9192 MGAT4B mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme B 
1.48E-03 
7199 Bt.54456 TFB2M transcription factor B2, mitochondrial 1.49E-03 
595 Bt.6522 DNAJB6 DnaJ (Hsp40) homolog, subfamily B, member 6 1.50E-03 
1686 Bt.33132 TRIM24 tripartite motif-containing 24 1.51E-03 
5143 Bt.4106 F3 coagulation factor III (thromboplastin, tissue factor) 1.51E-03 
2908 Bt.7221 PPID peptidylprolyl isomerase D (cyclophilin D) 1.51E-03 
11008 Bt.28567 NFE2L1 nuclear factor (erythroid-derived 2)-like 1 1.51E-03 
5836 Bt.64649 Znf313 zinc finger protein 313 1.52E-03 
4638 Bt.15915 IPO11 importin 11 1.53E-03 
11499 Bt.64697 LMNB2 lamin B2 1.54E-03 
9280 Bt.77424 Fubp1 far upstream element (FUSE) binding protein 1 1.54E-03 
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8933 Bt.30026  Full-length cDNA clone CS0DC015YK09 of 
Neuroblastoma Cot 25-normalized of Homo sapiens 
(human) 
1.54E-03 
2606 Bt.63071 ARRDC4 arrestin domain containing 4 1.54E-03 
8455 Bt.52379 QRICH1 glutamine-rich 1 1.56E-03 
10674 Bt.48127 Tia1 cytotoxic granule-associated RNA binding protein 1 1.57E-03 
337 Bt.17282 SNIP1 Smad nuclear interacting protein 1 1.58E-03 
761 Bt.49509 LZTFL1 leucine zipper transcription factor-like 1 1.59E-03 
8867 Bt.64897 IGFBP3 insulin-like growth factor binding protein 3 1.60E-03 
7528 Bt.49586 NET1 neuroepithelial cell transforming gene 1 1.60E-03 
6758 Bt.26855 LOC506746 hypothetical LOC506746 1.61E-03 
7193 Bt.3871 LOC506318 similar to VKORC1-like protein 1 1.61E-03 
6140 Bt.27014 FEZ2 fasciculation and elongation protein zeta 2 (zygin II) 1.62E-03 
6081 Bt.11128 MGC140717 similar to uracil-DNA glycosylase isoform UNG2 1.62E-03 
10830 Bt.20683 TP53INP2 tumor protein p53 inducible nuclear protein 2 1.62E-03 
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Table S4.3: Differentially expressed genes between HHP-treated embryos and controls.  
Spreadsheet 1: Up and down-regulated genes on 40 MPa treatment compared to control; 
Spreadsheet 2: Up and down-regulated genes on 60 MPa treatment compared to control; 
Spreadsheet 3: Up and down-regulated genes on 80 MPa treatment compared to control. 
 
 
Table S4.3 Sheet 1. Genes significantly changed upon 40 MPa treatment   
Probe UniGene.ID Gene name P-value 
Fold change  
(0.1 vs. 40 MPa) Comment 
1436 Bt.6451 HIST1H1E 4.92E-05 2.411047524 Up-regulated 
1436 Bt.6451 HIST1H1E 0.000470673 2.411047524 Up-regulated 
9020 Bt.4586 GNG2 1.81E-05 1.932158299 Up-regulated 
9020 Bt.4586 GNG2 3.28E-05 1.932158299 Up-regulated 
6659 Bt.3196 STRA6 0.000152416 1.868115792 Up-regulated 
6978 Bt.22374 MGC137396 9.39E-06 1.746985206 Up-regulated 
6978 Bt.22374 MGC137396 1.89E-05 1.746985206 Up-regulated 
4927 Bt.55759 DKFZp434K1815 7.42E-05 1.739437184 Up-regulated 
4927 Bt.55759 DKFZp434K1815 6.86E-08 1.739437184 Up-regulated 
6288 Bt.13965 CNTNAP1 2.48E-07 1.722992416 Up-regulated 
6288 Bt.13965 CNTNAP1 1.56E-06 1.722992416 Up-regulated 
8747 Bt.23521 DUSP26 2.74E-05 1.680996282 Up-regulated 
8747 Bt.23521 DUSP26 6.93E-05 1.680996282 Up-regulated 
1090 Bt.7391 APLP1 3.84E-06 1.666490366 Up-regulated 
1090 Bt.7391 APLP1 0.000618699 1.666490366 Up-regulated 
5625 Bt.45080 LRRC45 2.36E-05 1.622618529 Up-regulated 
5625 Bt.45080 LRRC45 0.000610941 1.622618529 Up-regulated 
5262 Bt.8206 SFRS7 0.000724622 1.605936136 Up-regulated 
5262 Bt.8206 SFRS7 0.000104799 1.605936136 Up-regulated 
4884 
 
SEMA3G 0.001075152 1.601008337 Up-regulated 
2112 Bt.44470 SATB1 0.000705402 1.578782385 Up-regulated 
10034 Bt.7363 LOC789389 0.000174731 1.565901939 Up-regulated 
6830 Bt.52335 IFT57 0.000455475 1.562051072 Up-regulated 
6830 Bt.52335 IFT57 0.000574792 1.562051072 Up-regulated 
8416 Bt.21965 ZNF358 2.10E-05 1.549758396 Up-regulated 
8416 Bt.21965 ZNF358 8.87E-05 1.549758396 Up-regulated 
626 Bt.38424 DST 0.000199418 1.536786643 Up-regulated 
8983 Bt.45485 KLF9 6.68E-05 1.533083305 Up-regulated 
8983 Bt.45485 KLF9 9.23E-05 1.533083305 Up-regulated 
3739 Bt.28081 POGZ 0.000189317 1.514137509 Up-regulated 
3739 Bt.28081 POGZ 0.001460923 1.514137509 Up-regulated 
1841 Bt.12138 RP11-413M3.2 6.48E-05 1.509031839 Up-regulated 
3495 Bt.8279 C3orf60 1.30E-06 1.508682322 Up-regulated 
3495 Bt.8279 C3orf60 1.85E-06 1.508682322 Up-regulated 
4802 Bt.22766 SART3 0.000322672 1.50529845 Up-regulated 
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7986 Bt.66 NDUFA3 0.000138015 1.503232005 Up-regulated 
7986 Bt.66 NDUFA3 0.000226394 1.503232005 Up-regulated 
3885 Bt.51520 C14orf94 0.000123869 1.499872772 Up-regulated 
3885 Bt.51520 C14orf94 0.000191948 1.499872772 Up-regulated 
6997 Bt.15697 PER2 0.001261833 1.496187981 Up-regulated 
2575 Bt.2041 AP2A2 3.05E-05 1.480948526 Up-regulated 
2575 Bt.2041 AP2A2 1.71E-05 1.480948526 Up-regulated 
5633 Bt.2568 ADFP 0.000157168 1.46820925 Up-regulated 
5633 Bt.2568 ADFP 0.000202974 1.46820925 Up-regulated 
393 Bt.58700 C9orf58 0.000166772 1.46778073 Up-regulated 
393 Bt.58700 C9orf58 0.000647975 1.46778073 Up-regulated 
2380 Bt.23564 C6orf120 1.02E-06 1.466207518 Up-regulated 
2380 Bt.23564 C6orf120 2.66E-06 1.466207518 Up-regulated 
9505 Bt.46839 SNRPD2 6.96E-05 1.458717013 Up-regulated 
9505 Bt.46839 SNRPD2 8.10E-05 1.458717013 Up-regulated 
9205 Bt.21568 FAM118B 0.001325776 1.450485835 Up-regulated 
9205 Bt.21568 FAM118B 0.000132473 1.450485835 Up-regulated 
8250 Bt.22175 KCNT1 7.92E-05 1.447039962 Up-regulated 
8250 Bt.22175 KCNT1 0.000618956 1.447039962 Up-regulated 
8877 Bt.48519 RBPMS 0.00063129 1.438466172 Up-regulated 
8266 Bt.16440 USP6NL 0.000800332 1.433541215 Up-regulated 
8266 Bt.16440 USP6NL 0.001046373 1.433541215 Up-regulated 
5768 Bt.49597 LOC528919 0.000113481 1.431943194 Up-regulated 
5768 Bt.49597 LOC528919 0.00051465 1.431943194 Up-regulated 
4707 Bt.46116 MXRA7 0.001246439 1.429316172 Up-regulated 
4263 Bt.23076 C1orf93 0.000764781 1.429229215 Up-regulated 
4263 Bt.23076 C1orf93 0.000783807 1.429229215 Up-regulated 
4237 Bt.87845 COX5B 2.00E-05 1.428369941 Up-regulated 
4237 Bt.87845 COX5B 4.62E-05 1.428369941 Up-regulated 
3263 Bt.37779 BPHL 0.000210985 1.415263686 Up-regulated 
3263 Bt.37779 BPHL 0.000358399 1.415263686 Up-regulated 
11275 Bt.2988 GNG11 0.000947206 1.413028655 Up-regulated 
8432 Bt.5633 TMEM129 2.38E-05 1.410996343 Up-regulated 
4243 Bt.6710 LOC440330 4.50E-05 1.410510514 Up-regulated 
4243 Bt.6710 LOC440330 7.53E-05 1.410510514 Up-regulated 
3585 Bt.26997 Ptpmt1 0.000530902 1.410002052 Up-regulated 
3045 Bt.36226 SMNDC1 0.001098454 1.409950628 Up-regulated 
11761 Bt.17953 FOXP1 0.000956226 1.406683227 Up-regulated 
11761 Bt.17953 FOXP1 0.001230279 1.406683227 Up-regulated 
3414 Bt.61384 UNC84B 0.000416827 1.405923185 Up-regulated 
3414 Bt.61384 UNC84B 0.00011637 1.405923185 Up-regulated 
3543 Bt.4055 BGLAP 0.001321025 1.401462282 Up-regulated 
1886 Bt.76825 LOC789371 0.000833992 1.400577385 Up-regulated 
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884 Bt.49509 LZTFL1 0.000919334 1.399418351 Up-regulated 
884 Bt.49509 LZTFL1 0.001590158 1.399418351 Up-regulated 
10674 Bt.48127 Tia1 0.001569778 1.393954831 Up-regulated 
4986 Bt.89574 KIAA0182 0.00015045 1.390348374 Up-regulated 
4986 Bt.89574 KIAA0182 0.000987792 1.390348374 Up-regulated 
1902 Bt.12743 ABCD4 0.00063545 1.387069515 Up-regulated 
11164 Bt.7658 RPL38 0.001398942 1.382080773 Up-regulated 
967 Bt.73261 LOC513955 6.85E-05 1.381148907 Up-regulated 
2887 Bt.61617 UHRF2 0.000904125 1.377190598 Up-regulated 
2887 Bt.61617 UHRF2 0.000439983 1.377190598 Up-regulated 
6124 Bt.43820 RPL36 0.000760297 1.376458819 Up-regulated 
6124 Bt.43820 RPL36 0.001325246 1.376458819 Up-regulated 
6385 Bt.9092 POLR2G 0.000122794 1.373601453 Up-regulated 
6385 Bt.9092 POLR2G 0.000220579 1.373601453 Up-regulated 
5945 Bt.26976 COX11 0.000101741 1.370818345 Up-regulated 
5945 Bt.26976 COX11 0.00020081 1.370818345 Up-regulated 
6155 Bt.7804 GYG1 0.000301114 1.368438996 Up-regulated 
6155 Bt.7804 GYG1 0.000905921 1.368438996 Up-regulated 
7193 Bt.3871 LOC506318 0.00160686 1.367978974 Up-regulated 
4345 Bt.17589 DMTF1 0.000879507 1.367584324 Up-regulated 
9896 Bt.58080 ZNF3 1.85E-06 1.36433034 Up-regulated 
9896 Bt.58080 ZNF3 7.52E-06 1.36433034 Up-regulated 
2807 Bt.64366 NDUFC2 0.00024111 1.360154624 Up-regulated 
6501 Bt.48788 RAB30 0.000717957 1.359494169 Up-regulated 
7223 Bt.500 HK1 0.000108524 1.352377959 Up-regulated 
7223 Bt.500 HK1 0.000187069 1.352377959 Up-regulated 
4532 Bt.4949 SF3B5 0.000553053 1.342608753 Up-regulated 
4532 Bt.4949 SF3B5 0.000798069 1.342608753 Up-regulated 
1536 Bt.66354 POLR2L 6.22E-06 1.342343172 Up-regulated 
1536 Bt.66354 POLR2L 1.19E-05 1.342343172 Up-regulated 
1019 Bt.9195 SIVA1 0.000493087 1.339920698 Up-regulated 
8159 
  
0.000169244 1.337835553 Up-regulated 
8159 
  
0.000509444 1.337835553 Up-regulated 
8159 Bt.30026 
 
0.001543259 1.337835553 Up-regulated 
8159 Bt.65788 
 
0.00021414 1.337835553 Up-regulated 
8159 Bt.732 
 
0.000471878 1.337835553 Up-regulated 
8159 Bt.6330 
 
0.001422256 1.337835553 Up-regulated 
9208 Bt.26958 LOC788996 0.000215607 1.33553659 Up-regulated 
8654 Bt.13784 TIMM10 0.001437679 1.330900944 Up-regulated 
8583 Bt.52379 QRICH1 0.001559509 1.330801741 Up-regulated 
8583 Bt.52379 QRICH1 0.000137079 1.330801741 Up-regulated 
4008 Bt.26835 RANGNRF 0.001169618 1.329837495 Up-regulated 
4008 Bt.26835 RANGNRF 0.000511388 1.329837495 Up-regulated 
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4656 Bt.32544 NVL 0.000128076 1.326912959 Up-regulated 
4400 Bt.49192 RPL15 0.000657603 1.321596299 Up-regulated 
4400 Bt.49192 RPL15 0.000774218 1.321596299 Up-regulated 
7122 Bt.22 PPP1R8 0.00131595 1.32005256 Up-regulated 
2877 Bt.30434 SFRS9 0.00091765 1.318511686 Up-regulated 
2569 Bt.7562 FLJ41352 3.66E-05 1.314844992 Up-regulated 
2569 Bt.7562 FLJ41352 0.00076392 1.314844992 Up-regulated 
4001 Bt.26739 TOMM40L 0.000557284 1.299224292 Up-regulated 
2357 Bt.5184 Ankrd40 2.39E-06 1.298987503 Up-regulated 
2357 Bt.5184 Ankrd40 0.000435507 1.298987503 Up-regulated 
5328 Bt.55867 HSPC152 2.62E-05 1.298459765 Up-regulated 
5328 Bt.55867 HSPC152 9.14E-05 1.298459765 Up-regulated 
11668 Bt.49238 HPRT1 0.001115084 1.297719755 Up-regulated 
11668 Bt.49238 HPRT1 0.00120866 1.297719755 Up-regulated 
4505 Bt.15915 IPO11 0.000488539 1.297146056 Up-regulated 
4505 Bt.15915 IPO11 0.001528633 1.297146056 Up-regulated 
11499 Bt.64697 LMNB2 0.001540602 1.294782438 Up-regulated 
6339 Bt.44021 WDR8 0.000830074 1.2883317 Up-regulated 
4349 Bt.66386 WRNIP1 4.59E-05 1.285299393 Up-regulated 
4349 Bt.66386 WRNIP1 6.48E-05 1.285299393 Up-regulated 
5987 Bt.13810 U2AF1 0.000815782 1.285213607 Up-regulated 
2471 Bt.49501 C15orf40 0.000680521 1.27986987 Up-regulated 
4931 Bt.27370 HEATR3 0.000707341 1.278728054 Up-regulated 
3472 Bt.49273 POLR2F 0.001433416 1.278467132 Up-regulated 
3472 Bt.49273 POLR2F 0.00090677 1.278467132 Up-regulated 
11028 Bt.30639 CNOT2 0.000466637 1.2781415 Up-regulated 
5836 Bt.64649 Znf313 0.001516718 1.276434672 Up-regulated 
2339 Bt.52556 RCP9 6.21E-05 1.263776461 Up-regulated 
2339 Bt.52556 RCP9 0.000280575 1.263776461 Up-regulated 
2654 Bt.4298 GPR172B 0.000194199 1.263467859 Up-regulated 
2654 Bt.4298 GPR172B 0.000251915 1.263467859 Up-regulated 
7621 Bt.9482 LOC504245 0.001291534 1.262970177 Up-regulated 
1858 Bt.62530 ITPK1 0.000482942 1.262815915 Up-regulated 
1858 Bt.62530 ITPK1 0.001071091 1.262815915 Up-regulated 
2415 Bt.46615 MGC138967 0.001483978 1.255239148 Up-regulated 
9907 Bt.59214 FGD5 8.01E-05 1.251449378 Up-regulated 
2193 Bt.52796 COPS6 0.000225488 1.244506582 Up-regulated 
10009 Bt.48940 PPAP2B 1.96E-06 1.243042178 Up-regulated 
6140 Bt.27014 FEZ2 0.001617183 1.241905343 Up-regulated 
2709 Bt.21070 MRPL10 0.000769143 1.241342612 Up-regulated 
5727 Bt.70 NDUFB10 0.000260029 1.239802419 Up-regulated 
5727 Bt.70 NDUFB10 0.000771141 1.239802419 Up-regulated 
7556 Bt.63484 SURF2 0.000466669 1.23945914 Up-regulated 
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10232 Bt.1858 C20orf108 0.000616414 1.238627466 Up-regulated 
10232 Bt.1858 C20orf108 0.000725454 1.238627466 Up-regulated 
2992 Bt.18512 ASF1A 0.000880779 1.237140595 Up-regulated 
1640 Bt.49587 GPI 0.000206942 1.231214321 Up-regulated 
1640 Bt.49587 GPI 0.000651686 1.231214321 Up-regulated 
2555 Bt.5528 SLC7A5 0.001005994 1.224638311 Up-regulated 
2555 Bt.5528 SLC7A5 0.001009624 1.224638311 Up-regulated 
2865 Bt.89629 EIF4B 0.001144637 1.223356364 Up-regulated 
2672 Bt.6612 DDX51 0.001257178 1.217956704 Up-regulated 
5773 Bt.38862 RALA 0.000703113 1.215908003 Up-regulated 
4914 Bt.64707 LOC146346 0.000776269 1.196658362 Up-regulated 
4144 Bt.49595 TMEM111 8.44E-05 1.185066377 Up-regulated 
3794 Bt.44982 CHRNA10 0.001086009 1.178015959 Up-regulated 
8460 Bt.5530 DHRS3 0.000816115 1.175738577 Up-regulated 
4834 Bt.8545 MRPL43 0.001262114 1.173020122 Up-regulated 
4834 Bt.8545 MRPL43 9.09E-05 1.173020122 Up-regulated 
5186 Bt.57711 NDUFB8 0.000654609 1.150863212 Up-regulated 
1689 Bt.39564 LOC506268 0.000332691 1.131055131 Up-regulated 
5271 Bt.4908 RBBP7 0.000265911 0.857163239 Down-regulated 
289 Bt.21926 LOC508142 0.000881912 0.828800813 Down-regulated 
6897 Bt.21510 GPR107 0.001032206 0.820087446 Down-regulated 
11849 Bt.9469 DNAJC10 0.000759213 0.818915235 Down-regulated 
5040 Bt.1786 YME1L1 0.00133787 0.778151768 Down-regulated 
5040 Bt.1786 YME1L1 0.000619741 0.778151768 Down-regulated 
288 Bt.28094 CASP7 1.68E-06 0.773399708 Down-regulated 
288 Bt.28094 CASP7 0.000112935 0.773399708 Down-regulated 
123 Bt.64291 H3F3A 0.000158185 0.768681681 Down-regulated 
123 Bt.64291 H3F3A 0.000471416 0.768681681 Down-regulated 
10194 Bt.62845 ASAH1 0.000518233 0.766830961 Down-regulated 
10194 Bt.62845 ASAH1 0.000996226 0.766830961 Down-regulated 
5766 Bt.65363 C16orf69 2.56E-05 0.765511665 Down-regulated 
5766 Bt.65363 C16orf69 0.000270629 0.765511665 Down-regulated 
3518 Bt.28502 FAM83D 0.000417802 0.763218429 Down-regulated 
3518 Bt.28502 FAM83D 0.000474399 0.763218429 Down-regulated 
3189 Bt.44977 SLC4A1AP 0.00145282 0.761790522 Down-regulated 
265 Bt.20277 TOP2A 0.00078607 0.758350021 Down-regulated 
779 Bt.90218 TES 0.000610689 0.755475675 Down-regulated 
10650 Bt.16032 ANXA1 0.001356986 0.751616221 Down-regulated 
874 Bt.22035 C5orf14 0.001283155 0.749024192 Down-regulated 
9841 Bt.87389 GAPDH 0.000629315 0.74867001 Down-regulated 
9841 Bt.87389 GAPDH 0.001215282 0.74867001 Down-regulated 
2719 Bt.75092 DIDO1 4.49E-07 0.747525798 Down-regulated 
8159 Bt.89557 
 
0.000463052 0.747476024 Down-regulated 
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8159 
  
0.000946699 0.747476024 Down-regulated 
3140 Bt.56130 SIAHBP1 0.001110559 0.739135751 Down-regulated 
3140 Bt.56130 SIAHBP1 0.001220173 0.739135751 Down-regulated 
1897 Bt.12732 NYREN18 3.57E-05 0.738596777 Down-regulated 
1897 Bt.12732 NYREN18 0.00011322 0.738596777 Down-regulated 
893 Bt.59331 UAP1 3.55E-05 0.730191033 Down-regulated 
893 Bt.59331 UAP1 6.66E-05 0.730191033 Down-regulated 
1782 Bt.53344 ARHGAP21 0.000850676 0.724781482 Down-regulated 
4305 Bt.89659 FKBP9L 3.78E-05 0.721420708 Down-regulated 
4305 Bt.89659 FKBP9L 2.02E-05 0.721420708 Down-regulated 
10996 Bt.22526 HSPB8 7.83E-05 0.719942034 Down-regulated 
10996 Bt.22526 HSPB8 0.001019679 0.719942034 Down-regulated 
7456 Bt.46948 LRRFIP2 0.001449248 0.715436627 Down-regulated 
11731 Bt.22575 TMEM167 0.000368237 0.709895119 Down-regulated 
1116 Bt.25186 BCAT1 0.001013464 0.70421284 Down-regulated 
10961 Bt.20683 TP53INP2 0.000874769 0.703614152 Down-regulated 
10961 Bt.20683 TP53INP2 0.001621616 0.703614152 Down-regulated 
7909 Bt.64563 RFFL 2.54E-05 0.701882852 Down-regulated 
7909 Bt.64563 RFFL 0.00069605 0.701882852 Down-regulated 
12100 Bt.30953 DOCK1 0.000300917 0.701335885 Down-regulated 
5143 Bt.4106 F3 0.00150891 0.693874794 Down-regulated 
595 Bt.6522 DNAJB6 0.001496388 0.687365516 Down-regulated 
3177 Bt.48951 ASB11 1.21E-05 0.682168948 Down-regulated 
3177 Bt.48951 ASB11 4.73E-05 0.682168948 Down-regulated 
8529 Bt.7930 NUCB1 0.001008492 0.680744745 Down-regulated 
7528 Bt.49586 NET1 0.001601412 0.674008596 Down-regulated 
538 Bt.13737 GALK2 0.0005438 0.673522651 Down-regulated 
5355 Bt.269 ATP2C1 5.96E-05 0.672029196 Down-regulated 
5355 Bt.269 ATP2C1 0.000228997 0.672029196 Down-regulated 
904 Bt.7418 ANKH 4.40E-05 0.656166025 Down-regulated 
904 Bt.7418 ANKH 6.37E-05 0.656166025 Down-regulated 
942 Bt.6650 GGH 0.000841897 0.655009257 Down-regulated 
4274 Bt.11909 DUSP6 0.000701201 0.652235376 Down-regulated 
4274 Bt.11909 DUSP6 0.000889526 0.652235376 Down-regulated 
5332 Bt.12314 PFKFB3 3.97E-05 0.637898738 Down-regulated 
5332 Bt.12314 PFKFB3 6.60E-05 0.637898738 Down-regulated 
747 Bt.28249 SEC24A 0.000173964 0.632782086 Down-regulated 
1290 Bt.63116 AKR1B1 0.000550475 0.627096985 Down-regulated 
1290 Bt.63116 AKR1B1 0.000678361 0.627096985 Down-regulated 
1968 Bt.53760 LOC728216 0.000104525 0.625218368 Down-regulated 
1968 Bt.53760 LOC728216 0.000116805 0.625218368 Down-regulated 
8644 Bt.8738 HSPH1 5.51E-05 0.624614079 Down-regulated 
8644 Bt.8738 HSPH1 9.29E-05 0.624614079 Down-regulated 
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281 Bt.9783 DDX3X 0.000421378 0.618222185 Down-regulated 
281 Bt.9783 DDX3X 0.000835839 0.618222185 Down-regulated 
6779 Bt.90151 LOC100008589 8.45E-07 0.601998463 Down-regulated 
6779 Bt.90151 LOC100008589 2.96E-06 0.601998463 Down-regulated 
2986 Bt.27527 STXBP3 0.000277868 0.597526182 Down-regulated 
2986 Bt.27527 STXBP3 0.001176051 0.597526182 Down-regulated 
1477 Bt.12399 NEU1 1.84E-05 0.582769853 Down-regulated 
1477 Bt.12399 NEU1 5.03E-05 0.582769853 Down-regulated 
7968 Bt.49157 APOA1 0.000973083 0.565725636 Down-regulated 
1794 Bt.64539 QSCN6 0.000535468 0.556775247 Down-regulated 
1794 Bt.64539 QSCN6 0.001353419 0.556775247 Down-regulated 
2402 Bt.7873 BCAM 6.99E-06 0.545012548 Down-regulated 
2402 Bt.7873 BCAM 1.10E-05 0.545012548 Down-regulated 
9586 Bt.88378 KIAA1303 1.52E-06 0.534767689 Down-regulated 




Table S4.3 Sheet 2. Genes significantly changed upon 60 MPa treatment   
Probe UniGene.ID Gene name P-value 
Fold change 
(0.1 vs. 60 MPa) comment 
7199 Bt.54456 TFB2M 0.001489348 2.689638309 Up-regulated 
4884 
 
SEMA3G 0.001075152 1.838760276 Up-regulated 
4927 Bt.55759 DKFZp434K1815 7.42E-05 1.755178583 Up-regulated 
4927 Bt.55759 DKFZp434K1815 6.86E-08 1.755178583 Up-regulated 
9020 Bt.4586 GNG2 1.81E-05 1.655132083 Up-regulated 
9020 Bt.4586 GNG2 3.28E-05 1.655132083 Up-regulated 
5966 Bt.5519 TncRNA 0.000328087 1.543041709 Up-regulated 
3543 Bt.4055 BGLAP 0.001321025 1.523434989 Up-regulated 
5262 Bt.8206 SFRS7 0.000104799 1.509690386 Up-regulated 
8128 Bt.33726 NPY 0.000388758 1.498029214 Up-regulated 
4243 Bt.6710 LOC440330 4.50E-05 1.48970907 Up-regulated 
4243 Bt.6710 LOC440330 7.53E-05 1.48970907 Up-regulated 
3585 Bt.26997 Ptpmt1 0.000530902 1.483292753 Up-regulated 
6997 Bt.15697 PER2 0.001261833 1.469871756 Up-regulated 
11164 Bt.7658 RPL38 0.001398942 1.447273881 Up-regulated 
2167 Bt.20080 WSB1 0.000214607 1.426672599 Up-regulated 
2167 Bt.20080 WSB1 0.000831809 1.426672599 Up-regulated 
1401 Bt.3199 RUSC1 0.000221096 1.424924532 Up-regulated 
9208 Bt.26958 LOC788996 0.000280312 1.410670624 Up-regulated 
9208 Bt.26958 LOC788996 0.000215607 1.410670624 Up-regulated 
4237 Bt.87845 COX5B 2.00E-05 1.406990258 Up-regulated 
4237 Bt.87845 COX5B 4.62E-05 1.406990258 Up-regulated 
4345 Bt.17589 DMTF1 0.000879507 1.402102734 Up-regulated 
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9205 Bt.21568 FAM118B 0.001325776 1.380979557 Up-regulated 
9205 Bt.21568 FAM118B 0.000132473 1.380979557 Up-regulated 
2654 Bt.4298 GPR172B 0.000194199 1.355529622 Up-regulated 
2654 Bt.4298 GPR172B 0.000251915 1.355529622 Up-regulated 
626 Bt.38424 DST 0.000199418 1.355261898 Up-regulated 
6288 Bt.13965 CNTNAP1 2.48E-07 1.345266634 Up-regulated 
6288 Bt.13965 CNTNAP1 1.56E-06 1.345266634 Up-regulated 
8654 Bt.13784 TIMM10 0.001437679 1.342819566 Up-regulated 
5 Bt.29924 MDM4 0.000824537 1.33956028 Up-regulated 
2877 Bt.30434 SFRS9 0.00091765 1.339324809 Up-regulated 
1895 Bt.42858 ABCC5 1.02E-05 1.336991574 Up-regulated 
1895 Bt.42858 ABCC5 2.23E-05 1.336991574 Up-regulated 
9505 Bt.46839 SNRPD2 6.96E-05 1.335226279 Up-regulated 
9505 Bt.46839 SNRPD2 8.10E-05 1.335226279 Up-regulated 
1090 Bt.7391 APLP1 3.84E-06 1.328202593 Up-regulated 
1090 Bt.7391 APLP1 0.000618699 1.328202593 Up-regulated 
8266 Bt.16440 USP6NL 0.000800332 1.327893163 Up-regulated 
8266 Bt.16440 USP6NL 0.001046373 1.327893163 Up-regulated 
7986 Bt.66 NDUFA3 0.000138015 1.306412347 Up-regulated 
7986 Bt.66 NDUFA3 0.000226394 1.306412347 Up-regulated 
1536 Bt.66354 POLR2L 6.22E-06 1.305545697 Up-regulated 
1536 Bt.66354 POLR2L 1.19E-05 1.305545697 Up-regulated 
7061 Bt.42818 POLR3B 0.000405958 1.304098893 Up-regulated 
7223 Bt.500 HK1 0.000108524 1.296405031 Up-regulated 
7223 Bt.500 HK1 0.000187069 1.296405031 Up-regulated 
5328 Bt.55867 HSPC152 2.62E-05 1.294876918 Up-regulated 
5328 Bt.55867 HSPC152 9.14E-05 1.294876918 Up-regulated 
564 Bt.28460 SNRPD3 0.000971154 1.294689883 Up-regulated 
8474 Bt.89593 PRPF4B 0.001438541 1.294309816 Up-regulated 
6217 Bt.11128 MGC140717 0.001127116 1.292296325 Up-regulated 
6217 Bt.11128 MGC140717 0.00162156 1.292296325 Up-regulated 
4263 Bt.23076 C1orf93 0.000764781 1.286025986 Up-regulated 
4263 Bt.23076 C1orf93 0.000783807 1.286025986 Up-regulated 
2380 Bt.23564 C6orf120 1.02E-06 1.286013992 Up-regulated 
2380 Bt.23564 C6orf120 2.66E-06 1.286013992 Up-regulated 
2887 Bt.61617 UHRF2 0.000439983 1.279022933 Up-regulated 
6124 Bt.43820 RPL36 0.000760297 1.275187577 Up-regulated 
6124 Bt.43820 RPL36 0.001325246 1.275187577 Up-regulated 
2471 Bt.49501 C15orf40 0.000680521 1.268427709 Up-regulated 
89 Bt.32543 IPO8 0.000191059 1.26532392 Up-regulated 
5768 Bt.49597 LOC528919 0.000113481 1.255821679 Up-regulated 
5768 Bt.49597 LOC528919 0.00051465 1.255821679 Up-regulated 
6385 Bt.9092 POLR2G 0.000122794 1.248232894 Up-regulated 
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6385 Bt.9092 POLR2G 0.000220579 1.248232894 Up-regulated 
2569 Bt.7562 FLJ41352 3.66E-05 1.240282952 Up-regulated 
2569 Bt.7562 FLJ41352 0.00076392 1.240282952 Up-regulated 
3495 Bt.8279 C3orf60 1.30E-06 1.233969501 Up-regulated 
3495 Bt.8279 C3orf60 1.85E-06 1.233969501 Up-regulated 
4008 Bt.26835 RANGNRF 0.000511388 1.206818212 Up-regulated 
4914 Bt.64707 LOC146346 0.000776269 1.202220304 Up-regulated 
3472 Bt.49273 POLR2F 0.00090677 1.195577264 Up-regulated 
4952 Bt.2642 ZNF706 0.000593589 1.184466128 Up-regulated 
6140 Bt.27014 FEZ2 0.001617183 1.182520808 Up-regulated 
8583 Bt.52379 QRICH1 0.000137079 1.180039699 Up-regulated 
5186 Bt.57711 NDUFB8 0.000654609 1.162510081 Up-regulated 
2865 Bt.89629 EIF4B 0.001144637 1.160682533 Up-regulated 
4834 Bt.8545 MRPL43 9.09E-05 1.157716265 Up-regulated 
5945 Bt.26976 COX11 0.00020081 1.155350621 Up-regulated 
8159 Bt.65788 
 
0.00021414 0.977496298 Up-regulated 
8159 Bt.732 
 
0.000471878 0.977496298 Up-regulated 
8159 Bt.6330 
 
0.001422256 0.977496298 Up-regulated 
4305 Bt.89659 FKBP9L 2.02E-05 0.858161966 Down-regulated 
5271 Bt.4908 RBBP7 0.000265911 0.84164316 Down-regulated 
5040 Bt.1786 YME1L1 0.00133787 0.826213324 Down-regulated 
5040 Bt.1786 YME1L1 0.000619741 0.826213324 Down-regulated 
3189 Bt.44977 SLC4A1AP 0.00145282 0.811971933 Down-regulated 
7456 Bt.46948 LRRFIP2 0.001449248 0.799930229 Down-regulated 
9071 Bt.66625 CNOT4 0.000437896 0.799324154 Down-regulated 
1607 Bt.4371 GADD45B 0.001314898 0.795554642 Down-regulated 
3140 Bt.56130 SIAHBP1 0.001110559 0.783701753 Down-regulated 
3140 Bt.56130 SIAHBP1 0.001220173 0.783701753 Down-regulated 
3701 Bt.24435 SYNCRIP 0.000975088 0.77774974 Down-regulated 
3701 Bt.24435 SYNCRIP 0.000980781 0.77774974 Down-regulated 
2287 Bt.27376 Bag4 4.25E-07 0.774820777 Down-regulated 
2287 Bt.27376 Bag4 0.000106309 0.774820777 Down-regulated 
10681 Bt.59095 C9orf97 0.000647743 0.773006175 Down-regulated 
8867 Bt.64897 IGFBP3 0.001597096 0.764593659 Down-regulated 
10996 Bt.22526 HSPB8 7.83E-05 0.755003559 Down-regulated 
10996 Bt.22526 HSPB8 0.001019679 0.755003559 Down-regulated 
3177 Bt.48951 ASB11 1.21E-05 0.749433209 Down-regulated 
3177 Bt.48951 ASB11 4.73E-05 0.749433209 Down-regulated 
11849 Bt.9469 DNAJC10 0.000759213 0.744953014 Down-regulated 
5355 Bt.269 ATP2C1 5.96E-05 0.742417945 Down-regulated 
5355 Bt.269 ATP2C1 0.000228997 0.742417945 Down-regulated 
2027 Bt.10259 PLK2 0.00014694 0.732118669 Down-regulated 
8644 Bt.8738 HSPH1 5.51E-05 0.725798249 Down-regulated 
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8644 Bt.8738 HSPH1 9.29E-05 0.725798249 Down-regulated 
2402 Bt.7873 BCAM 6.99E-06 0.686258068 Down-regulated 
2402 Bt.7873 BCAM 1.10E-05 0.686258068 Down-regulated 
7528 Bt.49586 NET1 0.001601412 0.685970046 Down-regulated 
11261 Bt.9525 RNF113A 0.000258404 0.67344634 Down-regulated 
11261 Bt.9525 RNF113A 0.000628905 0.67344634 Down-regulated 
2719 Bt.75092 DIDO1 0.000364325 0.63187093 Down-regulated 
2719 Bt.75092 DIDO1 4.49E-07 0.63187093 Down-regulated 
9586 Bt.88378 KIAA1303 1.52E-06 0.616588017 Down-regulated 
9586 Bt.88378 KIAA1303 6.94E-06 0.616588017 Down-regulated 
5154 Bt.52786 LOC100008588 0.000102515 0.600036918 Down-regulated 
5154 Bt.52786 LOC100008588 0.000160742 0.600036918 Down-regulated 
3671 Bt.27129 SLC39A9 0.001181192 0.588360292 Down-regulated 
8731 Bt.27784 PPP1R10 4.21E-07 0.588026867 Down-regulated 
8731 Bt.27784 PPP1R10 1.13E-06 0.588026867 Down-regulated 
6779 Bt.90151 LOC100008589 8.45E-07 0.486632109 Down-regulated 
6779 Bt.90151 LOC100008589 2.96E-06 0.486632109 Down-regulated 
6779 Bt.89284 LOC100008589 0.000106092 0.486632109 Down-regulated 




Table S4.3 Sheet 3. Genes significantly changed upon 80 MPa treatment   
Probe 
UniGene 
ID Gene name P-value 
Fold change  
(0.1 vs. 80 MPa) Comment 
1436 Bt.6451 HIST1H1E 4.92E-05 12.74953624 Up-regulated 
1436 Bt.6451 HIST1H1E 0.000470673 12.74953624 Up-regulated 
42 Bt.34521 RBM12 0.000452853 2.703349 Up-regulated 
8416 Bt.21965 ZNF358 2.10E-05 1.55765483 Up-regulated 
8416 Bt.21965 ZNF358 8.87E-05 1.55765483 Up-regulated 
4001 Bt.26739 TOMM40L 0.000557284 1.496010949 Up-regulated 
8159 Bt.89557 
 
1.96E-05 1.477117365 Up-regulated 
7986 Bt.66 NDUFA3 0.000138015 1.406306395 Up-regulated 
7986 Bt.66 NDUFA3 0.000226394 1.406306395 Up-regulated 
6288 Bt.13965 CNTNAP1 2.48E-07 1.398862236 Up-regulated 
6288 Bt.13965 CNTNAP1 1.56E-06 1.398862236 Up-regulated 
4927 Bt.55759 DKFZp434K1815 6.86E-08 1.374371341 Up-regulated 
8877 Bt.48519 RBPMS 0.00063129 1.373950549 Up-regulated 
2634 Bt.90254 HDAC8 0.000981392 1.355704704 Up-regulated 
9205 Bt.21568 FAM118B 0.000132473 1.29067183 Up-regulated 
2415 Bt.46615 MGC138967 0.001483978 1.288080872 Up-regulated 
7223 Bt.500 HK1 0.000108524 1.275324741 Up-regulated 
7223 Bt.500 HK1 0.000187069 1.275324741 Up-regulated 
1841 Bt.12138 RP11-413M3.2 6.48E-05 1.268377263 Up-regulated 
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884 Bt.49509 LZTFL1 0.000919334 1.267012976 Up-regulated 
884 Bt.49509 LZTFL1 0.001590158 1.267012976 Up-regulated 
2575 Bt.2041 AP2A2 1.71E-05 1.259958213 Up-regulated 
3414 Bt.61384 UNC84B 0.00011637 1.214418026 Up-regulated 
2865 Bt.89629 EIF4B 0.001144637 1.190531948 Up-regulated 
4914 Bt.64707 LOC146346 0.000776269 1.168484456 Up-regulated 
5040 Bt.1786 YME1L1 0.000619741 0.81416973 Down-regulated 
3865 Bt.52937 hCG_20417 0.00010856 0.810226455 Down-regulated 
3865 Bt.52937 hCG_20417 0.000139517 0.810226455 Down-regulated 
4305 Bt.89659 FKBP9L 3.78E-05 0.801611975 Down-regulated 
4305 Bt.89659 FKBP9L 2.02E-05 0.801611975 Down-regulated 
6779 Bt.89284 LOC100008589 0.000106092 0.793721372 Down-regulated 
6779 Bt.89284 LOC100008589 0.000208105 0.793721372 Down-regulated 
9829 Bt.27267 TMEM4 0.000150732 0.791384829 Down-regulated 
6758 Bt.26855 LOC506746 0.001605013 0.789528482 Down-regulated 
1685 Bt.77469 KCTD20 6.84E-05 0.786367218 Down-regulated 
1685 Bt.77469 KCTD20 0.000311099 0.786367218 Down-regulated 
1402 Bt.4279 SHC1 0.000135301 0.784658922 Down-regulated 
1402 Bt.4279 SHC1 0.00040895 0.784658922 Down-regulated 
1782 Bt.53344 ARHGAP21 0.000850676 0.783994648 Down-regulated 
9071 Bt.66625 CNOT4 0.000437896 0.769761713 Down-regulated 
3140 Bt.56130 SIAHBP1 0.001110559 0.769103488 Down-regulated 
3140 Bt.56130 SIAHBP1 0.001220173 0.769103488 Down-regulated 
5840 Bt.1658 DUSP1 0.000276438 0.769080319 Down-regulated 
5840 Bt.1658 DUSP1 0.001339091 0.769080319 Down-regulated 
3701 Bt.24435 SYNCRIP 0.000975088 0.766606894 Down-regulated 
3701 Bt.24435 SYNCRIP 0.000980781 0.766606894 Down-regulated 
5271 Bt.4908 RBBP7 0.000265911 0.765349306 Down-regulated 
3177 Bt.48951 ASB11 1.21E-05 0.762018911 Down-regulated 
3177 Bt.48951 ASB11 4.73E-05 0.762018911 Down-regulated 
337 Bt.17282 SNIP1 0.001581269 0.761885147 Down-regulated 
7456 Bt.46948 LRRFIP2 0.001449248 0.757525629 Down-regulated 
11849 Bt.9469 DNAJC10 0.000759213 0.754942748 Down-regulated 
3089 Bt.22538 FZD8 9.71E-05 0.739475424 Down-regulated 
10194 Bt.62845 ASAH1 0.000518233 0.733242501 Down-regulated 
10194 Bt.62845 ASAH1 0.000996226 0.733242501 Down-regulated 
3757 Bt.2005 LSM1 1.50E-07 0.733206298 Down-regulated 
3757 Bt.2005 LSM1 9.51E-06 0.733206298 Down-regulated 
10834 Bt.18408 CCDC117 0.001065327 0.725922458 Down-regulated 
10834 Bt.18408 CCDC117 0.001272419 0.725922458 Down-regulated 
7060 Bt.11280 BANP 0.00012219 0.72338105 Down-regulated 
7060 Bt.11280 BANP 0.00013219 0.72338105 Down-regulated 
10650 Bt.16032 ANXA1 0.001356986 0.722304465 Down-regulated 
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6408 Bt.52209 RAD54B 0.000316422 0.714724398 Down-regulated 
9841 Bt.87389 GAPDH 0.000629315 0.714170291 Down-regulated 
9841 Bt.87389 GAPDH 0.001215282 0.714170291 Down-regulated 
4027 Bt.11096 KPNA4 0.00070383 0.710854719 Down-regulated 
4027 Bt.11096 KPNA4 0.001347272 0.710854719 Down-regulated 
1897 Bt.12732 NYREN18 3.57E-05 0.708285051 Down-regulated 
1897 Bt.12732 NYREN18 0.00011322 0.708285051 Down-regulated 
1607 Bt.4371 GADD45B 0.001314898 0.704830784 Down-regulated 
4274 Bt.11909 DUSP6 0.000701201 0.704226522 Down-regulated 
4274 Bt.11909 DUSP6 0.000889526 0.704226522 Down-regulated 
1290 Bt.63116 AKR1B1 0.000550475 0.697691491 Down-regulated 
1290 Bt.63116 AKR1B1 0.000678361 0.697691491 Down-regulated 
893 Bt.59331 UAP1 3.55E-05 0.693202226 Down-regulated 
893 Bt.59331 UAP1 6.66E-05 0.693202226 Down-regulated 
1109 Bt.17683 DBF4 0.000560078 0.693128763 Down-regulated 
3671 Bt.27129 SLC39A9 0.001181192 0.692301399 Down-regulated 
4183 Bt.89506 NSL1 0.001051208 0.690574993 Down-regulated 
5143 Bt.4106 F3 0.00150891 0.680025782 Down-regulated 
8644 Bt.8738 HSPH1 5.51E-05 0.679349341 Down-regulated 
8644 Bt.8738 HSPH1 9.29E-05 0.679349341 Down-regulated 
4322 Bt.13666 ATP5S 0.001395012 0.678999792 Down-regulated 
8159 Bt.65398 
 
0.001454744 0.676994275 Down-regulated 
4066 Bt.73096 CTH 0.000403511 0.676064746 Down-regulated 
4066 Bt.73096 CTH 0.000528372 0.676064746 Down-regulated 
10681 Bt.59095 C9orf97 0.000647743 0.670492728 Down-regulated 
1477 Bt.12399 NEU1 1.84E-05 0.669743822 Down-regulated 
1477 Bt.12399 NEU1 5.03E-05 0.669743822 Down-regulated 
3093 Bt.53211 LOC615039 1.14E-05 0.668364363 Down-regulated 
3093 Bt.53211 LOC615039 0.000103313 0.668364363 Down-regulated 
9586 Bt.88378 KIAA1303 1.52E-06 0.663116964 Down-regulated 
9586 Bt.88378 KIAA1303 6.94E-06 0.663116964 Down-regulated 
5766 Bt.65363 C16orf69 2.56E-05 0.66155183 Down-regulated 
5766 Bt.65363 C16orf69 0.000270629 0.66155183 Down-regulated 
2559 Bt.64693 Dnaja1 0.000442293 0.659012958 Down-regulated 
2559 Bt.64693 Dnaja1 0.001322657 0.659012958 Down-regulated 
288 Bt.28094 CASP7 1.68E-06 0.656324763 Down-regulated 
288 Bt.28094 CASP7 0.000112935 0.656324763 Down-regulated 
904 Bt.7418 ANKH 4.40E-05 0.644975795 Down-regulated 
904 Bt.7418 ANKH 6.37E-05 0.644975795 Down-regulated 
8867 Bt.64897 IGFBP3 0.001597096 0.642292452 Down-regulated 
595 Bt.6522 DNAJB6 0.001496388 0.632396231 Down-regulated 
11924 Bt.37906 YOD1 3.39E-05 0.630172128 Down-regulated 
11924 Bt.37906 YOD1 0.000169627 0.630172128 Down-regulated 
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2027 Bt.10259 PLK2 0.00014694 0.618101393 Down-regulated 
2287 Bt.27376 Bag4 4.25E-07 0.614071777 Down-regulated 
2287 Bt.27376 Bag4 0.000106309 0.614071777 Down-regulated 
10996 Bt.22526 HSPB8 7.83E-05 0.608102329 Down-regulated 
10996 Bt.22526 HSPB8 0.001019679 0.608102329 Down-regulated 
8731 Bt.27784 PPP1R10 4.21E-07 0.587989706 Down-regulated 
8731 Bt.27784 PPP1R10 1.13E-06 0.587989706 Down-regulated 
8808 Bt.53659 ABHD13 4.64E-05 0.550445569 Down-regulated 
8808 Bt.53659 ABHD13 0.000432173 0.550445569 Down-regulated 
320 
 
TMEM121 2.64E-05 0.536403768 Down-regulated 
2719 Bt.75092 DIDO1 0.000364325 0.530232529 Down-regulated 
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Table S4.4: Unique differentially expressed genes between HHP-treated embryos and controls.  
Spreadsheet 1: Up and down-regulated genes specific to 40 MPa treatment compared to control; 
Spreadsheet 2: Up and down-regulated genes specific to 60 MPa treatment compared to control; 
Spreadsheet 3: Up and down-regulated genes specific to 80 MPa treatment compared to control. 
 
Table S4.4 Sheet 1. Genes uniquely differentially expressed at 40 Mpa*     
Probe UniGene ID Gene name P value 
0.1 vs. 40 
Mpa 
0.1 vs. 60 
MPa 
0.1 vs. 80 
MPa 
7909 Bt.64563 RFFL 2.54E-05 -1 0 0 
5332 Bt.12314 PFKFB3 3.97E-05 -1 0 0 
5332 Bt.12314 PFKFB3 6.60E-05 -1 0 0 
1968 Bt.53760 LOC728216 0.000104525 -1 0 0 
1968 Bt.53760 LOC728216 0.000116805 -1 0 0 
123 Bt.64291 H3F3A 0.000158185 -1 0 0 
747 Bt.28249 SEC24A 0.000173964 -1 0 0 
2986 Bt.27527 STXBP3 0.000277868 -1 0 0 
12100 Bt.30953 DOCK1 0.000300917 -1 0 0 
11731 Bt.22575 TMEM167 0.000368237 -1 0 0 
3518 Bt.28502 FAM83D 0.000417802 -1 0 0 
281 Bt.9783 DDX3X 0.000421378 -1 0 0 
8159 Bt.89557 
 
0.000463052 -1 0 0 
123 Bt.64291 H3F3A 0.000471416 -1 0 0 
3518 Bt.28502 FAM83D 0.000474399 -1 0 0 
1794 Bt.64539 QSCN6 0.000535468 -1 0 0 
538 Bt.13737 GALK2 0.0005438 -1 0 0 
779 Bt.90218 TES 0.000610689 -1 0 0 
7909 Bt.64563 RFFL 0.00069605 -1 0 0 
265 Bt.20277 TOP2A 0.00078607 -1 0 0 
281 Bt.9783 DDX3X 0.000835839 -1 0 0 
942 Bt.6650 GGH 0.000841897 -1 0 0 
10961 Bt.20683 TP53INP2 0.000874769 -1 0 0 
289 Bt.21926 LOC508142 0.000881912 -1 0 0 
8159 
  
0.000946699 -1 0 0 
7968 Bt.49157 APOA1 0.000973083 -1 0 0 
8529 Bt.7930 NUCB1 0.001008492 -1 0 0 
1116 Bt.25186 BCAT1 0.001013464 -1 0 0 
6897 Bt.21510 GPR107 0.001032206 -1 0 0 
2986 Bt.27527 STXBP3 0.001176051 -1 0 0 
874 Bt.22035 C5orf14 0.001283155 -1 0 0 
1794 Bt.64539 QSCN6 0.001353419 -1 0 0 
10961 Bt.20683 TP53INP2 0.001621616 -1 0 0 
9896 Bt.58080 ZNF3 1.85E-06 1 0 0 
10009 Bt.48940 PPAP2B 1.96E-06 1 0 0 
2357 Bt.5184 Ankrd40 2.39E-06 1 0 0 
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9896 Bt.58080 ZNF3 7.52E-06 1 0 0 
6978 Bt.22374 MGC137396 9.39E-06 1 0 0 
6978 Bt.22374 MGC137396 1.89E-05 1 0 0 
5625 Bt.45080 LRRC45 2.36E-05 1 0 0 
8432 Bt.5633 TMEM129 2.38E-05 1 0 0 
8747 Bt.23521 DUSP26 2.74E-05 1 0 0 
2575 Bt.2041 AP2A2 3.05E-05 1 0 0 
4349 Bt.66386 WRNIP1 4.59E-05 1 0 0 
2339 Bt.52556 RCP9 6.21E-05 1 0 0 
4349 Bt.66386 WRNIP1 6.48E-05 1 0 0 
8983 Bt.45485 KLF9 6.68E-05 1 0 0 
967 Bt.73261 LOC513955 6.85E-05 1 0 0 
8747 Bt.23521 DUSP26 6.93E-05 1 0 0 
8250 Bt.22175 KCNT1 7.92E-05 1 0 0 
9907 Bt.59214 FGD5 8.01E-05 1 0 0 
4144 Bt.49595 TMEM111 8.44E-05 1 0 0 
8983 Bt.45485 KLF9 9.23E-05 1 0 0 
5945 Bt.26976 COX11 0.000101741 1 0 0 
3885 Bt.51520 C14orf94 0.000123869 1 0 0 
4656 Bt.32544 NVL 0.000128076 1 0 0 
4986 Bt.89574 KIAA0182 0.00015045 1 0 0 
6659 Bt.3196 STRA6 0.000152416 1 0 0 
5633 Bt.2568 ADFP 0.000157168 1 0 0 
393 Bt.58700 C9orf58 0.000166772 1 0 0 
8159 
  
0.000169244 1 0 0 
10034 Bt.7363 LOC789389 0.000174731 1 0 0 
3739 Bt.28081 POGZ 0.000189317 1 0 0 
3885 Bt.51520 C14orf94 0.000191948 1 0 0 
5633 Bt.2568 ADFP 0.000202974 1 0 0 
1640 Bt.49587 GPI 0.000206942 1 0 0 
3263 Bt.37779 BPHL 0.000210985 1 0 0 
2193 Bt.52796 COPS6 0.000225488 1 0 0 
2807 Bt.64366 NDUFC2 0.00024111 1 0 0 
5727 Bt.70 NDUFB10 0.000260029 1 0 0 
2339 Bt.52556 RCP9 0.000280575 1 0 0 
6155 Bt.7804 GYG1 0.000301114 1 0 0 
4802 Bt.22766 SART3 0.000322672 1 0 0 
1689 Bt.39564 LOC506268 0.000332691 1 0 0 
3263 Bt.37779 BPHL 0.000358399 1 0 0 
3414 Bt.61384 UNC84B 0.000416827 1 0 0 
2357 Bt.5184 Ankrd40 0.000435507 1 0 0 
6830 Bt.52335 IFT57 0.000455475 1 0 0 
11028 Bt.30639 CNOT2 0.000466637 1 0 0 
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7556 Bt.63484 SURF2 0.000466669 1 0 0 
1858 Bt.62530 ITPK1 0.000482942 1 0 0 
4505 Bt.15915 IPO11 0.000488539 1 0 0 
1019 Bt.9195 SIVA1 0.000493087 1 0 0 
8159 
  
0.000509444 1 0 0 
4532 Bt.4949 SF3B5 0.000553053 1 0 0 
6830 Bt.52335 IFT57 0.000574792 1 0 0 
5625 Bt.45080 LRRC45 0.000610941 1 0 0 
10232 Bt.1858 C20orf108 0.000616414 1 0 0 
8250 Bt.22175 KCNT1 0.000618956 1 0 0 
1902 Bt.12743 ABCD4 0.00063545 1 0 0 
393 Bt.58700 C9orf58 0.000647975 1 0 0 
1640 Bt.49587 GPI 0.000651686 1 0 0 
4400 Bt.49192 RPL15 0.000657603 1 0 0 
5773 Bt.38862 RALA 0.000703113 1 0 0 
2112 Bt.44470 SATB1 0.000705402 1 0 0 
4931 Bt.27370 HEATR3 0.000707341 1 0 0 
6501 Bt.48788 RAB30 0.000717957 1 0 0 
5262 Bt.8206 SFRS7 0.000724622 1 0 0 
10232 Bt.1858 C20orf108 0.000725454 1 0 0 
2709 Bt.21070 MRPL10 0.000769143 1 0 0 
5727 Bt.70 NDUFB10 0.000771141 1 0 0 
4400 Bt.49192 RPL15 0.000774218 1 0 0 
4532 Bt.4949 SF3B5 0.000798069 1 0 0 
5987 Bt.13810 U2AF1 0.000815782 1 0 0 
8460 Bt.5530 DHRS3 0.000816115 1 0 0 
6339 Bt.44021 WDR8 0.000830074 1 0 0 
1886 Bt.76825 LOC789371 0.000833992 1 0 0 
2992 Bt.18512 ASF1A 0.000880779 1 0 0 
2887 Bt.61617 UHRF2 0.000904125 1 0 0 
6155 Bt.7804 GYG1 0.000905921 1 0 0 
11275 Bt.2988 GNG11 0.000947206 1 0 0 
11761 Bt.17953 FOXP1 0.000956226 1 0 0 
4986 Bt.89574 KIAA0182 0.000987792 1 0 0 
2555 Bt.5528 SLC7A5 0.001005994 1 0 0 
2555 Bt.5528 SLC7A5 0.001009624 1 0 0 
1858 Bt.62530 ITPK1 0.001071091 1 0 0 
3794 Bt.44982 CHRNA10 0.001086009 1 0 0 
3045 Bt.36226 SMNDC1 0.001098454 1 0 0 
11668 Bt.49238 HPRT1 0.001115084 1 0 0 
4008 Bt.26835 RANGNRF 0.001169618 1 0 0 
11668 Bt.49238 HPRT1 0.00120866 1 0 0 
11761 Bt.17953 FOXP1 0.001230279 1 0 0 
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4707 Bt.46116 MXRA7 0.001246439 1 0 0 
2672 Bt.6612 DDX51 0.001257178 1 0 0 
4834 Bt.8545 MRPL43 0.001262114 1 0 0 
7621 Bt.9482 LOC504245 0.001291534 1 0 0 
7122 Bt.22 PPP1R8 0.00131595 1 0 0 
3472 Bt.49273 POLR2F 0.001433416 1 0 0 
3739 Bt.28081 POGZ 0.001460923 1 0 0 
5836 Bt.64649 Znf313 0.001516718 1 0 0 
4505 Bt.15915 IPO11 0.001528633 1 0 0 
11499 Bt.64697 LMNB2 0.001540602 1 0 0 
8159 Bt.30026 
 
0.001543259 1 0 0 
8583 Bt.52379 QRICH1 0.001559509 1 0 0 
10674 Bt.48127 Tia1 0.001569778 1 0 0 
7193 Bt.3871 LOC506318 0.00160686 1 0 0 




Table S4.4 Sheet 2. Genes uniquely differentially expressed at 60 MPa*     
Probe UniGene ID Gene name P value 
0.1 vs. 40 
MPa 
0.1 vs. 60 
MPa 
0.1 vs. 80 
MPa 
5154 Bt.52786 LOC100008588 0.000102515 0 -1 0 
5154 Bt.52786 LOC100008588 0.000160742 0 -1 0 
11261 Bt.9525 RNF113A 0.000258404 0 -1 0 
11261 Bt.9525 RNF113A 0.000628905 0 -1 0 
1895 Bt.42858 ABCC5 1.02E-05 0 1 0 
1895 Bt.42858 ABCC5 2.23E-05 0 1 0 
89 Bt.32543 IPO8 0.000191059 0 1 0 
2167 Bt.20080 WSB1 0.000214607 0 1 0 
1401 Bt.3199 RUSC1 0.000221096 0 1 0 
9208 Bt.26958 LOC788996 0.000280312 0 1 0 
5966 Bt.5519 TncRNA 0.000328087 0 1 0 
8128 Bt.33726 NPY 0.000388758 0 1 0 
7061 Bt.42818 POLR3B 0.000405958 0 1 0 
4952 Bt.2642 ZNF706 0.000593589 0 1 0 
5 Bt.29924 MDM4 0.000824537 0 1 0 
2167 Bt.20080 WSB1 0.000831809 0 1 0 
564 Bt.28460 SNRPD3 0.000971154 0 1 0 
6217 Bt.11128 MGC140717 0.001127116 0 1 0 
8474 Bt.89593 PRPF4B 0.001438541 0 1 0 
7199 Bt.54456 TFB2M 0.001489348 0 1 0 
6217 Bt.11128 MGC140717 0.00162156 0 1 0 
*:  1: up-regualted; -1: down-regulated; 0: not significant differential expressed 
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Table S4.4 Sheet 3. Genes uniquely differentially expressed at 80 MPa*   
Probe UniGene ID Gene name P-value 
0.1 vs. 40 
MPa 
0.1 vs. 60 
MPa 
0.1 vs. 80 
MPa 
3757 Bt.2005 LSM1 1.50E-07 0 0 -1 
3757 Bt.2005 LSM1 9.51E-06 0 0 -1 
3093 Bt.53211 LOC615039 1.14E-05 0 0 -1 
320 
 
TMEM121 2.64E-05 0 0 -1 
11924 Bt.37906 YOD1 3.39E-05 0 0 -1 
8808 Bt.53659 ABHD13 4.64E-05 0 0 -1 
1685 Bt.77469 KCTD20 6.84E-05 0 0 -1 
3089 Bt.22538 FZD8 9.71E-05 0 0 -1 
3093 Bt.53211 LOC615039 0.000103313 0 0 -1 
3865 Bt.52937 hCG_20417 0.00010856 0 0 -1 
7060 Bt.11280 BANP 0.00012219 0 0 -1 
7060 Bt.11280 BANP 0.00013219 0 0 -1 
1402 Bt.4279 SHC1 0.000135301 0 0 -1 
3865 Bt.52937 hCG_20417 0.000139517 0 0 -1 
9829 Bt.27267 TMEM4 0.000150732 0 0 -1 
11924 Bt.37906 YOD1 0.000169627 0 0 -1 
5840 Bt.1658 DUSP1 0.000276438 0 0 -1 
1685 Bt.77469 KCTD20 0.000311099 0 0 -1 
6408 Bt.52209 RAD54B 0.000316422 0 0 -1 
4066 Bt.73096 CTH 0.000403511 0 0 -1 
1402 Bt.4279 SHC1 0.00040895 0 0 -1 
8808 Bt.53659 ABHD13 0.000432173 0 0 -1 
2559 Bt.64693 Dnaja1 0.000442293 0 0 -1 
4066 Bt.73096 CTH 0.000528372 0 0 -1 
1109 Bt.17683 DBF4 0.000560078 0 0 -1 
4027 Bt.11096 KPNA4 0.00070383 0 0 -1 
4183 Bt.89506 NSL1 0.001051208 0 0 -1 
10834 Bt.18408 CCDC117 0.001065327 0 0 -1 
10834 Bt.18408 CCDC117 0.001272419 0 0 -1 
2559 Bt.64693 Dnaja1 0.001322657 0 0 -1 
5840 Bt.1658 DUSP1 0.001339091 0 0 -1 
4027 Bt.11096 KPNA4 0.001347272 0 0 -1 
4322 Bt.13666 ATP5S 0.001395012 0 0 -1 
8159 Bt.65398 
 
0.001454744 0 0 -1 
337 Bt.17282 SNIP1 0.001581269 0 0 -1 
6758 Bt.26855 LOC506746 0.001605013 0 0 -1 
8159 Bt.89557 
 
1.96E-05 0 0 1 
42 Bt.34521 RBM12 0.000452853 0 0 1 
2634 Bt.90254 HDAC8 0.000981392 0 0 1 
*:  1: up-regualted; -1: down-regulated; 0: not significant differential expressed 
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Table S4.5: Common genes between 40 MPa and 60 MPa treatments compared to control. 
Probe UniGene ID Gene name P-value 
0.1 vs. 40 
MPa 
0.1 vs. 60 
MPa 
0.1 vs. 80 
MPa 
6779 Bt.90151 LOC100008589 8.45E-07 -1 -1 0 
6779 Bt.90151 LOC100008589 2.96E-06 -1 -1 0 
2402 Bt.7873 BCAM 6.99E-06 -1 -1 0 
2402 Bt.7873 BCAM 1.10E-05 -1 -1 0 
5355 Bt.269 ATP2C1 5.96E-05 -1 -1 0 
5355 Bt.269 ATP2C1 0.000228997 -1 -1 0 
5040 Bt.1786 YME1L1 0.00133787 -1 -1 0 
3189 Bt.44977 SLC4A1AP 0.00145282 -1 -1 0 
7528 Bt.49586 NET1 0.001601412 -1 -1 0 
2380 Bt.23564 C6orf120 1.02E-06 1 1 0 
3495 Bt.8279 C3orf60 1.30E-06 1 1 0 
3495 Bt.8279 C3orf60 1.85E-06 1 1 0 
2380 Bt.23564 C6orf120 2.66E-06 1 1 0 
1090 Bt.7391 APLP1 3.84E-06 1 1 0 
1536 Bt.66354 POLR2L 6.22E-06 1 1 0 
1536 Bt.66354 POLR2L 1.19E-05 1 1 0 
9020 Bt.4586 GNG2 1.81E-05 1 1 0 
4237 Bt.87845 COX5B 2.00E-05 1 1 0 
5328 Bt.55867 HSPC152 2.62E-05 1 1 0 
9020 Bt.4586 GNG2 3.28E-05 1 1 0 
2569 Bt.7562 FLJ41352 3.66E-05 1 1 0 
4243 Bt.6710 LOC440330 4.50E-05 1 1 0 
4237 Bt.87845 COX5B 4.62E-05 1 1 0 
9505 Bt.46839 SNRPD2 6.96E-05 1 1 0 
4927 Bt.55759 
DKFZp434K181
5 7.42E-05 1 1 0 
4243 Bt.6710 LOC440330 7.53E-05 1 1 0 
9505 Bt.46839 SNRPD2 8.10E-05 1 1 0 
4834 Bt.8545 MRPL43 9.09E-05 1 1 0 
5328 Bt.55867 HSPC152 9.14E-05 1 1 0 
5262 Bt.8206 SFRS7 0.000104799 1 1 0 
5768 Bt.49597 LOC528919 0.000113481 1 1 0 
6385 Bt.9092 POLR2G 0.000122794 1 1 0 
8583 Bt.52379 QRICH1 0.000137079 1 1 0 
2654 Bt.4298 GPR172B 0.000194199 1 1 0 
626 Bt.38424 DST 0.000199418 1 1 0 
5945 Bt.26976 COX11 0.00020081 1 1 0 
8159 Bt.65788 
 
0.00021414 1 1 0 
9208 Bt.26958 LOC788996 0.000215607 1 1 0 
6385 Bt.9092 POLR2G 0.000220579 1 1 0 
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2654 Bt.4298 GPR172B 0.000251915 1 1 0 
2887 Bt.61617 UHRF2 0.000439983 1 1 0 
8159 Bt.732 
 
0.000471878 1 1 0 
4008 Bt.26835 RANGNRF 0.000511388 1 1 0 
5768 Bt.49597 LOC528919 0.00051465 1 1 0 
3585 Bt.26997 Ptpmt1 0.000530902 1 1 0 
1090 Bt.7391 APLP1 0.000618699 1 1 0 
5186 Bt.57711 NDUFB8 0.000654609 1 1 0 
2471 Bt.49501 C15orf40 0.000680521 1 1 0 
6124 Bt.43820 RPL36 0.000760297 1 1 0 
2569 Bt.7562 FLJ41352 0.00076392 1 1 0 
4263 Bt.23076 C1orf93 0.000764781 1 1 0 
4263 Bt.23076 C1orf93 0.000783807 1 1 0 
8266 Bt.16440 USP6NL 0.000800332 1 1 0 
4345 Bt.17589 DMTF1 0.000879507 1 1 0 
3472 Bt.49273 POLR2F 0.00090677 1 1 0 
2877 Bt.30434 SFRS9 0.00091765 1 1 0 
8266 Bt.16440 USP6NL 0.001046373 1 1 0 
4884 
 
SEMA3G 0.001075152 1 1 0 
6997 Bt.15697 PER2 0.001261833 1 1 0 
3543 Bt.4055 BGLAP 0.001321025 1 1 0 
6124 Bt.43820 RPL36 0.001325246 1 1 0 
9205 Bt.21568 FAM118B 0.001325776 1 1 0 
11164 Bt.7658 RPL38 0.001398942 1 1 0 
8159 Bt.6330 
 
0.001422256 1 1 0 
8654 Bt.13784 TIMM10 0.001437679 1 1 0 
6140 Bt.27014 FEZ2 0.001617183 1 1 0 
*:  1: up-regualted; -1: down-regulated; 0: not significant differential expressed 
  
 
Table S4.6: Common genes among 40, 60, and 80 MPa treatments compared to control. 
Probe UniGene ID Gene name P-value Comment 
2719 Bt.75092 DIDO1 4.49E-07 Down-regulated 
9586 Bt.88378 KIAA1303 1.52E-06 Down-regulated 
9586 Bt.88378 KIAA1303 6.94E-06 Down-regulated 
3177 Bt.48951 ASB11 1.21E-05 Down-regulated 
4305 Bt.89659 FKBP9L 2.02E-05 Down-regulated 
3177 Bt.48951 ASB11 4.73E-05 Down-regulated 
8644 Bt.8738 HSPH1 5.51E-05 Down-regulated 
10996 Bt.22526 HSPB8 7.83E-05 Down-regulated 
8644 Bt.8738 HSPH1 9.29E-05 Down-regulated 
5271 Bt.4908 RBBP7 0.000265911 Down-regulated 
5040 Bt.1786 YME1L1 0.000619741 Down-regulated 
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11849 Bt.9469 DNAJC10 0.000759213 Down-regulated 
10996 Bt.22526 HSPB8 0.001019679 Down-regulated 
3140 Bt.56130 SIAHBP1 0.001110559 Down-regulated 
3140 Bt.56130 SIAHBP1 0.001220173 Down-regulated 
7456 Bt.46948 LRRFIP2 0.001449248 Down-regulated 
4927 Bt.55759 DKFZp434K1815 6.86E-08 Up-regulated 
6288 Bt.13965 CNTNAP1 2.48E-07 Up-regulated 
6288 Bt.13965 CNTNAP1 1.56E-06 Up-regulated 
7223 Bt.500 HK1 0.000108524 Up-regulated 
9205 Bt.21568 FAM118B 0.000132473 Up-regulated 
7986 Bt.66 NDUFA3 0.000138015 Up-regulated 
7223 Bt.500 HK1 0.000187069 Up-regulated 
7986 Bt.66 NDUFA3 0.000226394 Up-regulated 
4914 Bt.64707 LOC146346 0.000776269 Up-regulated 
2865 Bt.89629 EIF4B 0.001144637 Up-regulated 
 
 
Table S4.7: Differentially expressed genes of among different treatments of equilibration time. 
Spreadsheet 1: Up and down-regulated genes on 1 h treatment compared to control; Spreadsheet 
2 Up and down-regulated genes on 2 h treatment compared to control. 
Table S4.7 Sheet 1. Genes differentially expressed between 0 and 1h of recovery    
Probe UniGene ID Gene name P-value Fold change (0 vs. 1h) Comment 
5625 Bt.45080 LRRC45 2.36E-05 1.269131265 Up-regulated 
1109 Bt.17683 DBF4 0.000560078 1.243291605 Up-regulated 
6288 Bt.13965 CNTNAP1 2.48E-07 1.23071886 Up-regulated 
6288 Bt.13965 CNTNAP1 2.48E-07 1.23071886 Up-regulated 
7986 Bt.66 NDUFA3 0.000138015 1.230378288 Up-regulated 
7986 Bt.66 NDUFA3 0.000138015 1.230378288 Up-regulated 
3414 Bt.61384 UNC84B 0.00011637 1.207528134 Up-regulated 
3414 Bt.61384 UNC84B 0.00011637 1.207528134 Up-regulated 
6779 Bt.89284 LOC100008589 8.45E-07 1.199860282 Up-regulated 
6779 Bt.89284 LOC100008589 8.45E-07 1.199860282 Up-regulated 
5165 Bt.2056 APEH 0.000356549 1.176167778 Up-regulated 
5165 Bt.2056 APEH 0.000356549 1.176167778 Up-regulated 
6830 Bt.52335 IFT57 0.000455475 1.166629102 Up-regulated 
4237 Bt.87845 COX5B 2.00E-05 1.165799255 Up-regulated 
4237 Bt.87845 COX5B 2.00E-05 1.165799255 Up-regulated 
2274 Bt.44330 LRP10 0.000316879 1.067708969 Up-regulated 
1685 Bt.77469 KCTD20 6.84E-05 0.893326617 Down-regulated 
1685 Bt.77469 KCTD20 6.84E-05 0.893326617 Down-regulated 
5271 Bt.4908 RBBP7 0.000265911 0.892729784 Down-regulated 
779 Bt.90218 TES 0.000610689 0.875245348 Down-regulated 
2559 Bt.64693 Dnaja1 0.000442293 0.867036407 Down-regulated 
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2559 Bt.64693 Dnaja1 0.000442293 0.867036407 Down-regulated 
5633 Bt.2568 ADFP 0.000157168 0.856417406 Down-regulated 
2887 Bt.61617 UHRF2 0.000439983 0.856087424 Down-regulated 
9071 Bt.66625 CNOT4 0.000437896 0.855133904 Down-regulated 
5836 Bt.64649 Znf313 0.001516718 0.852494945 Down-regulated 
8035 Bt.38851 RHPN2 0.000230282 0.848287492 Down-regulated 
8474 Bt.89593 PRPF4B 0.001438541 0.845408454 Down-regulated 
1782 Bt.53344 ARHGAP21 0.000850676 0.843893588 Down-regulated 
3093 Bt.53211 LOC615039 1.14E-05 0.843690779 Down-regulated 
3093 Bt.53211 LOC615039 1.14E-05 0.843690779 Down-regulated 
5 Bt.29924 MDM4 0.000824537 0.836946262 Down-regulated 
3518 Bt.28502 FAM83D 0.000417802 0.815352753 Down-regulated 
3518 Bt.28502 FAM83D 0.000417802 0.815352753 Down-regulated 
8867 Bt.64897 IGFBP3 0.001597096 0.814325559 Down-regulated 
2719 Bt.75092 DIDO1 4.49E-07 0.79833497 Down-regulated 
2719 Bt.75092 DIDO1 4.49E-07 0.79833497 Down-regulated 
337 Bt.17282 SNIP1 0.001581269 0.794623117 Down-regulated 
288 Bt.28094 CASP7 1.68E-06 0.791653844 Down-regulated 
288 Bt.28094 CASP7 1.68E-06 0.791653844 Down-regulated 
893 Bt.59331 UAP1 3.55E-05 0.79045226 Down-regulated 
893 Bt.59331 UAP1 3.55E-05 0.79045226 Down-regulated 
2167 Bt.20080 WSB1 0.000214607 0.78232197 Down-regulated 
2167 Bt.20080 WSB1 0.000214607 0.78232197 Down-regulated 
10961 Bt.20683 TP53INP2 0.000874769 0.771774751 Down-regulated 
10961 Bt.20683 TP53INP2 0.000874769 0.771774751 Down-regulated 
1607 Bt.4371 GADD45B 0.001314898 0.770497271 Down-regulated 
1897 Bt.12732 NYREN18 3.57E-05 0.768407693 Down-regulated 
1897 Bt.12732 NYREN18 3.57E-05 0.768407693 Down-regulated 
5143 Bt.4106 F3 0.00150891 0.764778651 Down-regulated 
4274 Bt.11909 DUSP6 0.000701201 0.751863703 Down-regulated 
4274 Bt.11909 DUSP6 0.000701201 0.751863703 Down-regulated 
5332 Bt.12314 PFKFB3 3.97E-05 0.710209123 Down-regulated 
5332 Bt.12314 PFKFB3 3.97E-05 0.710209123 Down-regulated 
8731 Bt.27784 PPP1R10 4.21E-07 0.706705653 Down-regulated 
8731 Bt.27784 PPP1R10 4.21E-07 0.706705653 Down-regulated 
11924 Bt.37906 YOD1 3.39E-05 0.688987822 Down-regulated 
11924 Bt.37906 YOD1 3.39E-05 0.688987822 Down-regulated 
9151 Bt.77424 Fubp1 0.001387453 0.68726246 Down-regulated 
9151 Bt.77424 Fubp1 0.001387453 0.68726246 Down-regulated 
5840 Bt.1658 DUSP1 0.000276438 0.642889004 Down-regulated 
5840 Bt.1658 DUSP1 0.000276438 0.642889004 Down-regulated 
320 
 
TMEM121 2.64E-05 0.492582637 Down-regulated 
320 
 
TMEM121 2.64E-05 0.492582637 Down-regulated 
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967 Bt.73261 LOC513955 6.85E-05 0.418946684 Down-regulated 
 
 
Table S4.7 Sheet 2. Genes differentially expressed between 0 and 2h of recovery  
Probe UniGene ID Gene name P-value Fold change (0h  vs. 2h) Comment 
42 Bt.34521 RBM12 0.000452853 2.497810117 Up-regulated 
4986 Bt.89574 KIAA0182 0.00015045 1.650827373 Up-regulated 
4986 Bt.89574 KIAA0182 0.00015045 1.650827373 Up-regulated 
385 Bt.36587 APLN 0.000390659 1.50615348 Up-regulated 
6897 Bt.21510 GPR107 0.00052826 1.353259037 Up-regulated 
6897 Bt.21510 GPR107 0.00052826 1.353259037 Up-regulated 
6288 Bt.13965 CNTNAP1 2.48E-07 1.331670835 Up-regulated 
6288 Bt.13965 CNTNAP1 2.48E-07 1.331670835 Up-regulated 
7223 Bt.500 HK1 0.000108524 1.304444633 Up-regulated 
7223 Bt.500 HK1 0.000108524 1.304444633 Up-regulated 
5165 Bt.2056 APEH 0.000356549 1.297146386 Up-regulated 
5165 Bt.2056 APEH 0.000356549 1.297146386 Up-regulated 
265 Bt.20277 TOP2A 0.00078607 1.295875101 Up-regulated 
4001 Bt.26739 TOMM40L 0.000557284 1.289914225 Up-regulated 
3414 Bt.61384 UNC84B 0.00011637 1.279234189 Up-regulated 
3414 Bt.61384 UNC84B 0.00011637 1.279234189 Up-regulated 
6978 Bt.22374 MGC137396 9.39E-06 1.267036603 Up-regulated 
6978 Bt.22374 MGC137396 9.39E-06 1.267036603 Up-regulated 
4914 Bt.64707 LOC146346 0.000776269 1.266441112 Up-regulated 
1401 Bt.3199 RUSC1 0.000221096 1.245308408 Up-regulated 
8460 Bt.5530 DHRS3 0.000377253 1.225399019 Up-regulated 
8460 Bt.5530 DHRS3 0.000377253 1.225399019 Up-regulated 
3739 Bt.28081 POGZ 0.000189317 1.221355924 Up-regulated 
2709 Bt.21070 MRPL10 0.000769143 1.21338753 Up-regulated 
1116 Bt.25186 BCAT1 0.001013464 1.203687035 Up-regulated 
393 Bt.58700 C9orf58 0.000166772 1.201367218 Up-regulated 
393 Bt.58700 C9orf58 0.000166772 1.201367218 Up-regulated 
1109 Bt.17683 DBF4 0.000560078 1.196284515 Up-regulated 
2415 Bt.46615 MGC138967 0.001483978 1.181577304 Up-regulated 
8159 Bt.89557 
 
1.96E-05 1.166478459 Up-regulated 
8159 
  
1.96E-05 1.166478459 Up-regulated 
4349 Bt.66386 WRNIP1 4.59E-05 1.146309036 Up-regulated 
4349 Bt.66386 WRNIP1 4.59E-05 1.146309036 Up-regulated 
4144 Bt.49595 TMEM111 8.44E-05 0.876101945 down-regulated 
4144 Bt.49595 TMEM111 8.44E-05 0.876101945 down-regulated 
4834 Bt.8545 MRPL43 9.09E-05 0.874209742 down-regulated 
4834 Bt.8545 MRPL43 9.09E-05 0.874209742 down-regulated 
8583 Bt.52379 QRICH1 0.000137079 0.867103998 down-regulated 
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8404 Bt.76983 BIRC5 0.00034293 0.865148925 down-regulated 
5040 Bt.1786 YME1L1 0.000619741 0.861594366 down-regulated 
5040 Bt.1786 YME1L1 0.000619741 0.861594366 down-regulated 
8159 Bt.11282 
 
1.96E-05 0.857281154 down-regulated 
8159 Bt.11282 
 
1.96E-05 0.857281154 down-regulated 
1477 Bt.12399 NEU1 1.84E-05 0.835950196 down-regulated 
3140 Bt.56130 SIAHBP1 0.001110559 0.834894943 down-regulated 
3140 Bt.56130 SIAHBP1 0.001110559 0.834894943 down-regulated 
3806 Bt.25997 CABLES1 0.000852658 0.834548327 down-regulated 
11849 Bt.9469 DNAJC10 0.000759213 0.829061036 down-regulated 
3736 Bt.49705 PRDX6 0.001085807 0.827086914 down-regulated 
3736 Bt.49705 PRDX6 0.001085807 0.827086914 down-regulated 
7122 Bt.22 PPP1R8 0.00131595 0.821455382 down-regulated 
9896 Bt.58080 ZNF3 1.85E-06 0.81790242 down-regulated 
9896 Bt.58080 ZNF3 1.85E-06 0.81790242 down-regulated 
2887 Bt.61617 UHRF2 0.000439983 0.817883423 down-regulated 
2887 Bt.61617 UHRF2 0.000439983 0.817883423 down-regulated 
9907 Bt.59214 FGD5 8.01E-05 0.816453471 down-regulated 
4400 Bt.49192 RPL15 0.000657603 0.814329769 down-regulated 
4400 Bt.49192 RPL15 0.000657603 0.814329769 down-regulated 
2357 Bt.5184 Ankrd40 2.39E-06 0.812380507 down-regulated 
2357 Bt.5184 Ankrd40 2.39E-06 0.812380507 down-regulated 
595 Bt.6522 DNAJB6 0.001496388 0.811001765 down-regulated 
9071 Bt.66625 CNOT4 0.000437896 0.810971414 down-regulated 
4656 Bt.32544 NVL 0.000128076 0.803804047 down-regulated 
3472 Bt.49273 POLR2F 0.00090677 0.800728012 down-regulated 
3472 Bt.49273 POLR2F 0.00090677 0.800728012 down-regulated 
1090 Bt.7391 APLP1 3.84E-06 0.799066523 down-regulated 
7060 Bt.11280 BANP 0.00012219 0.79017418 down-regulated 
7060 Bt.11280 BANP 0.00012219 0.79017418 down-regulated 
5836 Bt.64649 Znf313 0.001516718 0.786717476 down-regulated 
3865 Bt.52937 hCG_20417 0.00010856 0.786277948 down-regulated 
3865 Bt.52937 hCG_20417 0.00010856 0.786277948 down-regulated 
5271 Bt.4908 RBBP7 0.000265911 0.783934201 down-regulated 
1685 Bt.77469 KCTD20 6.84E-05 0.773831736 down-regulated 
1685 Bt.77469 KCTD20 6.84E-05 0.773831736 down-regulated 
3177 Bt.48951 ASB11 1.21E-05 0.773298905 down-regulated 
3177 Bt.48951 ASB11 1.21E-05 0.773298905 down-regulated 
779 Bt.90218 TES 0.000610689 0.763933829 down-regulated 
10834 Bt.18408 CCDC117 0.001065327 0.759673645 down-regulated 
10834 Bt.18408 CCDC117 0.001065327 0.759673645 down-regulated 
3757 Bt.2005 LSM1 1.50E-07 0.746170346 down-regulated 
3757 Bt.2005 LSM1 1.50E-07 0.746170346 down-regulated 
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337 Bt.17282 SNIP1 0.001581269 0.744157241 down-regulated 
8808 Bt.53659 ABHD13 4.64E-05 0.742459346 down-regulated 
8808 Bt.53659 ABHD13 4.64E-05 0.742459346 down-regulated 
1897 Bt.12732 NYREN18 3.57E-05 0.734240435 down-regulated 
1897 Bt.12732 NYREN18 3.57E-05 0.734240435 down-regulated 
967 Bt.73261 LOC513955 6.85E-05 0.734214548 down-regulated 
4952 Bt.2642 ZNF706 0.000593589 0.728207851 down-regulated 
4952 Bt.2642 ZNF706 0.000593589 0.728207851 down-regulated 
3089 Bt.22538 FZD8 9.71E-05 0.726791936 down-regulated 
2287 Bt.27376 Bag4 4.25E-07 0.723285019 down-regulated 
2287 Bt.27376 Bag4 4.25E-07 0.723285019 down-regulated 
1782 Bt.53344 ARHGAP21 0.000850676 0.723115673 down-regulated 
8731 Bt.27784 PPP1R10 4.21E-07 0.719613028 down-regulated 
8731 Bt.27784 PPP1R10 4.21E-07 0.719613028 down-regulated 
8644 Bt.8738 HSPH1 5.51E-05 0.71875201 down-regulated 
8644 Bt.8738 HSPH1 5.51E-05 0.71875201 down-regulated 
5143 Bt.4106 F3 0.00150891 0.718339566 down-regulated 
3518 Bt.28502 FAM83D 0.000417802 0.713784544 down-regulated 
3518 Bt.28502 FAM83D 0.000417802 0.713784544 down-regulated 
5966 Bt.5519 TncRNA 0.000328087 0.710419396 down-regulated 
5966 Bt.5519 TncRNA 0.000328087 0.710419396 down-regulated 
2559 Bt.64693 Dnaja1 0.000442293 0.690349473 down-regulated 
2559 Bt.64693 Dnaja1 0.000442293 0.690349473 down-regulated 
10961 Bt.20683 TP53INP2 0.000874769 0.675668865 down-regulated 
10961 Bt.20683 TP53INP2 0.000874769 0.675668865 down-regulated 
893 Bt.59331 UAP1 3.55E-05 0.659111818 down-regulated 
893 Bt.59331 UAP1 3.55E-05 0.659111818 down-regulated 
4027 Bt.11096 KPNA4 0.00070383 0.651833157 down-regulated 
4027 Bt.11096 KPNA4 0.00070383 0.651833157 down-regulated 
7815 Bt.6432 FAM44B 0.001395402 0.642693905 down-regulated 
6997 Bt.15697 PER2 0.001261833 0.614594305 down-regulated 
10996 Bt.22526 HSPB8 7.83E-05 0.61047851 down-regulated 
10996 Bt.22526 HSPB8 7.83E-05 0.61047851 down-regulated 
11924 Bt.37906 YOD1 3.39E-05 0.60781931 down-regulated 
11924 Bt.37906 YOD1 3.39E-05 0.60781931 down-regulated 
2027 Bt.10259 PLK2 0.00014694 0.602727628 down-regulated 
320 
 
TMEM121 2.64E-05 0.601343868 down-regulated 
5332 Bt.12314 PFKFB3 3.97E-05 0.598072051 down-regulated 
5332 Bt.12314 PFKFB3 3.97E-05 0.598072051 down-regulated 
288 Bt.28094 CASP7 1.68E-06 0.5950576 down-regulated 
288 Bt.28094 CASP7 1.68E-06 0.5950576 down-regulated 
4274 Bt.11909 DUSP6 0.000701201 0.593725436 down-regulated 
4274 Bt.11909 DUSP6 0.000701201 0.593725436 down-regulated 
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8867 Bt.64897 IGFBP3 0.001597096 0.587502707 down-regulated 
5633 Bt.2568 ADFP 0.000157168 0.544075346 down-regulated 
5633 Bt.2568 ADFP 0.000157168 0.544075346 down-regulated 
5840 Bt.1658 DUSP1 0.000276438 0.509476418 down-regulated 
5840 Bt.1658 DUSP1 0.000276438 0.509476418 down-regulated 
7811 Bt.39540 IL15RA 0.000207216 0.44008029 down-regulated 
7811 Bt.39540 IL15RA 0.000207216 0.44008029 down-regulated 
 
 
Table S4.8: Unique differentially expressed genes among different treatments of equilibration 
time.  Spreadsheet 1: Up and down-regulated genes specific to 1 h treatment compared to 
control; Spreadsheet 2: Up and down-regulated genes specific to 2 h treatment compared to 
control. 
Table S4.8 Sheet 1. Unique differentials of the 0 vs. 1h comparison 
Probe UniGene ID Gene name P-value Comment 
4237 Bt.87845 COX5B 4.62E-05 Up-regulated 
5625 Bt.45080 LRRC45 2.36E-05 Up-regulated 
4237 Bt.87845 COX5B 2.00E-05 Up-regulated 
7986 Bt.66 NDUFA3 0.000138015 Up-regulated 
7986 Bt.66 NDUFA3 0.000226394 Up-regulated 
1109 Bt.17683 DBF4 0.000560078 Up-regulated 
2274 Bt.44330 LRP10 0.000316879 Up-regulated 
2719 Bt.75092 DIDO1 4.49E-07 Down-regulated 
3093 Bt.53211 LOC615039 1.14E-05 Down-regulated 
320 
 
TMEM121 2.64E-05 Down-regulated 
3093 Bt.53211 LOC615039 1.14E-05 Down-regulated 
2167 Bt.20080 WSB1 0.000214607 Down-regulated 
8035 Bt.38851 RHPN2 0.000230282 Down-regulated 
2719 Bt.75092 DIDO1 4.49E-07 Down-regulated 
5 Bt.29924 MDM4 0.000824537 Down-regulated 
2167 Bt.20080 WSB1 0.000214607 Down-regulated 
1607 Bt.4371 GADD45B 0.001314898 Down-regulated 
9151 Bt.77424 Fubp1 0.001387453 Down-regulated 
8474 Bt.89593 PRPF4B 0.001438541 Down-regulated 
9151 Bt.77424 Fubp1 0.001387453 Down-regulated 
     
	   	   	   	   	  
Table S8 Sheet 2. Unique differentials of the 0 vs. 2h comparison 
Probe UniGene ID Gene name P-value Comment 
6978 Bt.22374 MGC137396 9.39E-06 Up-regulated 
6978 Bt.22374 MGC137396 9.39E-06 Up-regulated 
4349 Bt.66386 WRNIP1 4.59E-05 Up-regulated 
4349 Bt.66386 WRNIP1 4.59E-05 Up-regulated 
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393 Bt.58700 C9orf58 0.000166772 Up-regulated 
3739 Bt.28081 POGZ 0.000189317 Up-regulated 







4001 Bt.26739 TOMM40L 0.000557284 Up-regulated 
393 Bt.58700 C9orf58 0.000166772 Up-regulated 
2709 Bt.21070 MRPL10 0.000769143 Up-regulated 
8460 Bt.5530 DHRS3 0.000377253 Up-regulated 
1109 Bt.17683 DBF4 0.000560078 Up-regulated 
2415 Bt.46615 MGC138967 0.001483978 Up-regulated 
9896 Bt.58080 ZNF3 1.85E-06 Down-regulated 
9896 Bt.58080 ZNF3 1.85E-06 Down-regulated 
1477 Bt.12399 NEU1 1.84E-05 Down-regulated 
8644 Bt.8738 HSPH1 5.51E-05 Down-regulated 
8644 Bt.8738 HSPH1 5.51E-05 Down-regulated 
3089 Bt.22538 FZD8 9.71E-05 Down-regulated 
7060 Bt.11280 BANP 0.00012219 Down-regulated 
3865 Bt.52937 hCG_20417 0.00010856 Down-regulated 
5966 Bt.5519 TncRNA 0.000328087 Down-regulated 
8404 Bt.76983 BIRC5 0.00034293 Down-regulated 
8808 Bt.53659 ABHD13 4.64E-05 Down-regulated 
2887 Bt.61617 UHRF2 0.000439983 Down-regulated 
5040 Bt.1786 YME1L1 0.000619741 Down-regulated 
11849 Bt.9469 DNAJC10 0.000759213 Down-regulated 
3472 Bt.49273 POLR2F 0.00090677 Down-regulated 
10996 Bt.22526 HSPB8 7.83E-05 Down-regulated 
3736 Bt.49705 PRDX6 0.001085807 Down-regulated 
3140 Bt.56130 SIAHBP1 0.001110559 Down-regulated 
5966 Bt.5519 TncRNA 0.000328087 Down-regulated 
3140 Bt.56130 SIAHBP1 0.001110559 Down-regulated 
3736 Bt.49705 PRDX6 0.001085807 Down-regulated 
4834 Bt.8545 MRPL43 9.09E-05 Down-regulated 
10834 Bt.18408 CCDC117 0.001065327 Down-regulated 
7122 Bt.22 PPP1R8 0.00131595 Down-regulated 
5040 Bt.1786 YME1L1 0.000619741 Down-regulated 
595 Bt.6522 DNAJB6 0.001496388 Down-regulated 
  
         
 
Table S4.9: Common genes among comparisons of different treatments of equilibration time. 
Table S9. Overlapped differentials of the 0 vs. 1h and 0 vs. 2h comparisons* 
Probe UniGene ID Gene name P-value 0  vs. 1h 0  vs. 2h 
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6288 Bt.13965 CNTNAP1 2.48E-07 1 1 
6288 Bt.13965 CNTNAP1 2.48E-07 1 1 
3414 Bt.61384 UNC84B 0.00011637 1 1 
5165 Bt.2056 APEH 0.000356549 1 1 
3414 Bt.61384 UNC84B 0.00011637 1 1 
5165 Bt.2056 APEH 0.000356549 1 1 
8731 Bt.27784 PPP1R10 4.21E-07 -1 -1 
8731 Bt.27784 PPP1R10 4.21E-07 -1 -1 
11924 Bt.37906 YOD1 3.39E-05 -1 -1 
893 Bt.59331 UAP1 3.55E-05 -1 -1 
1897 Bt.12732 NYREN18 3.57E-05 -1 -1 
5332 Bt.12314 PFKFB3 3.97E-05 -1 -1 
5332 Bt.12314 PFKFB3 3.97E-05 -1 -1 
893 Bt.59331 UAP1 3.55E-05 -1 -1 
967 Bt.73261 LOC513955 6.85E-05 -1 -1 
1897 Bt.12732 NYREN18 3.57E-05 -1 -1 
11924 Bt.37906 YOD1 3.39E-05 -1 -1 
1685 Bt.77469 KCTD20 6.84E-05 -1 -1 
3518 Bt.28502 FAM83D 0.000417802 -1 -1 
9071 Bt.66625 CNOT4 0.000437896 -1 -1 
2559 Bt.64693 Dnaja1 0.000442293 -1 -1 
3518 Bt.28502 FAM83D 0.000417802 -1 -1 
779 Bt.90218 TES 0.000610689 -1 -1 
4274 Bt.11909 DUSP6 0.000701201 -1 -1 
1782 Bt.53344 ARHGAP21 0.000850676 -1 -1 
10961 Bt.20683 TP53INP2 0.000874769 -1 -1 
4274 Bt.11909 DUSP6 0.000701201 -1 -1 
2887 Bt.61617 UHRF2 0.000439983 -1 -1 
2559 Bt.64693 Dnaja1 0.000442293 -1 -1 
5143 Bt.4106 F3 0.00150891 -1 -1 
5836 Bt.64649 Znf313 0.001516718 -1 -1 
337 Bt.17282 SNIP1 0.001581269 -1 -1 
10961 Bt.20683 TP53INP2 0.000874769 -1 -1 
288 Bt.28094 CASP7 1.68E-06 -1 -1 
1685 Bt.77469 KCTD20 6.84E-05 -1 -1 
288 Bt.28094 CASP7 1.68E-06 -1 -1 
5633 Bt.2568 ADFP 0.000157168 -1 -1 
5271 Bt.4908 RBBP7 0.000265911 -1 -1 
5840 Bt.1658 DUSP1 0.000276438 -1 -1 
5840 Bt.1658 DUSP1 0.000276438 -1 -1 
8867 Bt.64897 IGFBP3 0.001597096 -1 -1 
320   TMEM121 2.64E-05 -1 -1 
*: 1: up-regualted; -1: down-regulated 
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5.1.	  Abstract	  
The SWI/SNF (SWItch/Sucrose NonFermentable or BAF, Brg/Brahma-associated 
factors) complexes are epigenetic modifiers of chromatin structure and undergo progressive 
changes in subunit composition during cellular differentiation.  For example, in embryonic stem 
cells (ESCs) esBAF contains Brg1 and Baf155, while their homologs, Brm and Baf170, are 
present in BAF of somatic cells.  Here we sought to determine whether Brm and Baf170 play any 
roles in iPSC reprogramming by using shRNA-mediated knockdown studies in the mouse model.  
We found that knocking down Brm during early, mid and late stages (Days 3, 6 and 9 after initial 
iPSC induction) and knocking down Baf170 during late stage (Day 9) reprogramming improve 
the numbers of iPSC colonies formed.  We further showed that inhibition of these somatic BAF 
components also promotes complete reprogramming of partially reprogrammed somatic cells 
(pre-iPSCs).  Finally, we found that the expression of Brm and Baf170 during reprogramming 
was regulated by Jak/Stat3 activity.  Taken together, these data suggest that inhibiting somatic 
BAF improves complete reprogramming by facilitating the activation of the “pluripotency 
circuitry”. 
 
Key words: BAF complex, Brm, Baf170, Induced pluripotent stem cells, Reprogramming 
efficiency  
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5.2.	  Introduction	  
Induced pluripotent stem cells (iPSCs) are embryonic stem cell (ESC) – like cells 
reprogrammed using ectopic transcription factors Oct4, Sox2, Klf4, and c-Myc (OKSM) 1,2.  
However, transcription factor-mediated reprogramming is a slow and inefficient process, 
achieved by overcoming a series of epigenetic barriers 3.  Acquisition of induced pluripotency 
requires an intricate interplay among specialized transcriptional circuitries, signaling pathways 
and chromatin remodeling.  In addition to DNA and histone modifications, ATP-dependent 
enzymes that remodel chromatin are important controllers of chromatin structure and assembly, 
and are major contributors to regulations of gene expression 4,5.   
The SWI/SNF (SWItch/Sucrose NonFermentable) [also known as BAF (Brg/Brahma-
associated factors)] complex is consisted of at least 15 core subunits and has ATP-dependent 
chromatin remodeling activity.  It is essential for the formation of totipotent and pluripotent cells 
of early embryos 6.  In addition, BAF complex is the most frequently mutated chromatin 
regulatory complex in human cancers and thus their manipulation constitutes a major strategy for 
tumor suppression 7.  The BAF complex participates in numerous developmental transitions by 
changing its subunit composition.  For example, the BAF complex in embryonic stem cells 
(ESCs), esBAF, has a unique subunit composition defined by the presence of Brg, Baf155, and 
Baf60a, and the absence of their somatic cell homologues Brm, Baf170, and Baf60c 8.  Altering 
this subunit composition caused a reduction in self-renewal and pluripotency in mouse ESCs 
(mESCs) 8.  In addition, Baf250a is also essential for self-renewal and pluripotency in mESCs 
9,10.  It has been shown that the mechanisms of maintaining ESC pluripotency by esBAF are 
mediated by conditioning the genome for LIF/STAT3 signaling and by regulating the functions 
of the polycomb complex 11.  Conversely, adding esBAF components to fibroblasts facilitates 
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their reprogramming to pluripotent cells.  For example, Brg1 and Baf155, combined with Oct4, 
Sox2, Klf4 and c-Myc, synergistically increased reprogramming efficiency by enhancing the 
binding of Oct4 to target promoters 12.  These data also suggest that specific components of the 
BAF complex serve to facilitate the activation of the “pluripotency circuitry”. 
Given the influence of epigenetic factors over reprogramming fate and the documented 
role of SWI/SNF complexes in pluripotency, we sought to test the roles of somatic Brm and 
Baf170 in mouse iPSC generation through shRNA-mediated knockdown studies.  Using mouse 
embryonic fibroblasts (MEFs) harboring the green fluorescence protein (GFP) driven by the 
Oct4-promoter (OG-MEFs), we found that inhibiting components of the somatic BAF improves 
complete reprogramming by facilitating the activation of the “pluripotency circuitry”.  
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5.3.	  Materials	  and	  Methods	  
5.3.1.	  Chemicals	  and	  Protein	  Expression	  Constructs	  	  	  
Jak inhibitor I (Jaki) and doxycycline were purchased from EMD Millipore (Billerica, 
MA, USA).  Erk inhibitor PD0329501 and GSK3β inhibitor CHIR99021 (CHIR) were obtained 
from SelleckChem (Houston, TX, USA).  The vectors for pMXs-Oct4, Klf4, Sox2, and c-Myc 1, 
pLKO.1-puro, pLKO.1-scramble shRNA control 13, Retro- and Lenti-viral packaging constructs 
pUMVC, pCMV-VSV-G, and psPAX2 14 were all purchased from Addgene (Cambridge, MA, 
USA).  DNA oligos designed against the mouse Brm and Baf170 cDNA (shBrm_1, shBrm_2 and 
shBaf170_1, shBaf170_2) and scramble sequence (shCtl) (Table S5.1) were subcloned into 
pLKO.1-puro vector.  All DNA subcloning was performed using the standard restriction-enzyme 
digestion or Infusion PCR Cloning Kit (Clontech, Mountain View, CA, USA) and expression 
constructs of shBrm and shBaf170 were verified by DNA sequencing.  The human embryonic 
kidney cell line 293T for viral packaging was obtained from Invitrogen (Grand Island, NY, 
USA). 
5.3.2.	  Cell	  Culture,	  Viral	  Preparation,	  and	  Reprogramming	  Assay	  
OG-MEFs, as well as MEFs from CD1 mice were generated from E13.5 embryos as 
described 15.  OG-MEFs up to passage 4 were used for reprogramming.  Briefly, pMXs, pMCs- or 
pLKO.1-constructs, together with packaging vectors pUMVC (for retrovirus), psPAX2 (for 
lentivirus), and pCMV-VSV-G plasmids, were co-transfected into 293T cells according to 
Addgene protocols.  Retrovirus OKSM and lentiviral short hairpin RNA were collected 48 and 
72 hours after transfection.  The iPSC induction from OG-MEFs using viral OKSM and 
reprogramming medium was conducted as described 15.  Briefly, OG-MEFs were plated on 6-
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well-plates and transduced (Day 0) with retroviral OKSM with 10 mg/ml polybrene (American 
Bioanalytical, Natick, MA, USA).  After 24 hours of viral transduction (Day 1), cells were 
trypsinized and passaged onto two 2-well-plates pre-seeded with mitomycin C treated CD1 MEF 
feeders.  Lentiviral shBrm and shBaf170 constructs were then transduced to reprogrammed cells 
at different stages after OKSM transduction according to experiment design (Fig. S5.1A).  Dox 
was added after lentiviral shBrm and shBaf170 infection, and GFP+ colonies were counted 3 
weeks after OKSM transduction under a Nikon fluorescence microscope.  GFP+ iPSC colonies 
were picked 3 weeks after retroviral transduction and expanded in 2i/LIF medium until passage 5 
when further characterization was conducted.  The average size of colonies (areas; mean s + SD) 
was measured by using the ImageJ software (http://imagej.nih.gov/ij/index.html). 
Somatic cells partially reprogrammed by transfection of OKM (pre-iPSCs) were 
generated from our previous study 16.  These cells have ESC colony morphology but are GFP 
negative.  For complete reprogramming of pre-iPSCs to iPSCs, shBrm and shBaf170 were 
transduced (Day 0) and GFP+ colonies were counted 10 days after transfection (Fig. S5.1B) and 
mRNA of these reprogrammed cells were also subjected for quantitative real-time reverse 
transcription – polymerase chain reaction (qRT-PCR) analysis.  shCtl constructs were transduced 
to reprogrammed cells and pre-iPSCs as controls.   
For Jak inhibition, OG-MEFs were reprogrammed by OKSM and cultured with either 
DMSO control or a low dosage (1 mM) of Jaki, stating on Day 3 of reprogramming (Fig. S5.1A).  
mRNA of these cells were then collected for gene expression analysis at Day 18. 
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5.3.3.	  FACS	  analysis	  
Cells reprogrammed from pre-iPSCs were trypsinized and Flow cytometry analysis was 
performed using BD FACS ARIA III.  All data analysis was carried out using the Flowjo 
software. 
5.3.4.	  Embryoid	  Body	  (EB)	  Formation	  
Established iPSC cell lines at passage 6 were grown on CD1 MEF feeders.  After two 
days, the cells were trypsinized and replated to the original plate for 2 hours to allow MEFs to 
attach.  The iPSCs remained in the medium were collected and subsequently plated onto Petri-
dishes containing DMEM + 10% FBS (Invitrogen) without LIF.  Upon 7 days of differentiation, 
EBs formed and were transferred to 0.1% gelatin-coated cell culture dishes (Invitrogen).  The 
cells were allowed to re-attach and to continue differentiation for another 7 days before 
proceeding for RNA extraction, qRT-PCR, or immunostaining as described below. 
5.3.5.	  Alkaline	  Phosphatase	  (AP)	  Staining	  and	  Immunostaining	  
AP staining was performed using a Vector Red Alkaline Phosphate Substrate Kit I 
(Vector Laboratories, Burlingame, CA, USA) according to manufacturer’s instruction.  For 
immunostaining, cells were grown on 12 mm glass coverslips (Fisher Scientific, Waltham, MA, 
USA) in 6-well-plates containing CD1 MEFs as feeders.  Cells were fixed in 4% 
paraformaldehyde with 1% sucrose in PBS for 15 min at room temperature.  The cell membranes 
were permeabilized with 0.5% TX-100 in PBS-T, then incubated for 2 hours at 37ºC in 5% 
donkey or goat serum with mouse anti-SSEA1 IgM (1:100), rabbit anti-Sox2 IgG (1:100), or 
rabbit anti-Nanog IgG (1:100) (All from Millipore), or rabbit anti-Oct4 antibody (1:100, Santa 
Cruz, Dallas, Texas, USA), washed in PBS-T, and then incubated with Alexa Fluor 594 
conjugated donkey anti-rabbit or goat anti-mouse secondary antibodies (1:500, Invitrogen).  
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Cells incubated in serum without primary antibodies were kept as negative controls and R1-
ESCs were stained as positive controls.  After the washes, cells were counterstained with DAPI 
and mounted under coverslips.  Fluorescence images were taken using a Nikon fluorescence 
microscope. 
5.3.6.	  Western	  Blot	  Analyses	  
OG-MEFs were transduced with lentiviral-vector, shCtl, shBrm or shBaf170 and cultured 
in medium containing 10% FBS for four days.  OG-MEFs, Pre-iPSCs, iPSCs and R1-ESCs were 
cultured as described above.  Total cellular proteins were extracted using RIPA buffer (Thermo 
Scientific, Pittsburg, PA, USA) with 1 x proteinase and phosphatase inhibitors (Thermo 
Scientific).  Proteins were quantified with Pierce™ BCA Protein Assay Kit (Thermo Scientific), 
and subjected to 10% SDS-PAGE gel electrophoresis using BioRad mini-gel system and 
subsequently transferred to PVDF membranes.  
The blotted membranes were then blocked with 5% non-fat dry milk in TBS-T and 
incubated with primary antibodies at 4ºC overnight.  The antibodies used were as follows: anti-
Brm (1:1,000, Cell Signaling, Danvers, MA, USA), anti-Baf170 (1:1,000, Cell Signaling), and 
anti-GAPDH (1:2,000, Abcam Inc., Cambridge, MA, USA).  Membranes were then washed and 
blotted with HRP conjugated goat anti-mouse or goat anti-rabbit secondary antibodies (1:5,000, 
Santa Cruz). Blotting signals were detected by chemiluminescence using Pierce ECL Western-
Blot Substrate (Thermo Scientific) and quantified by ChemiDoc XRS+ imaging system with 
Image Lab™ Software (BIO-RAD). 
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5.3.7.	  Quantitative	  Real	  Time-­‐Reverse	  Transcription	  Polymerase	  Chain	  Reaction	  
Total RNA was extracted using the RNeasy Mini kit (Qiagen, Valencia, CA, USA) and 
reverse-transcribed using the SuperScript III Reverse Transcription Kit (Invitrogen).  qRT-PCR 
was performed with specific primers (Table S5.2) using SYBR Green PCR Master Mix (Applied 
Biosystems, Grand Island, NY, USA) and the ABI 7500 Fast instrument.  Combined and 
endogenous levels of Oct4, Sox2 and Klf4 were distinguished by primers designed at different 
regions.  Data were analyzed using the 7500 software version 2.0.2 provided with the instrument.  
Quantification was normalized to the endogenous glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as the internal control and relative mRNA expressions were calculated using R1-ESC 
as the reference. 
5.3.8.	  Statistical	  Analysis	  
Data were analyzed using One Way ANOVA with Tukey’s multiple comparisons or the 
Student’s t-test. All experiments were performed at least twice (N ≥ 2).  Values in figures were 
presented as mean ± standard deviation (SD).  A p-value < 0.05 (*) or < 0.01 (**) was 
considered statistically significant.  
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5.4.	  Results	  
5.4.1.	  Knockdown	  of	  Brm	  or	  Baf170	  at	  Different	  Stages	  Promotes	  Reprogramming	  
To investigate the roles of Brm and Baf170 in reprogramming and differentiation, we first 
measured their mRNA levels in OG-MEFs, OG-MEF-derived iPSC clones, OKM-reprogrammed 
pre-iPSCs and R1-ESCs.  The levels of mRNAs for Brm and Baf170 in OG-MEFs and in pre-
iPSCs were 5-8 times higher than those in iPSCs and R1-ESCs (Figure 5.1A).   We further found 
that subunits of esBAF (Baf60a, Baf200, Baf250a, Brg1 and Baf155) were up-regulated in iPSCs 
and R1-ESCs compared to OG-MEFs and pre-iPSCs (Figure S5.2), suggesting that BAF 
complex undergoes subunit changes while cells transit from differentiated to pluripotent states.  
Western blot analyses also revealed a dramatic higher level of proteins for Brm and Baf170 in 
OG-MEFs and pre-iPSCs than those in iPSCs and R1-ESCs (Figure 5.1D).  The inverse 
correlation between Brm, Baf170 and the state of differentiation, especially in partially 
reprogrammed pre-iPSCs, suggests that Brm and Baf170 may interfere with somatic 
reprogramming.  We then asked whether knocking down Brm or Baf170 would improve 
reprogramming.  Using lentiviral shRNA constructs designed specifically against either Brm or 
Baf170, we were able to knock down Brm and Baf170 mRNA levels in OG-MEFs by more than 
95% (Figure 5.1B, C, Figure S5.3A, B), which were also confirmed at protein levels by Western 
blot analyses (Figure 5.1E, F).  We then reprogrammed OG-MEFs with OKSM (Day 0) in the 
presence of either shBrm or shBaf170 or shCtl on Day 3 and cultured the cells in 2i/LIF medium.  
Two weeks after OKSM induction, dome-shaped, ESC-like GFP+ colonies started to appear in 
all treatment groups.  Knocking down of Brm resulted in a significant increase in GFP+ colonies 
compared to controls (Figure 5.1G).  On the contrary, knocking down Baf170 had minimal 
impact on GFP+ colony formation (Figure 5.1G).  To further dissect the effect of somatic BAF 
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components on reprograming, we knocked down Brm and Baf170 at later stages, i.e., on Days 6 
or 9.  Interestingly, similar results were obtained when treatments were given on Day 6 (Figure 
5.1H) while knocking down Baf170 on Day 9 produced a significant gain on reprogramming 
efficiency (Figure 5.1I).  Collectively, these observations demonstrate that Baf170 inhibits 
reprogramming at a later stage while removal of Brm at any stage improves reprogramming 
(Figure 5.1G, H and I).   
Subsequently we characterized the GFP+ colonies (Figure 2A) for their reprogramming 
status.  Interestingly, we found that the colonies induced by shBrm were significantly smaller 
than those treated with shBaf170 or shCtl (Figure 5.2B).  Furthermore, we observed that GFP+ 
colonies induced by shBrm and shBaf170 shared the following properties with the control ESC 
line, R1: 1) formation of tight, compact colonies with strong alkaline phosphatase (AP) activity 
(Figure5.2C); 2) propagation in 2i/LIF medium and positive immunostaining for pluripotent 
genes and surface markers including Oct4, Sox2 and SSEA1 (Figure 5.2D); and 3) formation of 
EBs in vitro (Figure 5.2E) and differentiation to cells expressing markers of the three germ layers 
(Data not shown).  Of note, no differences were found in the numbers of AP, Sox2, Oct4, and 
SSEA1 positive colonies or EBs between shBrm or shBaf170 and shCtl treated cells expect for a 
slightly smaller EB size in shBrm and shBaf170 treated cells.  The reprogramming was also 
relatively complete because the retroviral transgenes were virtually silenced in the induced iPS 
colonies (Figure 5.2F).  Taken together, the above data demonstrate that inhibition of Brm or 
Baf170 is critical for efficient reprogramming in a stage-specific fashion. 
5.4.2.	  Knockdown	  of	  Brm	  or	  Baf170	  Promotes	  Complete	  Reprogramming	  of	  pre-­‐iPSCs	  
Because we had determined that knockdown of Brm and Baf170 is critical for efficient 
late-stage reprogramming of OG-MEFs, and also Brm and Baf170 were highly expressed in pre-
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iPSCs (Figure 5.1A and D), we asked whether their inhibition is also required for the complete 
reprogramming of these cells.  We knocked down Brm and Baf170 in two stable pre-iPS cell 
lines from our previous study 16, and found that suppressing Brm and Baf170 increased the 
numbers of GFP+ colonies by 5.5- and 11-fold, respectively, compared to controls (Figure 
5.3A).  Similarly, FACS analysis showed that reduced Brm and Baf170 resulted in 49.1% and 
70.6% GFP+ cells, respectively, compared to controls (5.57%; Figure 5.3B).  Characterization of 
GFP+ colonies from the treated pre-iPSCs demonstrated that these colonies grew readily in 
2i/LIF medium, maintained bright GFP expression and ESC-like colony morphology under 
repeated passaging, stained positive for alkaline phosphatase activity and expressed ESC-specific 
gene markers such as Oct4, Sox2, Nanog and SSEA1 (Data not shown).  These data corroborated 
with those in OG-MEF reprogramming that inhibition of either Brm or Baf170 efficiently 
converted pre-iPSCs to iPSCs, while Baf170 knockdown at this late stage of reprogramming is 
more effective than Brm knockdown.   
5.4.3.	  Knockdown	  of	  Brm	  or	  Baf170	  Promotes	  Reprogramming	  by	  Activating	  the	  
“Pluripotency	  Circuitry”	  
As depletion of Brm or Baf170 enhanced reprogramming efficiency and promoted 
complete late stage reprogramming, we sought to investigate the mechanisms of these effects by 
examining the expression of ESC/iPSC-specific genes.  We found that early removal of Baf170 
(Days 3 and 6) did not affect the expression of core pluripotency genes (Figure 5.4A and B), 
while knockdown of Baf170 on Day 9 resulted in significant up-regulation of Sox2, Nanog, 
Esrrb and Tbx3 (Figure 5.4C).  On the contrary, inhibiting Brm at any stage of reprogramming 
significantly increased the expression of Nanog, Esrrb and Tbx3 (Figure 5.4A, B and C).  Brm 
inhibition also elicited stage-specific up-regulation of pluripotent genes.  For example, Oct4 and 
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Rex1 were induced on Day 3, Sox2 on Day 6, and Sox2 and Klf4 on Day 9.  Additionally, we also 
showed that Sox2, Nanog, Rex1, Esrrb and Tbx3 were significantly up-regulated when Brm and 
Baf170 were inhibited in pre-iPSCs (Figure 5.4D).  Taken together, these results demonstrated 
that inhibition of Brm or Baf170 promotes reprogramming efficiency by activating the 
“pluripotency circuitry” in a stage-specific manner. 
5.4.4.	  Inhibition	  of	  Brm	  or	  Baf170	  Promotes	  Jak/Stat3	  Signaling	  during	  Complete	  
Reprogramming	  
 It has been reported that esBAF facilitates pluripotency by conditioning the genome for 
LIF/Stat3 signaling 11.  We have also shown that Jak/Stat3 signaling plays an essential role in 
epigenetic regulation of late stage somatic cell reprogramming 16.  Here we sought to determine 
if somatic BAF components are involved in the intricate interplay of Stat3 signaling during 
reprogramming.  We analyzed Stat3 mRNA transcripts 10 days after shBrm or shBaf170 
transduction of pre-iPSCs.  Interestingly, we found that expression of Stat3 was significantly 
increased by inhibiting Brm or Baf170 in pre-iPSCs (Figure 5.5A).  We further revealed that 
knockdown of Brm or Baf170 significantly stimulated the expression of Socs3－the direct target 
of Stat3 (Figure 5.5A).  These results suggest that the presence of Brm and Baf170 inhibited the 
Stat3 pathway during reprogramming.   
 Retroviral silencing is a prerequisite for pluripotency establishment in retroviral 
transgene-mediated reprogramming and is achieved by de novo DNA methylation through DNA 
methyltransferases (Dnmts) 3a, 3b and Dnmt3L 16-20.  We have also shown previously that 
Jak/Stat3 activity facilitates Dnmt3L expression.  This, in turn, stimulates de novo DNA 
methylation which silences retroviral transgenes and possibly lineage commitment genes 16.  
Examining the expression of Dnmts here revealed that Brm and Baf170 knockdown drastically 
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increased the expression of de novo methyltransferase Dnmt3a and 3L (Figure 5.5B).  These 
results suggested that reducing somatic Brm or Baf170 stimulates de novo DNA methylation, 
which is correlated with the elevated Stat3 pathway.  Therefore somatic BAF reduction may 
coordinate with the Stat3-regulated epigenetic network for pluripotency establishment.  
To further dissect the intricate interplay of Brm/Baf170 and Jak/Stat3 signaling, we 
examined whether inhibiting Jak/Stat3 would affect Brm and Baf170.  We reprogrammed OG-
MEFs and cultured them with either DMSO control or a low dosage (1 mM) of the reversible Jak 
inhibitor I (Jaki), starting on Day 3 of reprogramming.  Jaki treatment virtually blocked the 
formation of all GFP+ colonies, however, this did not change the number of GFP negative 
colonies formed (data not shown).  Furthermore, mRNAs for components of esBAF, Baf60a, 
Baf250a, Brg1, Baf155, Baf47, Baf200, Baf60b and Baf57, were consistently expressed and 
unchanged while the somatic BAF components, Brm and Baf170, were significantly up-regulated 
in Jaki-treated cells compared to DMSO-treated control cells (Figure 5.5C).  To minimize the 
heterogeneity of cells in the analysis, three typical colonies from each treatment were collected 
three weeks after viral transduction and analyzed for their gene expression at passage 2 (P2).  A 
dramatic up-regulation of mRNAs for Brm and Baf170 were consistently observed in Jaki-treated 
cells, compared to the DMSO controls (Figure 5.5D).  Thus, a positive feedback loop exists 
between Jak/Stat3 and the inhibition of Brm and Baf170 during ground state pluripotency 
establishment.  
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5.5.	  Discussion	  
Induced pluripotent stem cells can be generated from somatic cells by ectopic expression 
of transcription factors such as Oct4, Sox2, Klf4 and Myc (OKSM) 1, but the efficiency remains 
low.  A variety of chromatin modifiers, such as Brg1/Baf155, Utx and MBD3/NuRD have been 
implicated in facilitating epigenetic changes leading to authentic iPSC reprogramming 12,21-24.  In 
this study we identified a negative role by Brm and Baf170 on OKSM-mediated reprogramming 
of OG-MEFs.  We found that shRNA-mediated knockdown of Brm or Baf170 led to an increase 
in reprogramming efficiency.  Specifically, Baf170 seems to be more inhibitory to 
reprogramming at the late stage, when the pluripotency network is becoming more stably 
established, while Brm inhibits reprogramming at all phases.  Also interesting to note was that 
colonies induced by Brm knockdown were significantly smaller than those from Baf170 
knockdown.  Sizes of ES colonies and EBs have been shown to affect their differentiation 
trajectories 25 through different gradients of signaling molecules 26.  The size difference observed 
may reflect a mechanism that cells employ to regulate their fates upon changes of BAF 
compositions. 
Components of esBAF have been shown to be important in both maintenance of mESCs 
and iPSC induction.  Deficiency in Brg1, Baf47, Baf155, or Baf250 impaired the ability of 
mESCs to proliferate and to maintain pluripotency 8-11,27,28.  Brg1 and Baf155, combined with 
Oct4, Sox2, Klf4 and c-Myc, can synergistically increase reprogramming efficiency 12.  Because 
iPSCs have similar properties with ESCs, it is logical to infer that homologues of Brg1 and 
Baf155, Brm and Baf170, obstruct reprogramming, which was proven in the current study.  Our 
results are also in agreement with the recent finding that levels of Brm increase during 
differentiation of ESCs 10.  Moreover, the dynamic composition of BAF seems to correlate with 
	   186	  
the differentiation status of the cells, i.e., Baf170 is more important in differentiated cells, 
whereas Baf155 is more important in undifferentiated ES cells 8,10.  Competition between Baf170 
and Baf155 subunits within the BAF complex was also observed during progression of 
neurogenesis and affected euchromatin structure and thereby modulated the binding efficiency of 
their targets 29.  Our results expanded this notion that BAF complex undergoes subunit changes 
while cells transit from differentiated to pluripotent states, i.e., acquisition of esBAF and 
disposition of the somatic BAF components (Brm and Baf170).  Moreover, it suggested somatic 
BAF inhibits the formation of esBAF, therefore serves as a barrier during reprogramming. 
We discovered that removal of Brm and Baf170 aids in full reprogramming.  At selective 
loci pre-iPSCs and somatic cells possess similar chromatin structures which are condensed and 
arrested epigenetically during reprogramming 30,31.  Pre-iPSCs can be completely reprogrammed 
to pluripotency by overexpressing Sox2 or Nanog 32.  The pre-iPSC stage is an epigenetically 
stable landmark along the journey of reprogramming and these cells can progress toward the 
authentic iPSCs through the removel of epigenetic determinants for the intermediate state 31.  
Here we provide a new insight that the presence of the somatic Brm and Baf170 are potential 
epigenetic barriers during reprogramming.  First, high levels of both Brm and Baf170 are present 
in pre-iPSCs.  Secondly knockdown of Brm or Baf170 up-regulated the expression of 
pluripotency-related core transcription factors such as Sox2, Nanog, Rex1, Tbx3 and Esrrb, 
suggesting that the somatic BAF complex may be inhibitory to the expression of pluripotency 
related genes.  Interestingly, during mouse somatic reprogramming, Brg1 and Baf155 were 
recruited by Oct4 in order to relax chromatin structure and facilitate the binding of other 
transcription factors that enhance reprogramming 12.  Genome-wide co-localization of Brg1 with 
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Oct4, Sox2 and Nanog 27,33 further suggests that the somatic components of BAF are not 
compatible with reprogramming.   
An important contribution of this study was to provide evidence that the suppressed Brm 
and Baf170 may coordinate with the Stat3-regulated epigenetic network during pluripotency 
establishment.  Activation of Jak/Stat3 signal pathway is essential for maintaining mouse ESC 
pluripotency 34 and for reactivating the endogenous pluripotency network in somatic cells 16,35.  
Although the role of SWI/SNF complex in Stat3 signaling was discovered previously, the finding 
was only limited for Brg1 11,36,37.  More recently, binding sites of Stat3 and esBAF had been 
shown to frequently overlap in the ESC genome 8,27.  Moreover, Ho et al. 11 provided evidence 
that esBAF is required to establish chromatin accessibility at Stat3 binding targets and to prepare 
these sites to respond to LIF signaling, therefore allowing in vitro preservation of ground-state 
pluripotency.  These studies established a strong connection between esBAF complex and Stat3 
activities.  For the first time, we demonstrated here a link between Brm, Baf170 and Stat3 
activities.  We not only showed that knocking down Brm and Baf170 stimulated Stat3 activity, 
but also inhibiting Jak/Stat3, in turn, increased the expression of Brm and Baf170 during 
reprogramming, thus revealing an interplay between Stat3 and somatic BAF during 
reprogramming.  In addition, we demonstrated that reducing somatic Brm and Baf170 drastically 
increased the expression of de novo methyltransferase Dnmt3a and 3L.  These changes were also 
seen when the Stat3 pathway was activated 16.  Therefore Brm and Baf170 inhibition integrates in 
the Stat3-regulated epigenetic network for pluripotency establishment.  Our results provide new 
insights that Stat3 may promote esBAF formation by inhibiting somatic BAF.  As Stat3 
activation is key to ground-state pluripotency establishment during somatic cell reprogramming 
16, our data here indicate that inhibiting Brm and Baf170 coordinates with the determining effects 
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of Stat3 in pluripotency establishment, and a mutually suppressive interaction between Stat3 and 
somatic BAF is one of the mechanisms involved. 
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Figure 5.1. Knockdown of Brm or Baf170 promotes reprogramming in a stage-specific fashion.  
(A) The levels (means + SD) of Brm and Baf170 mRNAs are low in induced pluripotent stem 
cells (iPSCs) and murine embryonic stem cells (R1-ESCs), but high in OG-MEFs, pre-iPSCs 
induced by ectopic Oct4/Klf4/c-Myc (OKM) infection (n = 3).  The OG-MEFs are mouse 
embryonic fibroblasts harboring the  green florescence protein (GFP) driven by the Oct4-
promoter.  Transfection of OG-MEFs with lentiviruses expressing different small hairpin RNAs 
against Brm (shBrm; B) and Baf170 (shBaf170; C) reduced Baf170 and Brm by 95% and 96%, 
respectively.  (D) Western blots showing the protein levels of Baf170 and Brm in OG-MEFs, 
Pre-iPSCs, iPSCs and R1-ESCs.  Both Baf170 and Brm are present in OG-MEFs and Pre-iPSCs, 
while nearly absent in iPSCs and R1-ESCs.  GAPDH was used as the loading control. 
Transfection of OG-MEFs with shBrm (E) and shBaf170 (F) efficiently reduced the protein 
levels of Brm and Baf170, respectively.  Knocking down Brm on Days 3 (G), 6 (H) and 9 (I) and 
knocking down Baf170 only on Day 9 (I) significant increased the numbers of GFP+ colonies 
(means + SD) induced by OKSM (** P values < 0.01; n = 3). 
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Figure 5.2. Cells reprogrammed by OKSM and Brm- or Baf170-knockdown are pluripotent.  (A) 
Representative iPSC colonies (passage 5) induced by OKSM plus shBrm or shBaf170 and 
cultured in 2i/LIF medium.  The GFP+ colonies indicate activation of the internal Oct4 gene 
(Scale bar = 250 µm, ** P values < 0.01; n = 3).  The average size of colonies (areas; means + 
SD) induced by shBrm is significantly smaller than that by shBaf170 and shCtl (B).  The induced 
colonies stained strongly for AP (C; passaged 5) and pluripotency markers including SSEA1, 
Oct4 and Sox2 (D; bar = 25 µm; passage 6).  The induced colonies also formed EBs after 7 days 
of differentiation (E; bar = 250 µm).  Nuclei of the cells were counterstained with DAPI.  All 
GFP+ colonies induced by shBrm and shBaf170 shared similar properties with the control R1-
ESCs.  (F) Similar levels of combined and endogenously (Oct4*, Sox2* and Klf4*) expressed 
transcription factors in OKSM-infected OG-MEFs also transfected with shBaf170 or shBrm 
were observed in the reprogrammed cells, suggesting the exogenous induction factors were 
silenced.  Values were normalized with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
and relative to R1-ESCs (n = 3). 
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Figure 5.3.  Knocking down Brm or Baf170 promotes complete reprogramming of pre-iPSCs.  
The numbers of GFP+ colonies (means + SD; A) significantly increased 10 days after pre-iPSCs 
were infected with shBrm or shBaf170.  Mean values of three independent experiments from two 
pre-iPS cell lines are shown (**P values < 0.01; n = 3).  The reprogrammed colonies contained 
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Figure 5.4. Knocking down Brm or Baf170 promotes reprogramming by activating the 
“pluripotency circuitry”.  Relative levels of mRNA for selected ESC-specific genes in OG-MEFs 
transfected with shBaf170, shBrm or shctl on Days 3 (A), 6 (B) and 9 (C) of OKSM 
reprogramming.  Oct4*, Sox2* and Klf4* represent mRNA expressed endogenously.  Values 
were normalized with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and relative to 
shCtl (*: p values <0.05; n = 3).  (D) Relative levels of mRNA for selected ESC-specific genes 
in pre-iPSCs 10 days after transfection with shBaf170, shBrm or shCtl (n = 3).  Results were 
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Figure 5.5. Inhibition of Brm or Baf170 promotes Jak/Stat3 signaling during complete 
reprogramming.  Relative levels of mRNA for (A) Stat3 and its direct target, Socs3, as well as do 
novo Dnmts (B) in pre-iPSCs 10 days after transfected with shBaf170 or shBrm.  Results were 
normalized with GAPDH and related to shCtl (**: p values <0.01; n = 3).  (C) Relative levels of 
mRNA for different subunits of BAF complex in OG-MEFs, R1-ESCs, and OKSM-transduced 
OG-MEFs 18 days after initial OKSM viral transduction.  The reprogrammed cells were treated 
with either DMSO or 1 µM Jaki.  Results were normalized with GAPDH and relative to those in 
R1-ESCs (*: p values <0.05; n = 3).  (D) Relative levels of mRNA for Brm and Baf170 in OG-
MEFs, R1-ESCs, and passage two (P2) of reprogrammed cells.  The reprogrammed cells were 
treated with either DMSO or 1 µM Jaki.  Results were normalized with GAPDH and relative to 
those in R1-ESC (*: p values <0.05; n = 3). 
Fig. 5.5 
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5.6.	  Supplementary	  Information	  	  
Table S5.1: Primer sequences for sub-cloning of lentiviral constructs. 













Table S5.2: Primer sequences for real time qRT-PCR.  
 






















Rex1 GACACGTGGCAAAAGAAGATAGTC  
AGTGAGGCGATCCTGCTTTC  
NM_009556.3  









































* denotes primers designed within the coding sequences of the genes and amplified both viral 
transgene and endogenous gene expression, primers of the same genes without the “*”were 
designed from 3’ UTR regions of the genes and amplified only endogenous gene expression.  
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Figures	  S5.1.	  Schemes	  depicting	  the	  generation	  of	  iPSCs	  by	  OKSM	  and	  knocking	  down	  Brm	  or	  Baf170	  at	  different	  stages	  of	  reprogramming	  in	  OG-­‐MEFs	  (A)	  and	  pre-­‐iPSCs	  (B).	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Figures	  S5.2.	  	  Levels	  (means	  +	  SD)	  of	  subunits	  of	  esBAF	  mRNAs	  are	  high	  in	  induced	  pluripotent	  stem	  cells	  (iPSCs)	  and	  murine	  embryonic	  stem	  cells	  (R1-­‐ESCs),	  but	  low	  in	  OG-­‐MEFs,	  pre-­‐iPSCs	  induced	  by	  ectopic	  Oct4/Klf4/c-­‐Myc	  (OKM)	  infection.	  	  In	  contrast,	  levels	  of	  somatic	  BAF	  components,	  Brm	  and	  Baf170	  (*P	  values	  <	  0.05;	  n	  =	  3)	  showed	  the	  reverse	  patterns.	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Figures	  S5.3.	  Transfection	  of	  OG-­‐MEFs	  with	  lentiviruses	  expressing	  different	  small	  hairpin	  RNAs	  against	  Baf170	  (shBaf170;	  A)	  and	  Brm	  (shBrm;	  B)	  does	  not	  affect	  expression	  of	  homologs	  of	  Baf170	  and	  Brm,	  or	  Baf155	  and	  Brg1,	  respectively.	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This dissertation evaluated three critically important areas to further the success of animal 
biotechnology: 1) the biology and the underlying molecular mechanisms of embryogenesis; 2) 
the molecular mechanisms of HHP treatment on embryo competence; and 3) the epigenetic 
mechanisms of complete reprogramming.  Specifically, the following conclusions are made: 
1. We obtained the first complete, timeless “gold standards” for all bovine embryos 
including those from assisted biotechnologies such as cloning and in vitro fertilization, and 
conducted the first co-expression module analysis among human, mouse and bovine pre-
implantation development.  Moreover, we identified potential master regulators of embryo 
development that are not well-studied or even annotated, thus providing directions of future 
studies in embryogenesis.   
2.  Twenty-six confirmed imprinted genes in the bovine were quantified in in vivo 
produced oocytes and embryos and further compared them to their counterparts in humans, mice 
and pigs.  We found differences in the imprinting status, levels and dynamics of expression 
among these four species.  
3. We showed that 40 and 60 MPa of HHP promoted the in vitro developmental 
competence of bovine embryos post-cryopreservation.  Furthermore, we identified specific gene 
expression changes induced by a positive effect of HHP on bovine IVF blastocysts. 
4.  Knocking down somatic BAF components, Brm and Baf170, inhibited reprogramming 
in a stage-specific fashion.  We further showed that this effect was exerted by facilitating the 
activation of the “pluripotency circuitry” and by constituting to the Stat3-regulated epigenetic 
network during pluripotency establishment. 
Our understanding of transcriptional machinery of early embryonic development and 
epigenetic mechanisms of reprogramming will provide insights to bypassing hurdle of bovine 
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iPSCs generation and to designing the optimal conditions of embryo biotechnologies.  Future 
investigations include comprehensive characterization of transcriptome, methylome, proteome 
and metabolome of pre-implantation development.  Our current results combined with future 
studies will also lead to the isolation of biomarkers for the ability of oocytes to fertilize and to 
develop to competent embryos.   
 
